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ABSTRACT

MACROPHAGE COX-2 AS A TARGET FOR IMAGING AND THERAPY OF
INFLAMMATORY DISEASES USING THERANOSTIC NANOEMULSIONS

By
Sravan Kumar Patel
March 2015

Dissertation supervised by Dr. Jelena M. Janjic
Personalized medicine can be an approach to address the unsatisfactory treatment
outcomes in inflammatory conditions such as cancer, arthritis, and cardiovascular
diseases. A common feature of chronic diseases is the infiltration of pro-inflammatory
macrophages at the disease loci. Infiltrating macrophages have been previously utilized
for disease diagnosis. These features suggest that macrophages can be broadly applicable
targets for simultaneous therapy and diagnosis. Cyclooxygenase-2 (COX-2), an enzyme
involved in the biosynthesis of a lipid inflammatory mediator, prostaglandin E2 (PGE2), is
over expressed in macrophages infiltrating the pathological site. Inhibition of PGE2 leads
to reduced inflammation, pain and macrophage infiltration. To utilize macrophages for
the purpose of simultaneous therapy and diagnosis, we proposed to integrate therapeutic
and imaging capabilities on a single nanomedicine platform, referred as theranostics. A
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stable 19F MRI visible nanoemulsion platform was developed, incorporating celecoxib for
COX-2 inhibition and near-infrared fluorescent dye(s) for fluorescence imaging. We
hypothesized that inhibition of COX-2 in macrophages using a theranostic nanoemulsion
will reduce the inflammation (and pain), and that this response can be visualized by
monitoring changes in macrophage infiltration. In vitro characterization demonstrated
that the theranostic displays excellent stability with no toxicity, and significant uptake in
macrophages. Furthermore, it delivers celecoxib to macrophages and reduces PGE2
production from these cells. In vivo studies in a murine paw inflammation model showed
nanoemulsion presence at the inflamed site, specifically in COX-2 expressing
macrophages compared to neutrophils. Supporting our hypothesis, celecoxib delivered
through a nanoemulsion demonstrated time-dependent reduction in fluorescence from the
inflamed paw, indicative of reduced macrophage infiltration. In a neuropathic pain
model, celecoxib delivered to macrophages led to reduced pain concomitant with reduced
macrophage infiltration at the inflamed site compared to free drug control (cross
reference: Kiran Vasudeva, Dissertation, 2015). In conclusion, inhibition of COX-2 in
macrophages using theranostic nanoemulsions proves to be an effective and generalized
strategy facilitating simultaneous therapy and diagnosis, which can be applied to many
chronic diseases. The diagnostic information during therapy can be used to tailor the
treatment and reduce patient variability leading to personalized medicine.

v

DEDICATION

This dissertation is dedicated to my parents, Sreedevi and Veeresham, my brother,
Arun, and my sisters, Sindhuja and Aishwarya.

vi

ACKNOWLEDGEMENT

This work would not have been possible without the help of family, friends and
colleagues. I would like to take this opportunity to thank those who helped shape my life
professionally and personally at Duquesne University.
I am extremely grateful to my advisor Dr. Jelena M. Janjic, for providing me with
the opportunity to pursue doctoral study in a highly collaborative environment. Her
guidance, training, vision, and constructive criticism helped me face academic challenges
successfully and grow professionally as a confident person. I will always remember and
cherish the professional and personal support I received from her, when I needed the
most.
I am immensely thankful to all my committee members for offering their
insightful guidance, and valuable time in completion of my doctoral dissertation. I
sincerely appreciate the valuable suggestions and training offered by Dr. John A. Pollock.
I would like to offer special thanks to Dr. Carl A. Anderson for his valuable guidance
throughout my time at Duquesne University, in courses as well as research. I would like
to thank Dr. Lisa Rohan for valuable advice and for generously allowing me to utilize
facilities in her laboratory at University of Pittsburgh. My other committee members,
Drs. Buckner and Wildfong shaped my understanding of pharmaceutical field through
their courses. I could always knock on their door for any technical questions and they
graciously supported me.
I am indebted to the friendship and support of my lab members, Claire O’Hanlon,
Yang Zhang, Konjit Amede, Meredith O’Hear, Robert Tunney, Jr., Simon George,

vii

Jonathan, Xun Yang, Gregory Mountain, Christina Bagia, Irenej Jeric, Sherlock Lu, and
Michelle Herneisey. My work has been a collaborative effort for which I am thankful to
all the friends and collaborators, Drs. Wissam Beaino and Carolyn Anderson, Kiran
Vasudeva, Muzamil Saleem, Dr. Anthony Balducci, Michael J. Patrick, Dr. Kevin
Hitchens, Bratislav Janjic, Virgil Simpleanu, Haibing Teng, Dr. Gayathri Withers, and
Dr. Lauren Ernst, without whom this work would not have been possible. Special
acknowledgements go to Dr. Wilson S. Meng for valuable suggestions towards my
research.
I will always be indebted to my friends, who were practically my family at
Duquesne University for their encouragement and constant support. Special thanks to
Sneha Potdar, Dipy Vasa, and Darshini Shah for their constant support and love. I thank
Namita Dalal, Shikhar Mohan, Anik Alam, Vishwa Shah, Sapna Jaiswal, Mayur Parmar,
Balasunder Dodda, Ravi Kumar Vyas, Karim Kutchi, Harsha Rathi, Rohith Kashyap,
Apurva Kulkarni, and Somraj Gosh.
I extend my acknowledgements to Drs. Diane Rhodes and Joyce Kossol for
providing me with necessary training to teach pharmacy labs. I am thankful to Graduate
School of Pharmaceutical Sciences and Dr. James K. Drennen, III for providing me with
financial support as teaching assistant. Thanks to Ms. Jackie Farrer, Ms. Deb Wilson, Ms.
Mary Caruso, and Ms. Nancy Hosni for taking care of the administrative work and timely
reminder of important events.
Special thanks to Carroline Lobo, for her love, support, patience, and friendship.
Finally, I thank my parents and family members. This dissertation is the result of
their blessings, relentless support, and love.

viii

TABLE OF CONTENTS
ABSTRACT ....................................................................................................................... iv
ACKNOWLEDGEMENT ................................................................................................ vii
LIST OF TABLES ........................................................................................................... xiv
LIST OF FIGURES .......................................................................................................... xv
LIST OF ABBREVIATIONS ......................................................................................... xvii
1

Macrophages as targets for simultaneous diagnosis and therapy of inflammatory

diseases ............................................................................................................................... 1

2

1.1

Statement of the problem .................................................................................... 1

1.2

Rationale, study hypothesis and aims ............................................................... 10

1.3

Role of macrophages in therapy and diagnosis of inflammation ...................... 13

1.3.1

Macrophages in inflammatory diseases – potential for therapy ................... 15

1.3.2

Imaging macrophages and disease diagnosis ................................................ 17

1.4

Nanosystem design considerations for effective macrophage targeting ........... 18

1.5

Theranostics for macrophage detection and therapy – state of the art .............. 20

1.5.1

Theranostics for macrophage ablation .......................................................... 21

1.5.2

Theranostics utilizing non-ablation approaches............................................ 25

1.5.3

Conclusions, Limitations and Future Perspective ......................................... 30

Rationale for Perfluorocarbon nanoemulsions as a platform to deliver celecoxib for

COX-2 inhibition in macrophages .................................................................................... 32
2.1
2.1.1

COX-2 in inflammatory diseases ...................................................................... 32
COX-2 in monocytes and macrophages as a therapeutic target ................... 34

ix

2.2

Pharmacology of COX-2 inhibitor, celecoxib .................................................. 35

2.3

Celecoxib toxicity and alternate formulations .................................................. 37

2.4

Perfluorocarbon nanoemulsions........................................................................ 39

2.4.1

Perfluorocarbons in biomedical applications ................................................ 39

2.4.2

Perfluorocarbons and challenges .................................................................. 41

2.4.3

Fluorescent/19F MRI nanoemulsions as tools for drug delivery and

macrophage imaging ................................................................................................. 42

3

2.4.3.1

19

2.4.3.2

Optical near-infrared fluorescence imaging.......................................... 44

2.4.3.3

PFC nanoemulsions for drug delivery and imaging ............................. 45

F magnetic resonance imaging ........................................................... 42

Nanoemulsion development of a lipophilic perfluorocarbon conjugate as a 19F MRI

tracer for macrophage imaging ......................................................................................... 48
3.1

Introduction ....................................................................................................... 48

3.1.1

Nanoemulsions .............................................................................................. 48

3.1.2

Nanoemulsion preparation using ultra sonication and microfluidization ..... 50

3.1.3

Ostwald ripening and instability of perfluorocarbon nanoemulsions ........... 51

3.1.4

Rationale ....................................................................................................... 53

3.2

Materials and methods ...................................................................................... 54

3.2.1

Materials ....................................................................................................... 54

3.2.2

Synthesis of C8/C12/C14 PFTEs .................................................................. 55

3.2.3

Nanoemulsion preparation using probe sonication and microfluidization ... 56

3.2.3.1

Nanoemulsions with Cremophor® EL and Pluronic® P105 ................ 56

3.2.3.2

Nanoemulsions with single and mixed Pluronic® surfactants ............. 57

x

3.2.4

Characterization for colloidal attributes, and cytotoxicity and uptake in RAW

264.7 cells ................................................................................................................. 59
3.3
3.3.1

Formulation development of C8-PFTE ........................................................ 65

3.3.2

In vitro cell culture studies ............................................................................ 72

3.4
4

Results and discussion ...................................................................................... 62

Conclusions, limitations and alternatives ......................................................... 75

Development of fluorescent celecoxib-loaded PFPE nanoemulsions for drug

delivery and imaging in macrophages .............................................................................. 77

5

4.1

Introduction ....................................................................................................... 77

4.2

Materials and methods ...................................................................................... 79

4.2.1

Materials ....................................................................................................... 79

4.2.2

Preparation and characterization of PFPE nanoemulsions ........................... 80

4.3

Results and Discussion ..................................................................................... 88

4.4

Conclusion ...................................................................................................... 103

Dual fluorescent PFPE nanoemulsions for improved optical imaging capabilities 104
5.1

Introduction ..................................................................................................... 104

5.2

Materials and methods .................................................................................... 105

5.2.1

Materials ..................................................................................................... 105

5.2.2

Preparation and characterization of dual fluorescent nanoemulsions ......... 105

5.3
5.3.1

Results and discussion .................................................................................... 107
Colloidal and imaging characterization of dual fluorescent nanoemulsions
108

5.3.2

Evaluation in a neuropathic pain rat model ................................................ 114

xi

5.4
6

Conclusions ..................................................................................................... 114

Development and in vitro characterization of PFPE nanoemulsion for increased MR

sensitivity ........................................................................................................................ 116
6.1

Rationale ......................................................................................................... 116

6.2

Materials and methods .................................................................................... 118

6.2.1

Materials ..................................................................................................... 118

6.2.2

Preparation and characterization of fluorescent PFPE nanoemulsions....... 119

6.3

Results and discussion .................................................................................... 125

6.3.1

Preparation and characterization of nanoemulsions ................................... 125

6.3.2

In vitro evaluation in RAW 264.7 macrophages ........................................ 133

6.4
7

Conclusions ..................................................................................................... 139

In vivo evaluation of PFC nanoemulsions in inflammatory models ....................... 141
7.1

Introduction ..................................................................................................... 141

7.2

Materials and methods .................................................................................... 141

7.2.1

Inflammation models .................................................................................. 141

7.2.2

In vivo studies in a mouse paw inflammation model .................................. 142

7.2.2.1

Pilot study to assess the imaging potential of nanoemulsion .............. 142

7.2.2.2

In vivo study to evaluate theranostic potential of nanoemulsions....... 143

7.2.3
7.3

In vivo imaging in a neuropathic pain rat model......................................... 145
Results and discussion .................................................................................... 147

7.3.1

In vivo studies in a mouse paw inflammation model .................................. 147

7.3.2

In vivo studies in a neuropathic pain rat model........................................... 158

7.4

Conclusions ..................................................................................................... 161

xii

8

Summary and future directions ............................................................................... 163

9

References ............................................................................................................... 166

xiii

LIST OF TABLES
Page
Table 1.1. Table summarizing macrophage-targeted theranostics reported in the literature
........................................................................................................................................... 26
Table 3.1. Summary of formulations prepared with 10% w/v olive oil and 3% w/v
surfactant system. Where two surfactants are used, they were at 1:1 w/w ratio............... 68
Table 3.2. Summary of nanoemulsions prepared with C8-PFTE/olive oil (1:1) and
Pluronic® P123 and P105 as surfactants (3% w/v). ......................................................... 69
Table 4.1. Table showing components of PFPE nanoemulsions A, B, and C. ................. 81
Table 4.2. Compilation of assessed HPLC method parameters. ....................................... 93
Table 4.3. Average droplet diameter and PDI of nanoemulsions A and B before and after
incubation in media. .......................................................................................................... 95
Table 6.1. Proposed factors and levels for nanoemulsion optimization ......................... 118
Table 6.2. DLS characterization of nanoemulsions NE1, NE2 and NE3. ...................... 126

xiv

LIST OF FIGURES
Page
Figure 1.1. Self-reported presence of chronic diseases in the United States. ..................... 3
Figure 1.2. Schematic showing proposed role of theranostics in personalized treatment. . 7
Figure 1.3. Current and future use of imaging functionality of macrophage theranostics. 9
Figure 1.4. Schematic showing acute and chronic inflammatory events .......................... 14
Figure 1.5. Schematic showing the multifunctional theranostic systems utilized for
imaging and therapy of macrophages. Originally published elsewhere.2 ......................... 21
Figure 2.1. Formation of prostanoids from arachidonic acid............................................ 34
Figure 2.2. The chemical structure of celecoxib. .............................................................. 36
Figure 2.3. Chemical structures of PFCs utilized in biomedical applications. ................. 40
Figure 3.1. Synthesis and representative 19F NMR of PFTE analogs. .............................. 64
Figure 3.2. Instability of CrEL/P105/PFTE nanoemulsions based on droplet size changes
with time. .......................................................................................................................... 65
Figure 3.3. Droplet diameter changes with surfactant amount for olive oil nanoemulsions.
........................................................................................................................................... 68
Figure 3.4. Effect of olive oil on C8-PFTE nanoemulsion stability. ................................ 70
Figure 3.5. Physical characterization of microfluidized olive oil (M1) and C8-PFTE/olive
oil (M2) nanoemulsions using DLS. ................................................................................. 72
Figure 3.6. In vitro characterization of olive oil (M1) and C8-PFTE/olive oil (M2)
nanoemulsions in mouse macrophages. ............................................................................ 74
Figure 4.1. Proposed schematic of PFPE nanoemulsion droplet structure.128 .................. 90
Figure 4.2. Characterization of nanoemulsions A and B using DLS. ............................... 92
Figure 4.3. Representative chromatogram of celecoxib from extracted nanoemulsion
sample. .............................................................................................................................. 93
Figure 4.4. Characterization of nanoemulsion B for imaging functionalities................... 94
Figure 4.5. Macrophage cell viability post 24-hour exposure to nanoemulsions A and B.
........................................................................................................................................... 97
Figure 4.6. Characterization of cellular uptake of nanoemulsion B. ................................ 98
Figure 4.7. Confocal microscopy of macrophages exposed to nanoemulsion C. ........... 100
Figure 4.8. Confocal microscopy to assess intracellular localization of nanoemulsion C.
......................................................................................................................................... 101
Figure 4.9. Effect of nanoemulsion-mediated celecoxib delivery on PGE2 production by
LPS activated macrophages. ........................................................................................... 103
Figure 5.1. Droplet size changes with days of dual fluorescent nanoemulsions stored at 4
° C. Originally published elsewhere. 217 ......................................................................... 108
Figure 5.2. Optical assessment of dual fluorescent PFPE nanoemulsions. .................... 110
Figure 5.3. Linear correlation of imaging signals with nanoemulsion concentration. ... 112
Figure 5.4. Confocal images of macrophages exposed to dual fluorescent nanoemulsion.
......................................................................................................................................... 113
Figure 6.1. Gating strategy employed in flow cytometry based on FSC and SSC of cells.
......................................................................................................................................... 122
Figure 6.2. Size and stability of dye-free PFPE nanoemulsions. .................................... 129
Figure 6.3. Effect of dye-free PFPE nanoemulsions on macrophage viability. .............. 130

xv

Figure 6.4. Characterization of the optimized fluorescent dye-loaded nanoemulsions,
DFNE and CXBNE, using DLS...................................................................................... 131
Figure 6.5. Fluorescence characterization of DiD dye in nanoemulsions and solution. . 132
Figure 6.6. Effect of DFNE and CXBNE on macrophage viability and activation. ....... 133
Figure 6.7. Characterization of nanoemulsion uptake in macrophages using fluorescence
methods. .......................................................................................................................... 135
Figure 6.8. Cellular uptake kinetics of nanoemulsions. .................................................. 138
Figure 6.9. Comparison of PGE2 in supernatants of LPS activated macrophages
pretreated with celecoxib in solution and nanoemulsion. ............................................... 139
Figure 7.1. Representative fluorescence/white light image showing in vivo imaging
method and ROIs used for quantification. ...................................................................... 143
Figure 7.2. Schematic showing the proposed theranostic potential of PFPE nanoemulsion.
......................................................................................................................................... 147
Figure 7.3. Pilot in vivo study showing characterization of CFA and CG mouse models.
......................................................................................................................................... 149
Figure 7.4. Tissue analysis for nanoemulsion accumulation in macrophages and
neutrophils....................................................................................................................... 151
Figure 7.5. In vivo NIRF imaging of DFNE and CXBNE in mouse paw inflammation
model............................................................................................................................... 152
Figure 7.6. Biodistribution of DFNE and CXBNE. ........................................................ 154
Figure 7.7. Representative 1H/19F MRI composite image of excised inflamed paw. ..... 154
Figure 7.8. Histology of excised paw 72 h after CFA injection showing nanoemulsion
accumulation in COX-2 expressing macrophages. ......................................................... 156
Figure 7.9. Histology of paw 72 h after inducing inflammation to assess nanoemulsion
accumulation in macrophages and neutrophils. .............................................................. 157
Figure 7.10. In vivo and ex vivo NIRF imaging of neuropathic pain rat model to assess
dual fluorescent PFPE nanoemulsion accumulation. Arrow points to the surgical site
showing fluorescence at the injured sciatic nerve in chronic constriction injury (CCI) rat.
......................................................................................................................................... 159
Figure 7.11. Imaging and pain behavior assessment of theranostic PFCE nanoemulsion in
a neuropathic pain rat model. .......................................................................................... 161

xvi

LIST OF ABBREVIATIONS

AA

Arachidonic Acid

AD

Alzheimer’s Disease

ANOVA

Analysis of Variance

19

19

F MRI

F Magnetic Resonance Imaging

CatB

Cathepsin-B

CAM

Cell Adhesion Molecule

CD

Cluster of Differentiation

CFA

Complete Freund’s Adjuvant

CG

Carrageenan

COPD

Chronic Obstructive Pulmonary Disease

COX-2

Cyclooxygenase-2

CrEL

Cremophor® EL

CXBNE

Celecoxib Nanoemulsion

DFNE

Drug-free Nanoemulsion

DiD

1,1'-Dioctadecyl-3,3,3',3'-Tetramethylindodicarbocyanine
Perchlorate

DiR

1,1'-Dioctadecyl-3,3,3',3'-Tetramethylindotricarbocyanine Iodide

DMSO

Dimethyl Sulfoxide

CT

Computed Tomography

DAMPs

Damage-associated Molecular Patterns

DC

Dendritic Cell

xvii

DIAD

Diisopropylazodicarboxylate

DLS

Dynamic Light Scattering

DPBS

Dulbecco’s Phosphate-buffered Saline

ECM

Extracellular Matrix

ELISA

Enzyme Linked Immunosorbent Assay

Em

Emission

EPR

Enhanced Permeability and Retention

Ex

Excitation

FBS

Fetal Bovine Serum

FITC

Fluorescein Isothiocyanate

FSC

Forward Scatter

Gd

Gadolinium

GNR

Gold Nanorods

HPLC

High Performance Liquid Chromatography

IBD

Inflammatory Bowel Disease

IONP

Iron Oxide Nanoparticle

i.v.

Intravenous

LOD

Limit of Detection

LOQ

Limit of Quantitation

LPS

Lipopolysaccharide

MCP-1

Monocyte Chemoattractant Protein-1

MI

Myocardial Infarction

MMP

Matrix Metalloproteinase

xviii

MRI

Magnetic Resonance Imaging

NIR

Near-infrared

NIRF

Near-infrared Fluorescence

NMR

Nuclear Magnetic Resonance

NO

Nitric Oxide

NP

Nanoparticle

NSAIDs

Nonsteroidal Anti-inflammatory Drugs

OR

Ostwald Ripening

O/W

Oil-in-Water

P105

Pluronic® 105

P123

Pluronic® 123

PAMPs

Pathogen-associated Molecular Patterns

PDI

Polydispersity Index

PDIw/2

Half-width of Polydispersity Index

PDT

Photodynamic Therapy

PEG

Polyethylene glycol

PEO

Polyethylene Oxide

PET

Positron Emission Tomography

PFC

Perfluorocarbon

PFC-HC

Perfluorocarbon-Hydrocarbon

PFCE

Perfluoro-15-crown-5-ether

PFOB

Perfluorooctyl bromide

PFPE

Perfluoropoly (ethylene glycol) ether

xix

PFTE

Perfluoro-tert-butyl ether

PGE2

Prostaglandin E2

PPO

Polypropylene Oxide

PTT

Photothermal Therapy

RA

Rheumatoid Arthritis

RES

Reticuloendothelial System

RFU

Relative Fluorescence Units

ROI

Region of Interest

ROS

Reactive Oxygen Species

RSD

Relative Standard Deviation

RT

Room Temperature

s.c.

Subcutaneous

SD

Standard Deviation

SEM

Standard Error of Mean

siRNA

Small interfering Ribonucleic Acid

SSC

Side Scatter

TAM

Tumor Associated Macrophages

TFA

Trifluoroacetic Acid

TNF-α

Tumor Necrosis Factor-α

USPIO

Ultrasmall Paramagnetic Iron Oxide

W/O

Water-in-Oil

90

Yttrium-90

Y

xx

1

Macrophages as targets for simultaneous diagnosis and therapy of
inflammatory diseases

1.1 Statement of the problem
Inflammation is involved in the pathogenesis of many common diseases such as
cancer, rheumatoid arthritis (RA), obesity, cardiovascular-related ailments, chronic
obstructive pulmonary disease (COPD), asthma, inflammatory bowel disease (IBD),
diabetes, Alzheimer’s, and infection-related diseases.1-3 Although it is beneficial in
defending the body from injury or infection, unresolved inflammation can lead to
substantial tissue injury, which is involved in the initiation, promotion and progression of
diseases.1,3,4 Inflammatory diseases are associated with considerable economic burden. In
2003, the Centers for Disease Control and Prevention reported that total expenditures due
to arthritis and other rheumatic disorders were $128 billion, which was equivalent to
1.2% of the 2003 United States gross domestic product.5 The direct and indirect costs
attributable to asthma increased by six percent from $53 billion in 2002 to $56 billion in
2007.6 In 2010, cardiovascular diseases were estimated to have total costs of $444
billion.7 Figure 1.1 shows the prevalence of heart diseases, diabetes and asthma in the
United States.
Methods to effectively intercept pathways that lead to chronic inflammation are
under intense development. While substantial progress has been made in the development
of new drugs, inflammatory disease treatment and management still face significant
problems. Inter- and intra-patient variability is one of the major factors contributing to the
failure of current treatment approaches.8-10 The traditional treatment strategies rely on
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diagnosis of the disease and administration of the appropriate therapy based on the
severity of the disease. Disease severity is obtained from generalized diagnostic methods
and other patient-specific parameters such as body surface area, weight, and past and
current medication. Although the treatment is, in a way, tailored to the patient based on
the diagnostic profile, often times a great variability in efficacy is observed between
patients leading to the failure of the treatment. This variability could be attributed to the
inhomogeneity transpiring at the molecular level in disease pathogenesis i.e. differences
in protein expression, genetic predisposition, resistance to therapy, and other similar
factors. For example, inflammatory biomarkers detected in COPD show significant
variability between patients.11 Additionally, RA affecting synovial tissue in multiple
joints can manifest as similar clinical symptoms in patients.12 However, marked
variability in leukocyte infiltration and cytokine profile has been observed in their
synovial tissues.13 This could be the reason for the variable clinical response to antiinflammatory drugs such as infliximab, and etanercept, which reduce the inflammatory
cytokine, tumor necrosis factor-α (TNF- α). Inter- and intra-patient variability can also be
a result of variable pharmacokinetics among patients as observed for infliximab
treatment.14,15

2

Figure 1.1. Self-reported presence of chronic diseases in the United States.
The above figure shows the prevalence of major inflammatory diseases in the United
States according to the results of the National Health Interview Survey (2002 and
2012).16,17 The numbers represent the percentage of people who had ever been told by a
doctor or other health professional that they had heart diseases, diabetes mellitus or
asthma.

Therefore, the traditional model of “one drug for all” has proven sub-optimal, at
least for chronic diseases, and a paradigm shift has been observed towards patienttailored treatment methods. Rapid advancements in genomics has led to the utilization of
genetic information to stratify patient population known to respond to the therapy to
increase efficacy and reduce unwanted side effects. This treatment model is referred to as
personalized medicine.12,18 According to the U.S. Food and Drug Administration,19
personalized or precision medicine is described as “the right patient with the right drug at
the right dose at the right time”, and “the tailoring of medical treatment to the individual
characteristics, needs and preferences of a patient during all stages of care, including
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prevention, diagnosis, treatment and follow-up.” For example, breast cancer presents in
different forms, where certain patients do not respond to therapies due to changes in
molecular expression of biomarkers.20 These differences among patients are now
recognized and treatment strategies are tailored leading to personalization of treatment.
For example, treatment of metastatic breast cancer patients diagnosed positive for human
epidermal growth factor receptor 2 (HER2) with an anticancer drug, Herceptin®
(Trastuzumab), specific for these receptors increased the efficacy. Therefore,
development of dedicated therapeutic interventions based on specific disease markers
(companion diagnostics) is a new way of achieving the goal of personalized
inflammatory diseases treatment.
The approach of combining a biomarker or a diagnostic method to tailor the
therapy is referred to as “theranostics”.21 Theranostics are also defined as an integration
of therapeutic and diagnostic or imaging functionalities on a single platform that can
diagnose disease, deliver drugs and monitor therapy leading to individualized treatment.18
In this dissertation, the latter definition is used to refer to theranostics. Nanotechnology
has been central in the development of theranostics because therapeutic and diagnostic
components can be integrated together using nanoparticles (NPs).22 NPs offer several
advantages such as high surface-area-volume ratio to obtain high loading of drug and
imaging agents. They have been functionalized to increase blood circulation time by
coating the surface with hydrophilic polymers such as polyethylene glycol (PEG).23
Additionally, NPs can be functionalized to modulate the drug release based on
environmental stimuli such as pH, temperature, enzymes, and redox potential, and their
use can increase uptake in specific cells.24 Due to their tunable size and surface
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properties, anatomical and physiological changes during inflammation can be exploited
for targeted NP accumulation, namely through leaky vasculature by enhanced
permeability and retention (EPR) phenomenon and through utilization of macrophages’
disease-homing characteristic.25,26
These multifunctional NPs have been utilized to longitudinally visualize
bioaccumulation in a live animal and ex vivo in tissue samples, assess cellular uptake
kinetics, optimize the physicochemical aspects of theranostics for desired results, and
guide therapy based on imaging i.e. image-guided surgery and phototherapy.2,18 The
biodistribution information could guide clinical decision making such as continuing with
therapy, changing dose or switching to a different therapy early in the treatment process.
These entities can be assumed analogous to therapeutic radionuclides. For example,
TheraSphere® technology uses microspheres containing radioactive Yttrium-90 (90Y) to
treat inoperable liver carcinoma.27,28 These microspheres are delivered to liver through
intra-arterial catheter-based delivery, where the internal radiation released by 90Y kills the
cancer

cells.

Because

microspheres

can

be

detected

by

positron

emission

tomography/computed tomography (PET/CT), their liver distribution can be visualized to
identify poorly implanted tumor regions and assess treatment options.27
In addition to visualizing biodistribution, a significant challenge lies in
monitoring the therapeutic response with theranostic NPs. There is a need to monitor the
effectiveness of therapy because disease environment can change during therapy and/or
develop resistance during therapy, leading to ineffective treatment. Cellular and
molecular biomarkers are ever changing spatially and temporally during the disease
pathogenesis and treatment. One particular mechanism relevant to inflammatory diseases
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is the development of drug resistance observed in cancer, infectious diseases and
RA.20,29,30 The development of drug resistance in these diseases could vary among
patients. Another example involves observing reduction in macrophage infiltration or
lack thereof in response to anti-rheumatic drug therapy in RA.29 Macrophages exacerbate
the disease, so it is conceivable that an ineffective drug therapy would fail to cause a
reduction in macrophage infiltration. This issue, if detected early, could guide clinicians
to change the drug dose or therapy. Identification of these dynamics and adjustment of
therapeutic interventions based on real-time therapy response early in the treatment
process could, thereby, save time and increase patient outcomes.
Current theranostic NPs provide crucial biodistribution information. However,
they have not been utilized to monitor therapeutic response. Therefore, the next step
forward in the existing model of personalized medicine is personalizing the treatment
while the therapy is ongoing. Figure 1.2 illustrates how theranostic NPs can help realize
the goal of concurrent therapy and therapy monitoring.31 Accumulation of theranostic at
the target site can be quantified to define dosing regimen for successive doses. For
example, increase the dose if the accumulation leads to sub-therapeutic drug
concentration. The imaging aspect can also be used for image-guided therapy such as
delivering light precisely to the diseased areas in photo-based therapies. Additionally, if
the theranostic can detect spatio-temporal changes in inflammation during therapy (based
on the changes in imaging information), effective clinical decision-making regarding the
dose adjustments or switching to an alternate therapy can be made, early in the treatment
strategy. Essentially, the imaging component of the theranostic is utilized to assess
biodistribution as well as monitor the efficacy of the therapeutic intervention. These
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proposed roles of theranostic could achieve personalized medicine by monitoring
response to the therapy in individual patients and accordingly adjust doses and switch to
alternate therapies.

Figure 1.2. Schematic showing proposed role of theranostics in personalized
treatment.
Text in the ellipse shows the clinical decision-making possibilities based on the
diagnostic information obtained from theranostic functionalities. Inspired from Moore et
al.31

In this dissertation, we achieved drug response monitoring using theranostics by
harnessing the natural pathophysiological mechanisms of macrophages, namely their
phagocytic potential and disease-homing properties. Macrophages are widely
investigated for simultaneous imaging and therapy in inflammatory diseases using
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theranostics.2 These cells migrate to the injured site in response to chemokines and
cytokines released during inflammation and participate in pro-inflammatory processes.
Thus, theranostics can be delivered to these cells to suppress the pro-inflammatory
activity and simultaneously image their infiltration. Delivering theranostics to
macrophages is possible because they are naturally phagocytic and readily internalize
NPs.32 Current theranostics act by either depleting macrophages or reducing their
inflammatory activity.2 Due to the aggressive nature of macrophage depletion, which
could lead to toxicities, theranostics inhibiting inflammatory mediators produced by
macrophages is a safer and more effective approach.
One of the key enzymes expressed by inflammatory macrophages is
cyclooxygenase-2 (COX-2). COX-2 is overly expressed in all the diseases with an
inflammation component, where it contributes to disease pathogenesis and is a target for
many clinically used non-steroidal anti-inflammatory drugs (NSAIDs).33 Celecoxib, a
selective COX-2 inhibitor has shown preclinical and clinical efficacy in cancer, RA,
neurological disorders, and atherosclerosis34-40 through its inhibitory effect on
prostaglandin E2 (PGE2) production and macrophage infiltration. Large oral doses of
celecoxib are associated with cardio-toxicity, which potentiates the use of alternate
delivery routes.41-46 Therefore, NP theranostics could reduce celecoxib-associated toxicity
and facilitate drug delivery to macrophages for COX-2 inhibition, as well as monitor
response by imaging macrophages and evaluating the dynamics of infiltration as a
function of time and therapeutic delivery.
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Figure 1.3. Current and future use of imaging functionality of macrophage
theranostics.
Black arrows show the current areas where the imaging aspect of theranostics is used as
reported in the literature. Red dotted line shows the possible future use.

As discussed previously, utilization of the imaging feature of macrophage
theranostics was limited to in vitro characterization, in vivo biodistribution, and ex vivo
histological analysis (Figure 1.3). We believe that simultaneous investigation of imaging
and therapeutic aspects of disease treatment to monitor therapy will make the
combinatorial approach more efficient for personalized medicine. To date, simultaneous
therapeutic delivery and response monitoring using a single theranostic entity were not
reported. We proposed that this could be achieved by exploiting the physiological and
pathophysiological aspects i.e. phagocytic potential of macrophages, involvement in
disease pathogenesis47, migration to inflamed sites, and accumulation changes in
response to the treatment.29
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In summary, this dissertation addresses the current challenge of theranostics and
demonstrates response monitoring by exploiting the therapeutic and diagnostic roles of
macrophages. By design, this approach is generally applicable to different inflammatory
diseases, where macrophages play pathological role and possess diagnostic significance.
The work presented in this dissertation is believed to advance the field and fuel additional
research by increasing the utilization of imaging and therapeutic functionalities.

1.2 Rationale, study hypothesis and aims
A careful investigation of current literature (chapters 1 and 2) and our own data
(chapters 4, 5, and 6) shows the following crucial findings relevant to macrophagetargeted theranostics. 1) Macrophages are a key cell type involved in the pathogenesis of
inflammatory diseases. 2) Macrophages and COX-2 are abundantly present in
inflammatory diseases making them feasible targets for therapy and diagnosis. 3)
Inhibition of myeloid COX-2 has shown efficacy in inflammation models. 4) Inhibition
of COX-2 using celecoxib has shown to reduce inflammation by inhibiting PGE2 and
leukocyte recruitment. 5) Long term oral use of celecoxib is associated with
cardiovascular and renal toxicity. 6) Macrophages can readily internalize NPs and
migrate to the sites of inflammation. 7) Dual mode perfluorocarbon (PFC) nanoemulsions
can provide unambiguous detection of macrophage infiltration in inflammatory diseases
using fluorescence and
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F magnetic resonance imaging (19F MRI) and can facilitate in

vitro/ex vivo characterization using fluorescent methods.
The combination of these findings prompted us to target macrophage COX-2
with a fluorescent PFC nanoemulsion incorporating celecoxib for simultaneous
therapeutic and diagnostic effects. Newer reports are emerging where NPs were utilized
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to inhibit or silence COX-2 in macrophages to treat underlying pathology.
Chitosan/siRNA (small interfering ribonucleic acid) NPs were used to silence
macrophage COX-2 in kidney injury.48 Celecoxib NPs were investigated to target
macrophage COX-2 in a breast cancer animal model as a possible chemotherapeutic and
chemopreventive strategy.49 Although theranostic aspects are not investigated, these
studies are encouraging and further support our lead hypothesis identifying macrophage
COX-2 as a generalizable anti-inflammatory intervention target.
By exploiting the natural phagocytic ability and disease-migration aspects of
macrophages, we aimed to detect the inflammatory loci, deliver celecoxib to
macrophages, and monitor temporal changes in infiltration in response to therapeutic
delivery using fluorescent PFC nanoemulsions. This dissertation is based on the central
hypothesis that celecoxib-loaded fluorescent PFC nanoemulsions produce antiinflammatory effects while facilitating simultaneous imaging by optical fluorescence
and 19F magnetic resonance of activated macrophages in an adjuvant-induced murine
inflammation model. The following aims were proposed.
Aim 1: Preparation, characterization and optimization of PFC nanoemulsions
encapsulating celecoxib and near-infrared fluorescent (NIRF) dye and demonstration of
acceptable stability and toxicity profiles.
Aim 2: Characterization of PFC nanoemulsions in mouse macrophages for toxicity,
uptake, and COX-2 inhibition.
Aim 3: In vivo assessment of celecoxib-loaded theranostic nanoemulsion for antiinflammatory effect and imaging efficacy in an adjuvant-induced mouse inflammation
model.

11

Through these study aims, PFC nanoemulsions were developed for macrophage
imaging and assessment of infiltration changes. Efforts made to prepare a stable nontoxic nanoemulsion with optimized imaging potential are summarized in chapters 3, 4, 5,
and 6. Chapter 3 deals with the synthesis and characterization of PFC-lipid conjugates,
formulation development, characterization for colloidal attributes, toxicity and uptake
evaluation in model mouse macrophages of a candidate conjugate (C8-PFTE). Due to
slight toxic effect on cell viability and further development anticipated to be costineffective, the focus shifted to a commercially available and clinically utilized PFC,
perfluoropoly (ethylene glycol) ether (PFPE). The development and in vitro assessment
as well as problems encountered with 19F MR imaging aspects of PFPE nanoemulsion are
described in chapters 4 and 5. Ultimately, the development of an improved formulation
with higher PFPE content with desired stability and in vitro efficacy is demonstrated in
chapter 6.
Chapter 7 describes the in vivo assessment of theranostic systems in adjuvant
induced mouse paw edema and rat neuronal injury inflammatory models. In this chapter,
combination of in vivo live animal imaging and ex vivo tissue analysis showed the
specific accumulation of nanoemulsion in macrophages at the inflamed site. Furthermore,
simultaneous therapy and monitoring changes in macrophage infiltration is demonstrated.
Pain sensitivity reduction in the neuronal injury model further validated the approach of
inhibiting COX-2 in macrophages for therapy and diagnostic imaging.
This dissertation demonstrates that targeting macrophage COX-2 has the potential
to be a general approach applicable to inflammatory diseases, that provides
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individualized treatment options based on the patient’s response to the treatment, namely
the extent of macrophage infiltration and associated temporal changes.

1.3 Role of macrophages in therapy and diagnosis of inflammation
Inflammation can be broadly defined as a host’s response to infection, injury or
metabolic imbalance, which acts to restore homeostasis.4 It represents a highly complex
network of cellular and sub-cellular components, which work in a regulated fashion to
defend the host against deleterious stimuli.3 In a typical inflammation setting, local
endothelial and immune cells release inflammatory mediators, which increase blood flow
and vascular permeability at the site. Leukocytes such as neutrophils and macrophages
migrate to the site of injury based on released chemotactic factors (cytokines and
chemokines) by a process known as diapedesis.50 The inflammatory endothelium and
local immune cells also upregulate cell adhesion molecules (CAMs) such as selectins,
integrins, and cadherins, which further aid in the adhesion and transmigration of
leukocytes.50,51 Neutrophils are recruited first to the site of injury and they act to remove
the injurious stimuli by phagocytosis and the release of inflammatory mediators.
Neutrophils are present in the first few hours to days, while macrophages are recruited by
further downstream signals to aid in resolution and repair.51 Macrophages populate the
inflammation sites to neutralize the injurious stimuli by modulation of adaptive
immunity, tissue remodeling, and removal of pathogens, cell debris, and senescent cells.52
This cascade is known as acute inflammation, which is self-limiting and results in the
restoration of homeostasis (Figure 1.4). Failure to cease the injurious stimuli leads to
persistent (chronic) inflammation resulting in tissue damage (Figure 1.4).
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Figure 1.4. Schematic showing acute and chronic inflammatory events
A. Features of acute inflammation are summarized as presentation of pathogen-associated
molecular patterns (PAMPs) to the recognition receptors, which illicit inflammatory
response with macrophage recruitment and removal of pathogen. Reversible damage
created during this process is resolved leading to restoration of homeostasis. B.
Presentation of damage-associated molecular patterns (DAMPs) leads to initial response
through cytokines and chemokines produced by immune cells, which cannot eradicate the
stimulus. Persistent stimulus leads to amplification of signal by positively influencing the
production of DAMPs leading to tissue damage and chronic inflammation. From: Tabas
I, Glass CK 2013. Anti-inflammatory therapy in chronic disease: challenges and
opportunities. Science 339(6116):166-172.1 Reproduced with permission from AAAS.
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Macrophages are a type of leukocyte belonging to the mononuclear phagocytic
system, derived from progenitor cells of hematopoietic origin in bone marrow.53 They are
replenished on a regular basis from circulating blood monocytes.53 Macrophages are
constitutively present in all tissues, where they participate in tissue survival, regulation
and modeling processes.52 Their primary function is to clear apoptotic cells and cellular
debris generated during tissue remodeling and necrosis. In addition to these homeostatic
roles, macrophages are essential immune cells that participate in both innate and adaptive
immunity.47 During the chronic phase, macrophages are continuously recruited and
release inflammatory mediators such as chemokines, cytokines, lipid mediators, proteases
and reactive oxygen species (ROS).47 These mediators cause detrimental effects to the
host leading to initiation, exacerbation and progression of several infectious and noninfectious diseases.
1.3.1 Macrophages in inflammatory diseases – potential for therapy
There is increasing evidence that macrophages significantly contribute to the
pathogenesis of many common chronic diseases. This section is primarily focused on
pathologies involving non-infectious chronic inflammatory conditions. One example of
these is RA, in which macrophages play a prominent role through their production of
inflammatory mediators such as TNF-α, which can cause considerable inflammation and
joint destruction.54 Another example is Type 2 diabetes, in which accumulation of
macrophages is associated with several complications such as neuropathy, nephropathy
and atherosclerosis.55 A third example is atherosclerosis, in which macrophages uptake
low density lipoprotein and transform into lipid-laden cells called foam cells that
contribute to the initiation and progression of atherosclerotic lesions.56 Additionally,
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proteases produced by macrophages degrade the extracellular matrix (ECM), which leads
to plaque rupture and myocardial infarction (MI). In cancer, tumor-associated
macrophages (TAMs) are involved in several tumorigenic activities leading to
angiogenesis and metástasis.57 Similarly, macrophages are involved in several stages of
pathogenesis in neurological, autoimmune, cardiovascular and pulmonary diseases.54,58,59
In addition to the discussed pathogenic roles, macrophages also display protective
functions in chronic inflammatory diseases. Depending on the pathological environment,
they adapt to different phenotypes, which, either intensify or resolve the disease.52 They
are broadly classified as classically activated (M1) pro-inflammatory and alternatively
activated anti-inflammatory (M2) phenotypes mirroring Th1 and Th2 states of T cells.60
Due to the vast biochemical and physiological differences within M1 and M2, it was
suggested that macrophages form part of a continuum and possess overlapping functions
of different macrophage subsets. For the purpose of this discussion, only the two extreme
states of macrophages, M1 and M2 are considered. The diverse roles of macrophages are
attributed to these phenotypes. For example, TAMs exhibit M1 and M2 phenotypes
depending on the local cytokine milieu. M2 macrophages are involved in the release of
growth factors, angiogenesis and degradation of the ECM leading to metastasis, while
M1 macrophages exhibit tumoricidal activity.61 In atherosclerosis, macrophages
participate in the initiation, progression and rupturing of atheroma.62 In contrast, a subset
of macrophages (M2) is involved in the resolution of the disease and tissue remodeling.63
Likewise, macrophages play a diverse role in autoimmune,54 pulmonary,58 and
neurological diseases.59 Therefore, macrophages represent promising targets for the
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treatment of inflammatory diseases. Section 1.5 reviews some of the targets expressed by
macrophages that can be intercepted by anti-inflammatory therapies.
1.3.2 Imaging macrophages and disease diagnosis
Imaging tools are indispensible in advancing our understanding of diseases for
improved drug design and also for disease detection, diagnosis and assessment of
treatment effects. Prime reasons to utilize macrophages for disease diagnosis include: (1)
their abundance in the inflammatory milieu (2) their migration to the diseased locales and
(3) the correlation observed between macrophage number and disease severity. A recent
review by Weissleder et al.64 detailed the aspects of nanomaterials and imaging
modalities for macrophage detection in inflammatory diseases in both preclinical and
clinical settings. Magnetic resonance imaging (MRI) contrast agents, namely iron oxide
nanoparticles (IONPs) and ultrasmall paramagnetic iron oxide (USPIO) NPs that are
internalized by macrophages and infiltrate the inflamed site have been used clinically for
non-invasive detection of atherosclerosis65, MI66, and type 1 diabetes.67 Trivedi et al.65
applied USPIO NPs (Sinerem®, Guerbet, now withdrawn) to detect atherosclerotic
plaques using MRI, which could be a viable diagnostic method to identify patients with
high-risk for plaque rupture. A macrophage-targeted PET tracer was investigated for its
ability to detect early synovitis in arthritic patients.68 The study identified that the
accumulation of PET tracer is proportional to disease severity. Also, detection of PET
tracer in the contralateral knee of the arthritic patients provided possibility of using this
mode of macrophage imaging to detect subclinical synovitis. The effect of atorvastatin
therapy was monitored by imaging macrophages using USPIO-enhanced MRI in the
well-known ATHERMO (Atorvastatin Therapy: Effects on Reduction of Macrophage
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Activity) study.69 Significant changes in signal intensity compared to baseline were
observed with treatment in the carotid plaque, indicating changes in macrophage
accumulation. These studies strongly support the use of macrophages as biomarkers for
disease detection, disease severity assessment, and treatment effectiveness. Imaging
macrophages has the potential to be a generalized method for disease diagnosis and
prognosis, thus driving the personalized medicine in inflammatory diseases.

1.4 Nanosystem design considerations for effective macrophage targeting
NPs have been utilized to deliver imaging and therapeutic agents to macrophages
with or without targeting ligands,70 because they are readily internalized by macrophages’
natural phagocytic ability (“big eaters”). Although macrophages can readily internalize
NPs, several attributes, namely size, shape, surface charge, concentration, targeting
ligands, and surface functionalization with PEG influence the in vivo targeting efficiency
and performance. One of the major limitations of current nanomedicine formulations is
their non-specific uptake by macrophages of reticuloendothelial system (RES), which
reduce both blood circulation time and target site accumulation. However, this aspect can
be exploited for macrophage-targeted therapies.
Macrophages exhibit size-, concentration- and time-dependent uptake of NPs.
Cell surface is negative and hence it has been proposed that positively charged NPs can
bind to the cell surface and be internalized.71 However, many reports suggest that this
effect is true for non-phagocytic cells. It should be noted that positively charged NPs
induce cytotoxicity, thus reducing biocompatibility. Contrary to the uptake behavior of
non-phagocytic cells, phagocytic cells show preferential uptake of anionic NPs.72 For
liposomal formulation, highly charged anionic and cationic formulations show greater
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uptake compared to the neutral ones.32,73 Negatively charged liposomes display greater
biocompatibility. One report claims that NP size is a stronger determinant of macrophage
uptake than charge,74 with 100 nm particles showing greater uptake than 40 nm. It is
likely that larger particles can bind to multiple receptors triggering internalization
through clustered receptors.
NPs in circulation possess different properties due to electrostatic interactions
with serum components, protein adsorption and opsonization, which can mask their
native surface functional groups and charge, giving them a different set of properties for
uptake. The recognition of NPs for uptake is mediated by opsonin coating (e.g. IgG) in
the blood stream and subsequent interaction with cell surface receptors (Fc) for uptake.
The extent of coating and recognition depends on size, surface charge, and the presence
of functional groups. Finally, surface presence of PEG is essential for NP stability in the
aqueous medium and for increase in blood circulation time. However, PEG can reduce
the opsonization process and hence the uptake potential.75 Therefore, a critical balance
needs to be established to obtain NPs displaying high stability and uptake in
macrophages.
In addition to these passive targeting approaches, targeting ligands can be used to
increase uptake. Macrophages express several receptors that have been targeted with
ligands such as dextran, folic acid, mannose, hyaluronate, and tuftsin, antibodies against
F4/80 and cluster of differentiation (CD) 169.26,73,76,77 The disrupted vasculature in the
inflammatory environment provides an additional opportunity to passively target
nanosystems.25,26,78 Monocytes and macrophages have an intrinsic disease-homing
property, which can be utilized for delivering NPs to inflamed sites.25,26 Through these
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properties, macrophages have been used as Trojan horses to deliver drugs and imaging
agents to the disease site.26
While a universal criterion for NP design is not feasible to propose based on the
literature, some features can be considered for effective macrophage uptake. The size of
the nanosystem is a critical factor identified in many studies, with >100 nm showing
significant uptake. Charge effect on differential uptake of NPs is documented; it is
conceivable to use neutral or anionic NPs to avoid biocompatibility problems generally
associated with cationic NPs. The concentration of surface PEG should balance stability
and uptake. Finally, targeting ligands can be utilized to increase cell uptake, but synthesis
of these conjugates, cost, and large-scale production entail careful evaluation. Unlike
cancer or endothelial cells, the use of targeting ligands has lesser effect on uptake in
macrophages because macrophages possess intrinsic phagocytic ability. Active targeting
strategies could be highly useful to preferentially target a specific macrophage phenotype.

1.5 Theranostics for macrophage detection and therapy – state of the art
Anti-inflammatory therapies targeting macrophages by specific ablation,
inhibition of their infiltration and reduction of pro-inflammatory mediator release have
been applied in RA, atherosclerosis, vascular injury and cancer. However, variable
efficacy results across the patient population were observed.14,15,79,80 In some instances,
significant depletion of macrophages has been associated with immunosuppression,
infection81 and reduced wound healing.82 This combination of therapeutic and harmful
effects can be attributed to the different activated states of macrophages in disease
environments. To delineate the protective and detrimental effects of targeting
macrophages, there is a need to bring therapy and diagnosis together. In this regard,
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theranostics could provide essential information about the delivery of drug carriers to
macrophages as well as their biodistribution, treatment efficacy and toxicity profile in
real-time, leading to better therapeutic intervention. Table 1.1 shows a summary of the
theranostics reported in the literature, different targets, targeting ligands utilized and
comments showing the highlights of the study. A schematic of multifunctional
theranostics for macrophages is shown in Figure 1.5.

Figure 1.5. Schematic showing the multifunctional theranostic systems utilized for
imaging and therapy of macrophages. Originally published elsewhere.2

1.5.1 Theranostics for macrophage ablation
Photo and chemotherapy based approaches are utilized to reduce macrophage
numbers at the diseased site. Reduction in these cells deprives the pathological
environment of macrophage-mediated pro-inflammatory mechanisms, and thus reduces
inflammation. Selective macrophage ablation was the major strategy used in
experimental studies to investigate their role in pathogenesis of several diseases.
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Macrophage depletion has been applied in the treatment of atherosclerosis,83 restenosis,84
RA,85 and cancer86 in preclinical and clinical subjects.
Photodynamic therapy (PDT) and Photothermal therapy (PTT) are treatment
modalities that use a combination of light and a photoactive agent to induce cell death.
PDT uses photosensitizers that produce cytotoxic oxygen species upon illumination.87
PTT utilizes photoabsorbers such as organic dyes to generate localized hyperthermia
upon illumination by visible to near-infrared (NIR) light.88 Hyperthermia can induce cell
death by protein denaturation and disruption of the cytoskeleton. In PDT and PTT, NIRactive (650-900 nm) material is preferred to enable treatment of deep tissues (up to a few
centimeters) and also to reduce tissue scattering effects, which allows for reliable
imaging. Since photosensitizer/photoabsorber accumulation and photo-irradiation are
required for cell death, these are selective techniques. PDT and PTT agents can be
referred to as theranostics due to their inherent fluorescence/absorbance and their ability
to induce cell death. Of note, light based therapies are already applied clinically to treat
cancer, skin conditions and other surface accessible pathologies.87
Several NPs incorporating photosensitizers for disease imaging and macrophage
ablation have been reported as shown in Table 1.1. Some of these theranostics were
designed to increase macrophage uptake through targeting ligands such as hyaluronic
acid and dextran. Theranostics have been investigated to detect and deplete macrophages
in arthritic joints89 and atherosclerotic plaques.90,91 Imaging the theranostic facilitated the
detection of arthritic joints, the assessment of residence time and the directing of light.89
To confer additional selectivity, a stimuli-responsive theranostic was also reported, which
utilized protease activation to selectively deplete cathepsin-B (Cat B) producing

22

macrophages.92 Cathepsin is a protease enzyme involved in matrix degradation, which
can cause plaque rupture.
For PTT, several nanomaterials such as gold nanorods (GNRs), nanoshells and
carbon nanotubes have been studied as NIR absorbing materials.93-95 These materials
have optical properties that can be used for in vitro and in vivo imaging. As outlined in
Table 1.1, targeted and non-targeted NPs have been investigated for photothermal
ablation of macrophages. For example, dextranated IONPs with surface gold coating
were used for thermal ablation of atherosclerotic macrophages.95 GNRs coated with
dextran or a macrophage targeting monoclonal antibody (CD11b) were tested in vitro for
their cytotoxic potential.94,96
Limited light penetration makes photo-based therapies impractical for
inflammatory conditions in deeper tissues where surgical or invasive endoscopic
intervention is required, as performed in some of the studies in Table 1.1. In these
conditions, target-specific accumulation of cytotoxic chemotherapeutic drugs could be an
alternative. Several cytotoxic drugs such as clodronate, glucocorticoids, doxorubicin and
methotrexate are utilized for this purpose.97-99 Systemic release of a cytotoxic drug can
reduce the global macrophage population, thereby affecting homeostasis and making the
host prone to infections. In this regard, theranostics could be employed to target cytotoxic
drugs to inflamed tissue through EPR, while the imaging functionality could help
visualize biodistribution. For example, the effect of prednisolone phosphate encapsulated
in MRI-fluorescence active liposomes was studied on TAMs.98 Fluorescence was used
for histological analysis and microscopy, while contrast enhanced MRI with gadolinium
(Gd) liposomes was used to evaluate drug delivery to the tumor site and intra-tumoral
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theranostic distribution in a mouse melanoma model. Imaging has assisted in the
quantification of theranostic reaching the tumor site, which was found to be 5% in TAMs.
However, a 90% reduction in systemic leukocyte count was observed. This reduction, as
opposed to TAM depletion, could be the reason for therapeutic efficacy. While systemic
reduction could reduce the tumor-infiltrating monocytes, a high drop in their count could
make the host susceptible to infections. This study highlighted the importance of imaging
functionality in the theranostic, which facilitated in the interpretation of mechanism of
anticancer effect caused by these liposomes.
Macrophage ablation therapies are inherently aggressive; therefore, selectivity is
very crucial to reduce immunosuppression and infections. Although light-mediated
theranostics are selective, they have been shown to cause significant tissue damage and
induce inflammatory reactions, which could lead to recurrence of the disease.100
Additional challenges included focused irradiation of target tissues, release of cellular
products

post

cell

death,

toxicity

due

to

long

term

accumulation

of

photosensitizers/photoabsorbers, light penetration depth in clinical subjects and
dissipation of heat by blood flow. It is important to note that in certain diseases, a subset
of macrophages show beneficial effects (e.g. M2 macrophages in atherosclerosis), and
their depletion could hamper wound healing. Chemotherapeutic ablation of macrophages
is useful in the treatment of deep-tissue pathologies that are inaccessible by PDT and
PTT. Conferring the theranostic with tissue selectivity by targeting ligands, stimuli
sensitivity, or external activation is vital in order to confine the activity to the target
tissue. Although these aggressive approaches are valuable in life-threatening diseases
such as cancer and less invasive alternatives need to be explored.
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1.5.2 Theranostics utilizing non-ablation approaches
Reducing the pathogenic activity of macrophages could be promising since this
approach would avoid detrimental effects caused by macrophage ablation and the
released toxic products. Macrophages produce a plethora of pro-inflammatory mediators
that damage the host tissue and these can be targeted by theranostics.
Harel-Adar et al.101 reported the utility of phosphatidylserine-presenting iron
oxide loaded liposomes to modulate macrophage phenotype in MI. PS is expressed on
apoptotic cells, which are recognized by macrophages and cleared. Apoptotic cells inhibit
the production of pro-inflammatory cytokines from macrophages concomitant with the
secretion of anti-inflammatory cytokines. The presence of iron oxide enabled
visualization of theranostic accumulation at the infarct site after femoral vein injection in
a rat model of acute MI. Following uptake of PS-liposomes by macrophages, an increase
in anti-inflammatory markers and a reduction in pro-inflammatory markers were
observed both in vitro and in vivo showing the shift of macrophage phenotypes from M1
to M2. In vivo, theranostic-treated rats showed effective wound healing. Such
theranostics could also be effective in other diseases. For example, celecoxib theranostic
could be applied in cancer because celecoxib has shown to change the TAM phenotype
from pro-tumor (M2) to tumoricidal M1-like.102 Specific receptors are expressed by
macrophages displaying different phenotype, which could be used for selective
targeting.103,104
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Table 1.1. Table summarizing macrophage-targeted theranostics reported in the literature
Target
Synovial macrophages 89a

Theranostic
Nanogels incorporating
photosensitizer
Cross-linked IONPs
incorporating
photosensitizer
Protease activated
photodynamic agent

Ligand
Hyaluronic
acid
Dextran

Disease model
Arthritic mouse

None

Atherosclerotic
mouse

Dextran

Macrophages in vitro 96a

Surface gold coated
IONPs
GNRs

Atherosclerotic
rabbit model
-

Macrophages in vitro 94a

GNRs

Plaque macrophages 93a

Single walled carbon
nanotubes
Prednisolone phosphate
encapsulating Gdfluorescent liposomes

-

Coumarin-6 incorporating
SPIO-PLGA NPs with
cytotoxic methotrexate
and clodronate
Phosphatidyl serineliposomes

F4/F80
antibody

-

-

Acute MI rat
model

Plaque macrophages 90,91a
Cat B-producing
macrophages 92a
Plaque macrophages 95a
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TAMs 98a

In vitro macrophages 99b

Infarct macrophages 101b

CD11b
antibody
Dextran

-

Atherosclerotic
mouse

Atherosclerosis
mouse
Melanoma
mouse

Comments
Imaging to visualize joint retention time,
invasive local injection
Imaging to visualize plaque macrophages
and guide therapy, PDT after surgical
exposure of carotid artery
Imaging to visualize uptake and therapy
response, selective for CatB-producing
macrophages, multiple i.v.
administration
Imaging to visualize uptake in
macrophages in histological samples
Similar cell death between naked and
targeted GNRs
Increased cell death with targeted
compared to naked GNRs
Imaging to visualize accumulation in
ligated carotid arteries, ex vivo PTT
Dual mode imaging, fluorescence for
histology and MRI to assess intratumoral
distribution and therapy effect
(measuring tumor size by MRI)
Fluorescence imaging to assess
macrophage uptake in vitro
MRI used to visualize infarct
accumulation of liposomes, in vivo
studies showed phenotype change (M1 to
M2)

MCP-1/CCR2
inflammatory
monocytes/macrophages

Fluorescently-tagged
siRNA-loaded theranostic
lipid NP

-

Fluorescently-tagged
microparticles
incorporating Map4k4
siRNA
Fluorescent
Supramolecular selfassembled NPs

1,3-βglucan

105b

TNF-α 106b

TNF-α 107b

TNF-α from synovial
macrophages 108b
Hydrogen peroxide 109b
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Myeloid-related protein8/14 110b

a

Anti-TNF-α siRNAloaded fluorescent
liposomes (wraposomes)
Chemiluminescent antioxidant Pluronic® F127
micelles incorporating
hydroxyl benzyl alcohol
(HBA) and a fluorescent
dye
anti-Mrp antibody coupled
with Gd NP

MI,
atherosclerosis,
diabetes and
cancer
LPS-injected
mouse

Mannose,
chitosan,
cysteamin,
polypeptide
-

LPS-induced
mouse hepatic
injury

-

LPS-induced
inflammation
(s.c.) mouse
model

PS and ωcarboxynon
anoylcholesteryl
ester

Atherosclerotic
mouse model

Arthritis mouse
model

Fluorescence imaging for
biodistribution, target site accumulation
and histology
Fluorescence imaging to assess tissue
and cellular uptake, oral delivery to
reduce systemic TNF-α, high dosing
frequency
Multivalent targeting, fluorescence
imaging for biodistribution, single oral
dose lead to 80% reduction in systemic
TNF-α
Fluorescence imaging for
biodistribution, accumulation in 70% of
synovial macrophages
Fluorescent imaging was stimulisensitive (hydrogen peroxide)

Plaque distribution by MRI

Macrophage ablation; bNon-ablation approach
PLGA - poly(lactic-co-glycolic acid); i.v. - intravenous; LPS – lipopolysaccharide; MCP-1 - monocyte chemoattractant protein-1

Pro-inflammatory mediators produced by macrophages have been targeted for
simultaneous therapeutic delivery and imaging. Monocyte chemoattractant protein-1
(MCP-1) is a chemokine upregulated in inflammatory monocytes/macrophages, which is
involved in their movement to the disease site. Leuschner et al. developed a
fluorescently-tagged siRNA (small interfering RNA)-loaded theranostic lipid NP for
CCR2 silencing activity in inflammatory monocytes.105 A detailed study outlining the
utility of this delivery vehicle in MI, atherosclerosis, diabetes and cancer showed
compelling results.

Fluorescence

imaging

was

used

to

visualize NP/siRNA

biodistribution, which were predominantly present in splenic, bone marrow and blood
inflammatory monocytes. In addition to MCP-1, CAMs can also be targeted to reduce
macrophage infiltration.
Dysregulated production of TNF-α, a potent pro-inflammatory cytokine produced
by M1 macrophages, has been implicated in cancer, RA, IBD, and Alzheimer’s disease
(AD).111,112 Theranostics facilitated the targeted delivery of TNF-α inhibitors, such as
siRNA, to inflammatory macrophages and increased their oral absorption.106,107 These
theranostics were surface functionalized with multivalent targeting capabilities (Table
1.1) for increased uptake. Komano et al. reported the use of anti-TNF-α siRNA-loaded
liposomes called wraposomes that targeted synovial macrophages in a mouse model of
arthritis.108 Despite the absence of a targeting moiety, 70% of synovial macrophages were
shown to uptake the theranostic. In these studies, imaging was utilized to confirm uptake
in macrophages and to assess biodistribution.
Excessive production of ROS can cause oxidative stress in diseases. Activated
macrophages and neutrophils are the major source of ROS in the inflammatory

28

environment. Cho et al. showed in vitro and in vivo the anti-inflammatory activity of
stimuli-responsive chemiluminescent antioxidant micelles that incorporated the
antioxidant, hydroxyl benzyl alcohol and a fluorescent dye.109 The presence of ROS
(H2O2) resulted in a POCL (peroxylate chemiluminescence) reaction that lead to the
transfer of energy to the nearby dye, causing the dye to fluoresce. The stimuli-sensitive
fluorescence of this theranostic was verified in an inflammation model. It could enable
detection of the ROS-active inflamed site as well as assessment of therapeutic effect
because reduction in ROS will lead to reduced fluorescence.
Mrp-8/14 is a member of the S100-family of Ca2+-modulated proteins. It
participates in vascular inflammation, macrophage recruitment, and pro-inflammatory
cytokine release. Mrp-8/14 is detected in the cytoplasm of neutrophils and macrophages.
Maiseyeu et al. targeted Mrp-8/14 in a mouse atherosclerotic model using a multivalent
theranostic containing PS, ω-carboxynonanoyl-cholesteryl ester and an anti-Mrp antibody
coupled with Gd-NP (aMrp-NP).110 The ω-carboxynonanoyl-cholesteryl ester (expressed
on foam cells) and PS were utilized for uptake by macrophages, whereas the anti-Mrp
antibody was used as an anchor for retention in atherosclerotic plaques. In vitro studies in
BMDMs of the atherosclerotic mouse showed neutralization of Mrp 8/14 proinflammatory effects with aMrp-NP, potentially caused by antigen-antibody interactions.
In vivo MRI studies in the murine atherosclerotic model confirmed the presence of aMrpNP around the plaque.
In addition to the above-discussed targets, macrophages express many enzymatic,
protein and lipid based targets for therapeutic intervention. Compared to aggressive
macrophage depletion, these approaches are non-destructive and the likelihood of benign
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tissue damage is minimal, since no cytotoxic products are released. These studies
demonstrate the feasibility of targeting macrophages for simultaneous imaging and
therapy using a variety of theranostic systems.
1.5.3 Conclusions, Limitations and Future Perspective
As detailed in this chapter, macrophage-targeted theranostics have shown
promising results in preclinical models for simultaneous imaging and therapy. A number
of molecular targets in macrophages that are indicated in several diseases were
investigated. Based on these studies, it can be concluded that the theranostics targeting of
macrophages holds great promise for diagnosis and treatment of the inflammatory
diseases, which could lead to effective disease management.
However, limitations in current technology pertaining to the choice of imaging
and therapeutic functionalities, and the utility of imaging aspect still need to be
addressed. For example, the majority of the presented theranostics utilized optical
imaging, which is limited by light penetration. Optical imaging can be reserved for
surface pathologies, histological analysis and preclinical evaluation. To obtain unlimited
tissue penetration in clinical subjects, theranostics that incorporate paramagnetic MRI
contrast agents can be used, but the inherent tissue background limits unambiguous
detection of macrophages. An alternative method is 19F MRI, which detects fluorine (19F)
from externally introduced PFCs. This imaging technique holds great potential due to
near-zero background leading to quantitative detection. 19F MRI aspects are discussed in
chapter 2, section 2.4.3.
Current anti-inflammatory therapies are majorly concentrated in targeting
inflammatory mediators such as TNF-α, prostaglandins (COX-2) and inhibition of
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macrophage migration. In this regard, biologics such as siRNA and monoclonal
antibodies have shown potent anti-inflammatory properties; however, these biologics are
usually associated with severe toxicities. While theranostics could limit these toxicities
by site-specific targeting, challenges associated with large-scale production of
biologics113 could add to the existing limitations of theranostics for clinical translation.
Alternately, small molecule anti-inflammatory drugs with well-characterized efficacy,
toxicity and safety profiles could be applied for theranostic research. Amongst these
drugs, NSAIDs have shown efficacy across inflammatory disease models. NSAIDs are
one of the commonly used anti-inflammatory drugs targeted against COX enzymes. The
role of COX-2 in inflammatory diseases is discussed in chapter 2.
Finally, as discussed earlier, therapy and imaging the response to the therapy have
been investigated separately. A simultaneous approach to monitor the therapy could be
very useful in the identification of the subgroup of patients that respond effectively to the
treatment (i.e. to the theranostic under investigation). To achieve this goal, our efforts
focused on the development of a macrophage COX-2 inhibiting theranostic. Chapter 2
details background information and the synthesis of rationale for the developed
theranostic.

Parts of chapter 1 were originally published in the review by Patel and Janjic.2
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2

Rationale for Perfluorocarbon nanoemulsions as a platform to
deliver celecoxib for COX-2 inhibition in macrophages

2.1 COX-2 in inflammatory diseases
Cyclooxygenase (COX) enzymes, COX-1 and COX-2 are involved in several
homeostatic functions. COX enzymes catalyze the conversion of arachidonic acid (AA)
into biologically active lipids called prostaglandins (PGs), namely PGG2 followed by
PGH2.114 AA is released from the plasma membranes in the presence of phospholipase A2
(Figure 2.1). PGH2 serves as a substrate for the formation of further downstream products
such as PGI2, PGD2, PGE2, PGF2α, and thromboxane A2 (TXA2), in the presence of
respective synthases. COX-1 is constitutively present and involved in ‘housekeeping’
functions such as the maintenance of gastric mucosa and renal blood flow.115 COX-2 is
induced in response to injury or inflammatory stimuli.114,115 The increased production of
PGs is responsible for pain, increased vascular permeability, edema and immune cell
infiltration observed during inflammation.116 Immune cell infiltration has been associated
with the effect of PGE2 on the upregulation of CAMs117 and MCP-1, which are involved
in leukocyte recruitment. MCP-1, for instance, is induced by activated PGE2/EP4
signaling.118
COX-2 plays an important role in the pathogenesis of inflammatory diseases,
where it is over-expressed. In fact, the development of COX-2 specific PET and
fluorescence imaging agents for cancer and inflammation detection signify the ubiquitous
presence of COX-2 in inflammatory diseases.119,120 For example, in osteoarthritis and
RA, the synovial cavity is infiltrated with cells expressing COX-2, which is responsible
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for pain. NSAIDs targeting COX-2 reduce pain and inflammation in arthritic patients.
Evidence of reduced inflammatory cell infiltrate and inflammation in the synovium was
also reported in a rat model of arthritis with selective COX-2 inhibition.121 In cancer,
COX-2 expression has been correlated with poor prognosis, increased angiogenesis and
metastasis. COX-2 silencing has shown delayed tumor formation and reduced metastasis
in preclinical models.122 COX-2-mediated release of PGE2 is involved in the suppression
of cancer cell apoptosis, increase in proliferation and angiogenesis.36 In support of these
properties, long-term use of selective COX-2 inhibitors has shown beneficial anticancer
effects in several clinical trials.123,124 COX-2 is also widely implicated in cardiovascular
diseases such as atherosclerosis,125 where it is involved in macrophage recruitment and
plaque rupture through MCP-1 and matrix metalloproteinases (MMPs). COX-2
expressing cells are present around the amyloid-plaques in AD,126 and selective COX-2
inhibitors have shown protection against AD. COX-2 is also shown to be involved in the
pathogenesis of Parkinson’s disease, where it can contribute to neurodegeneration by
oxidative stress.127
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Figure 2.1. Formation of prostanoids from arachidonic acid.
Phospholipase A2 converts membrane phospholipids to AA in response to stimuli, which
can be converted to different prostanoids under the action of COX-1/COX-2 and related
synthases.

2.1.1 COX-2 in monocytes and macrophages as a therapeutic target
Based on the studies presented in section 1.3.1 and section 2.1, COX-2 and
macrophages have been implicated separately and together in many inflammatory
diseases. Activated macrophages/monocytes such as TAMs in cancer and foam cells in
atherosclerosis are one of the key cells expressing COX-2 in the inflammatory milieu.
Therefore, we proposed that inhibition of macrophage COX-2 could be an effective
strategy to reduce inflammation.128 Consistent with this hypothesis, recent reports
indicate that targeting macrophage PGE2 can be applied to reduce cancer and
atherosclerosis. COX-2 is overexpressed in foam cells and its selective inhibition has
34

reduced early atherogenesis. PGE2 produced by COX-2 expressing macrophages has
been implicated in the release and activation of MMPs, which play an important role in
plaque stability and macrophage infiltration in atherosclerosis.125 A COX-dependent
pathway was indicated for monocyte chemotaxis in atherosclerosis.129 Consequently,
selective COX-2 inhibition by celecoxib has exhibited reduction in MCP-1 and
macrophage infiltration.40 Chen et al.130 recently reported that the deletion of myeloid cell
mPGES-1, which catalyzes the synthesis of PGE2, reduces atherogenesis in mice.
Likewise, deletion of COX-2 in myeloid cells contributed to reduced mammary tumor
growth through increased cytotoxic T-cell function.131 In AD, COX-2 expressing
macrophages were shown to infiltrate the brain and damage the blood brain barrier,126
indicating a potential therapeutic effect by targeting these cells. Evidence from the
literature supports that macrophage COX-2 inhibition could find widespread applicability
in inflammatory diseases.

2.2 Pharmacology of COX-2 inhibitor, celecoxib
Celecoxib (Figure 2.2) is one of the widely used NSAID for selective COX-2
inhibition. Celecoxib exhibits anti-inflammatory, analgesic and antipyretic activities. The
IC50 of celecoxib is 40 nM and it displays 375-fold higher selectivity for COX-2 over
COX-1 based on human recombinant enzyme assays.33 Unlike aspirin, celecoxib binds
reversibly to the COX-2 enzyme pocket. The binding pocket of the COX-2 enzyme
differs from COX-1 at one relevant position of 523. At this position, COX-2 has a valine
while COX-1 has an isoleucine. This difference causes celecoxib bind strongly to COX-2
and weakly to COX-1.34
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Celecoxib is a BCS (Biopharmaceutics classification system) class II drug with a
high membrane permeability (Log P = 3.64) and a low aqueous solubility of 7 μg/mL.132
It has low (22-40%) oral bioavailability in dogs133 (to our knowledge absolute
bioavailability in humans has not been reported). It is highly protein bound (90%) and it
is also rapidly eliminated from the plasma (t1/2 = 11.2 h).33,46,134 It is metabolized
primarily by cytochrome P450 enzyme, CYP2C9. Following hepatic metabolism,
celecoxib is eliminated in urine and feces.34 Celecoxib is prescribed to reduce pain and
inflammation in arthritis, juvenile RA, ankylosing spondylitis, and menstrual pain. It is
also prescribed to treat colon polyps. It is dosed perorally in tablets and capsules.

Figure 2.2. The chemical structure of celecoxib.

The therapeutic effects of celecoxib span a wide spectrum of inflammatory
diseases. Selective COX-2 inhibition with celecoxib has shown reduced atherosclerotic
lesions in the mouse model, possibly by reducing inflammatory cell recruitment due to its
inhibitory effect on the expression of CAMs.35 Reduced MCP-1 and macrophage
infiltration was also observed with celecoxib treatment in a rabbit model of
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atherosclerosis.40 It has been reported to suppress and delay tumor growth in preclinical
models.46,135 Epidemiological studies have provided evidence of reduced risk of colon,
breast, lung and prostate cancers with regular use of celecoxib.136 In cancer, it acts as a
multifunctional drug that simultaneously induces COX-2 independent apoptosis, inhibits
PGE2 mediated anti-apoptotic proteins and inhibits angiogenesis.36 Recently, celecoxib
has also been shown to alter the phenotype of macrophages from protumor (M2) to
antitumor (M1) subtype via COX-2 inhibition.102 It has been shown to reduce vascular
endothelial growth factor expression and vascular leakage, which are important
contributors to the pathogenesis of diabetic retinopathy.41 Celecoxib showed protection
against dopamine neuron loss in a preclinical model of Parkinson’s disease39, indicating
its applicability in neurodegenerative diseases.

2.3 Celecoxib toxicity and alternate formulations
Selective COX-2 inhibitors reduce the risk of gastrointestinal side effects, which
are associated with non-specific COX inhibitors. However, long-term use of specific
COX-2 inhibitors is associated with cardiovascular and renal toxicity, which led to the
withdrawal of Rofecoxib and Valdecoxib in 2004 and 2005 respectively. Selective COX2 inhibition reduces prostacyclin production by vascular endothelium, with no inhibitory
effect on TXA2 production. This selective reduction in protective prostacyclin predispose
patients to vascular injury and cardiac events such as MI.137 Celecoxib is generally well
tolerated, but in clinical cancer studies, high oral doses (200 – 400 mg, twice daily) were
administered for several months leading to cardiovascular side effects, which may be
severe.123 To overcome side effects and increase target site accumulation, which could
reduce the required dose, alternate formulations of celecoxib have been investigated.
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Microparticle and NP formulations of celecoxib have been attempted for specific delivery
of celecoxib to the target tissue. Celecoxib has been incorporated in albumin
microspheres,45 PLGA NPs,138 chitosan NPs,46 high density lipoprotein NPs,49
liposomes,139 and immunoliposomes140 for intravenous (i.v.) applications in RA and
cancer. Nanoemulsions, microemulsions and gels have been investigated for transdermal
delivery of celecoxib.44,141 To reduce toxicity associated with oral administration,
Soliman et al.44 reported microemulsion gels and tested the anti-inflammatory effect of
celecoxib via transdermal route in carrageenan-induced paw edema model. Using
radiolabeled celecoxib and microspheres, Thakkar et al.45 showed that microspheres
produced 2.5 fold greater accumulation in arthritic joints compared to control after i.v.
administration. The solution formulation of celecoxib revealed no difference between
control and arthritic knees. This study demonstrates the advantage of using colloidal
formulation to target inflamed sites for greater celecoxib accumulation. Likewise,
Venkatesan et al.46 used chitosan NPs to deliver celecoxib to colon cancer tissue, which
showed tumor inhibitory effects. To reduce side effects and increase local levels of
celecoxib, Kompella and group42 formulated celecoxib into microparticles, which showed
sustained release and reduced inflammation indicators in a diabetic retinopathy model
utilizing an ocular route of delivery. Based on the studies, it can be concluded that
alternate formulations and delivery routes have great potential to reduce limitations of
oral celecoxib delivery, while increasing efficacy and safety.
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2.4 Perfluorocarbon nanoemulsions
2.4.1 Perfluorocarbons in biomedical applications
PFCs are the hydrocarbons in which all or most of the hydrogens are replaced
with fluorine. Fluorine, being the most electronegative atom with low polarizability.
renders PFCs with strong intramolecular bonds and very weak intermolecular
interactions.142 Large numbers of low polarizable fluorine atoms and very weak van der
Waals forces render unique physicochemical properties to PFCs such as low cohesivity,
surface tension, viscosity, friction, aqueous solubility and diffusion rate, and high
spreading, fluidity, compressibility, thermal and chemical resistance, biological inertness,
high density, “superhydrophobicity” and lipophobicity.142,143 The low polorizability of
PFCs make them possess gas-like intermolecular bonds, thus leading to efficient gasdissolving capability. The large van der Waals radius of fluorine compared to hydrogen
(1.47 Å vs. 1.20 Å) makes fluorocarbon chains bulkier as compared to hydrocarbons. The
bulkiness of the fluorine and low polarizability results in both enhanced hydrophobicity
and lipophobicity. Due to the highly stable C-F bond, PFCs tend to show high chemical
and thermal resistance, as well as biological inertness.142
Since PFCs are non-toxic and biologically inert, they have been investigated for
more than 40 years in a variety of biomedical applications.143 Figure 2.3 shows some of
the PFCs widely investigated for biomedical applications. One of the earliest applications
utilized the oxygen carrying capacity of PFCs for organ preservation, wound healing,
liquid ventilation, and as artificial blood substitution. They have also been employed as
contrast agents for CT, sonography and MR imaging.144 The oxygen dissolving capacity
was also exploited to sense partial oxygen pressure in order to image tumor
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hypoxia.145,146 The biological inertness and the light refraction properties of PFC
polymers have also been applied in ophthalmology to prepare contact lenses and
implantable cornea lenses.147 PFC polymers were also used in reconstructive surgeries as
vascular grafts and other devices.143 Recently, there has been a renewed interest in the
application of PFCs for
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useful
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tracking

F MRI of externally injected formulations, which has been
cells

as

well

as

in
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macrophages/monocytes in a variety of diseases.148 One of the emerging applications of
PFCs is to combine their ultrasound echogenicity with the light absorbing potential of
NIR dyes to obtain hybrid photo-acoustic images.149

Figure 2.3. Chemical structures of PFCs utilized in biomedical applications.
Applications of these PFCs is described elsewhere.148,150-152
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2.4.2 Perfluorocarbons and challenges
Neat PFCs have been administered orally for image contrast purposes or directly
to tumor tissues for oxygen sensing.144 However, many applications necessitate access to
blood circulation through i.v. route. Oral administration shows only a miniscule amount
of PFCs in the systemic circulation. Neat PFCs cannot be injected because they are
hydrophobic and lipophobic and hence can lead to vascular embolism. They do not
interact with cell membranes and do not enter cells. Therefore, PFCs have been
emulsified with surfactants to obtain biocompatible submicron-sized emulsions (i.e.
nanoemulsions), which are typical formulations for in vivo applications. Chapter 3
provides more details about PFC formulations.
Although PFCs are biocompatible, there are several limitations when using them
for clinical applications. Due to their hydrophobic and lipophobic nature, PFCs do not
interact with biological material, and there are no known PFC-metabolizing enzymes,152
rendering them biologically inert. However, many PFCs tend to accumulate in the tissues
for a long time. They are eliminated in feces if administered orally. In i.v. applications,
their body residence time can range from a few hours to months depending on their
molecular weight, chemical structure, and vapor pressure. They are usually eliminated
through lungs and hence high vapor pressure PFCs such as perfluorohexane (Figure 2.3)
are exhaled faster. PFC emulsions accumulate in RES organs such as the liver and spleen,
and they are cleared based on their vapor pressure. PFCs with lipophilic character, such
as perfluorooctyl bromide (PFOB), are cleared relatively faster (biological t1/2 = 12 days)
when compared to fully fluorinated structures such as perfluoro-15-crown-5-ether (PFCE,
Figure 2.3) whose biological half-life is greater than 250 days.150 As a result, biomedical
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applications that demand the injection of large amounts of PFCs are usually limited to
preclinical research because high dose requirement makes obtaining regulatory approval
a challenge.
2.4.3 Fluorescent/19F MRI nanoemulsions as tools for drug delivery and
macrophage imaging
PFC nanoemulsions have been increasingly used to image macrophages using 19F
MRI. NIRF modified PFC nanoemulsions to facilitate in vitro and in vivo imaging and
confer multimodality have also been investigated. In this section, imaging modalities are
described, followed by nanoemulsion application for macrophage imaging and drug
delivery.
2.4.3.1

19F

magnetic resonance imaging

MRI is a commonly used non-invasive clinical diagnostic tool applied in
detection, staging, image guided surgery, and assessment of therapy responses in many
diseases. MRI can detect nuclei containing an odd number of protons or neutrons, which
exhibit spin. Charged nuclei with this spin produce a magnetic moment.153 In the
presence of a strong external magnetic field (1.5 to 11 Tesla), these magnetically
susceptible nuclei such as 1H align with the field and precess with a frequency called
Larmor frequency. The combined effect of these precessing nuclei contributes to the net
magnetization. Radio frequency pulses matching the Larmor frequency are then used to
tilt the nuclei away from the direction of the external magnetic field. Once the pulse is
removed, the nuclei release energy in the form of radio frequency signal and return to
their native alignment with the magnetic field, which is detected to construct an image.
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Based on the tissue environment, the density and relaxation properties of 1H nuclei vary
leading to contrast.
MRI can evidently delineate soft tissues and can be used for repetitive imaging
sessions. It has high spatial resolution (~100 μm) and unlimited tissue penetration.151
MRI has low sensitivity (10-3 to 10-9 M) and requires a long acquisition time.22 Signal to
noise ratio (SNR) in MRI can be increased by targeted contrast agents (SPIO or Gd),
which function by altering the relaxation time of the surrounding protons, thereby
producing contrast. Although contrast can enhance the local signal, the inherent
inhomogeneities of tissues limit the unambiguous detection of a pathological
condition.151
Alternatively, 19F MRI can be used to circumvent the mentioned limitations of 1H
MRI.

19

F MRI detects organic fluorine, which is introduced exogenously into the body.

Similar to 1H, the fluorine (19F) nucleus has a half spin, comparable MRI sensitivity
(83%) and resonance (differs by 6%) to 1H.154 Therefore, 1H MRI machines can detect
19

F nuclei by tuning to an appropriate frequency. 19F MRI is not contrast imaging because

there is virtually no imageable endogenous fluorine present in the body, except in the
bones and teeth, where it is immobilized and cannot be detected by general MRI
methods.155 Due to this near zero background,
1

19

F MRI is a highly quantitative method.

H MRI can be registered during the same session to obtain anatomical context for the 19F

signal. Similar to 1H MRI,

19

F MRI has low detection sensitivity, which necessitates the

introduction of highly fluorinated PFCs into the body in biocompatible formulations such
as NPs, liposomes and nanoemulsions. Unlike 1H contrast agents, imaging prior to PFC
administration is not required. Clinical use of
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19

F MRI is still in its infancy. However,

recently its use has been documented in cancer patients for imaging injected therapeutic
dendritic cells (DCs).156
2.4.3.2 Optical near-infrared fluorescence imaging
Optical fluorescence imaging is a widely employed tool for cellular, sub-cellular,
and whole animal imaging in preclinical research, due to its low cost and high detection
sensitivity (picomolar to femtomolar).22 Fluorescence is the emission of light of a longer
wavelength by molecules (fluorophores) absorbing a shorter wavelength of light. When
fluorophores absorb photons, they are transitioned to an excited state. In this excited
state, the molecule loses energy to its environment, finally returning to the ground
state.157 Because energy is dissipated in the excited state, the emitted light is seen at a
longer wavelength, which forms the basis for fluorescence detection methods. The
difference between the maxima of these excited and emitted light wavelengths is called
the stokes shift.157 Wavelengths in the visible to NIR region are used for fluorescence
imaging.158 Typically, an externally introduced fluorophore is used for fluorescence
imaging. Light scattering and tissue attenuation limits the use of fluorophores active in
the visible light region for deep tissue in vivo imaging. Absorption of tissue components,
namely hemoglobin, water and lipids, are low in the NIR region (650-900 nm).
Therefore, fluorophores active in the NIR region can reduce tissue absorption and
increase penetration depth up to few centimeters.158 Fluorescence imaging is regularly
used in preclinical settings to visualize macrophages and the bioaccumulation of NPs.64
Many organic and inorganic fluorescent dyes are used for this purpose such as cyanine
derivatives (indocyanine green) and quantum dots.159 Fluorescence imaging is clinically
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used for surface tissue imaging (breast), intravital microscopy, and real-time image
guided surgery.
Since no imaging modality provides all of the features for an optimal image
construction, multiple imaging agents are integrated onto a single platform. Multimodal
NPs with complementary imaging agents could offer high sensitivity detection,
anatomical localization, and data validation from different imaging modalities. NIRF
imaging is a promising technique due to low NIR absorbance by living tissues, high
detection sensitivity, and minimal autofluorescence, but it is limited by fluorescence
quenching, photobleaching, and tissue penetration.

19

F MRI has unlimited tissue

penetration and it is a quantitative method, but it requires relatively large amounts of 19F
nuclei (μM to mM) at the target site.155 By combining NIRF and

19

F MRI agents,

sensitivity, specificity, and high tissue penetration can be obtained.160 Aspects of
multimodal imaging applied to drug delivery and macrophage imaging is discussed in the
following section.
2.4.3.3 PFC nanoemulsions for drug delivery and imaging
19

F MRI has been widely investigated in the last decade for mostly cell tracking,

and inflammation imaging through macrophage detection. Excellent reviews have been
published in the area of in vivo cell tracking using

19

F MRI.151,152,161 Briefly, cells of

interest such as DCs and T-cells can be labeled ex vivo using PFC nanoemulsions and
injected into the subject. The fate of these cells in the intact animal can be studied using
19

F MRI. Cell tracking has been applied to investigate the dynamic accumulation and

clearance of T-cells from lymph nodes in a murine model.162 It has been used to visualize
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DC migration,163 as well as to investigate the disease homing aspects of diabetogenic Tcells in a diabetes model.164
A more recent application of PFC nanoemulsions is in situ labeling of
macrophages and imaging their accumulation to detect the inflammation loci. Successful
in vivo macrophage visualization using 19F MRI has been reported in a variety of chronic
inflammatory models such as cancer,165 RA,166 IBD,167 pulmonary inflammation,168 and
transplantation models.169 Balducci et al.166 utilized this approach to quantify
inflammation and assess treatment effect in a rat model of RA. Excellent correlation was
observed between clinical score of arthritis and the number of
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F atoms detected in the

arthritic joints. Furthermore, the effect of standard corticosteroid treatment showed a
reduction in 19F content indicating reduced inflammation. 19F MRI has been used in other
inflammation models (e.g. IBD and graft rejection), where the macrophage burden is
reduced with therapeutic intervention concomitant with reduced

19

F content.167,169

Recently multimodal fluorescent PFC nanoemulsions were investigated, where
fluorescent dye enabled characterization by commonly employed fluorescent methods.170
Balducci, and Wen et al.171 reported a NIRF fluorescent PFC nanoemulsion to detect
tumor-associated inflammation by 19F MRI and NIRF. A strong correlation between these
two imaging signals was observed in different organs. The presence of fluorescent dye
facilitated the assessment of nanoemulsion accumulation in specific cell type using flow
cytometry and histology.
The use of PFC nanoemulsions in drug delivery is slowly emerging. In these
applications, PFCs were utilized to facilitate imaging by

19

F MRI, ultrasound, and

photoacoustic methods.172-174 An additional use was to trigger drug release by ultrasound.
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Wickline and Lanza published several studies utilizing PFOB NPs incorporating
fumagilin, melittin and other drugs for contact-mediated drug delivery in many disease
models, which is reviewed elsewhere.175,176 In these studies, 19F MRI was used to detect
the inflamed site and assess NP distribution to confirm drug deposition at the target site.
Using an integrin-targeted PFC nanoemulsion, Fang et al.177 developed acoustically
active PFC nanoemulsions incorporating camptothecin and investigated in vitro
anticancer effect. PFC was used to trigger drug release with ultrasound. To date, PFC
nanoemulsions were never utilized to target macrophages in inflammation for
simultaneous drug delivery and imaging.
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3

Nanoemulsion development of a lipophilic perfluorocarbon
conjugate as a 19F MRI tracer for macrophage imaging

3.1 Introduction
As discussed in chapter 2, current PFC nanoemulsions face several challenges
regarding their long half-life, imaging artifacts due to multiple peaks, and formulation
challenges due to their immiscibility with common pharmaceutical excipients. These
challenges prompted us to synthesize a new class of lipophilic PFC conjugates. The
formulation of these conjugates was soon encountered with instability, specifically
Ostwald ripening (OR). In this chapter, the efforts made to resolve this instability leading
to a stable formulation will be discussed. In vitro assessment for stability, toxicity in
model macrophages and uptake to establish

19

F MR properties is also presented. A

theoretical background on nanoemulsions, their preparation methods, the mechanism of
OR and the methods to form stable emulsions is provided. Part of the work presented in
this chapter was originally published elsewhere.178
3.1.1 Nanoemulsions
An emulsion is a mixture containing immiscible phases, where one liquid is
dispersed as droplets (dispersed phase) in another liquid (continuous phase). The
dispersed phase is stabilized using surfactants in the continuous phase. A surfactant is a
molecule containing amphiphilic parts in its structure that adsorbs at the interface of oil
and water to reduce the interfacial tension and stabilize the droplets against coalescence
by repulsive steric or electrostatic forces.179 Emulsions can be oil-in-water (o/w) and
water-in-oil (w/o), where water and oil are the continuous phases respectively. Emulsion
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formation is not a spontaneous process and requires energy input. An exception to this is
microemulsions, which are formed in the presence of large amount of surfactants and
they are thermodynamically stable. The total free energy of emulsion formation (ΔG) is
given by:179
∆G = γ∆A − T∆S

Equation 3.1

where, ΔA is the change in interfacial area, γ is interfacial tension, T is temperature, and
ΔS is change in entropy of the system.
Based on Equation 3.1, as smaller emulsion droplets are formed, new interfacial
area is created, thereby increasing the free energy of the system. Surfactants are utilized
to reduce the interfacial tension and the free energy.
Nanoemulsions are kinetically stabilized metastable systems with the droplet size
below 100 nm. Although microemulsions can exist in this droplet size, they are not
classified as nanoemulsions due to the fundamental difference in the mechanism of
formation. In order to break an emulsion droplet into sub-micron sized droplets,
enormous energy is required to overcome the Laplace pressure (Π) of the droplet, which
is given by:
Π = 2γ/r

Equation 3.2

where, r is the radius of the droplet. Smaller droplets have higher Laplace pressure and
hence higher energy is required to break these droplets. Surfactants can reduce the
Laplace pressure by reducing interfacial tension, making the droplet breakdown process
easier. Following the breakdown, surfactants adsorb to the newly formed interface and
stabilize the emulsions.
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3.1.2 Nanoemulsion preparation using ultra sonication and microfluidization
The formation of nanoemulsions requires enormous energy in order to overcome
the Laplace pressure (Equation 3.2) and break the larger oil droplets into nanometer size.
Nanoemulsions can be prepared by low-energy and high-energy methods.180,181 Lowenergy methods generally utilize changes in composition (phase inversion), rate and
sequence of ingredient addition, and environmental factors such as temperature (phase
inversion

temperature)

to

form

nanoemulsions.

Method

of

preparing

self-

nanoemulsifying drug delivery systems (SNEDDS) is widely utilized for pharmaceutical
formulations, which can be categorized as low-energy method. However, these systems
require a large amount of surfactants (20-50%), which could lead to undesirable side
effects when administered. Also, these methods are limited by long-term stability and
large-scale production.180
High-energy

methods

utilize

high

shear

such

as

homogenization,

microfluidization and ultrasonication, to break the droplets and form nanoemulsions.
High-energy emulsification methods such as sonication and microfluidization are widely
used at laboratory and industrial scale. In fact, these two processing methods are
commonly employed to prepare PFC nanoemulsions. In ultrasonication methods, acoustic
waves are generated, which disperse droplets of dispersed phase in continuous phase. An
ultrasound-driven mechanical vibrator produces sound waves at frequencies greater than
20 KHz and high power causing shear and cavitation required for size reduction.181-183
Ultrasonication equipment is readily available and it is an efficient method for generation
of nanoemulsions at small scale. The inhomogeneous sound fields require constant
recirculation/agitation of the mixture to achieve uniform size and low polydipsersity.
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Microfluidization utilizes microfluidic technology, which was patented in 1985.184 An
air- or nitrogen-driven intensifier pump pushes the crude emulsion through an interaction
chamber containing 75 μm channels in Y or Z shape. The fluid is forced through these
microchannels as two process streams that collide at an impingement area.181 This
process creates high shear required to produce nanosized droplets. Microfluidization is a
highly reproducible method and produces droplets with narrow size distribution.
3.1.3 Ostwald ripening and instability of perfluorocarbon nanoemulsions
Emulsions are thermodynamically unstable and hence emulsion breakdown is a
spontaneous process to reduce free energy (Equation 3.1). Emulsions can destabilize by
several mechanisms such as coalescence, flocculation, sedimentation, and creaming,
which leads to phase separation.185,186 In nanoemulsions, however, Ostwald ripening
(OR) is observed as a major destabilizing mechanism. This degradation occurs due to the
difference in chemical potential between large and small droplets in the internal phase.185
Based on the Kelvin equation, small droplets display high local solubility. As a result,
large droplets grow as the dispersed phase molecules from smaller droplets dissolve and
diffuse in the continuous phase, finally leading to phase separation.185 Because the size of
the droplets in nanoemulsions is very small, the driving force for OR is greater. Several
reports have emerged theorizing OR and solutions to reduce the same in emulsions. The
theory proposed by Lifshitz, Slyzov and Wagner (LSW)187,188 for solid dispersions has
also been applied to emulsions, where the OR rate (ω) is given by:
ω=

dr 3
8 C∞ γVm D
= [
]
dt
9 ρRT

Equation 3.3
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where, D is the diffusion coefficient of the dispersed phase molecules in the dispersion
medium, C∞ is the saturation solubility of the dispersed phase in the continuous phase, C
is the concentration of dispersed phase, γ is the interfacial tension between the two
phases, and ρ is the density of the dispersed phase, Vm is the volume of dispersed phase, r
is the radius of the emulsion droplets. R and T are the ideal gas constant and temperature
respectively.
According to LSW theory, the OR rate can be decreased by reducing interfacial
tension using surfactants, solubility of the oil phase by employing low aqueous solubility
oils, and diffusivity of the dissolved oil by increasing the continuous phase viscosity. One
of the widely utilized method involves use of a second oil phase with lower aqueous
solubility then the disperse phase at the same time showing miscibility with the dispersed
phase.185 This second oil phase partitions between droplets and expected to be more
associated with smaller droplets, thus reducing the solubility and the chemical potential
difference between droplets leading to reduced OR.
The growth in droplet size of PFC nanoemulsions under storage was a key
challenge to apply them as artificial blood substitutes during 1980s and 1990s. Kabalnov
et al. published theoretical and experimental reports189,190 suggesting that similar to
hydrocarbon emulsions, PFC nanoemulsions also undergo OR, despite PFCs displaying
low aqueous solubility. For example, one of the earliest PFC emulsions prepared with
polyethylene oxide (PEO) and polypropylene oxide (PPO) block copolymers (F68)
showed considerable increase in size under storage.189,190 It has been observed that
fluorocarbon emulsion stability depends on the nature of fluorocarbon, with long chain
and highly fluorinated PFCs showing lower ripening rates, presumably due to the reduced
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solubility in the aqueous phase.189 It has also been shown that adding a second PFC with
lower aqueous solubility can reduce the ripening rate similar to hydrocarbon
emulsions.190 It should be noted that the biological half-life of these PFCs are
proportional to their molecular weights and structure, and hence the choice of PFCs
depend on their potential interactions with biological systems. The use of fluorinated
surfactants that solubilize in fluorous and aqueous phases is also proposed as another
alternative to reduce OR by reducing interfacial tension between the phases, which
reduces the driving force for diffusion. However, high toxicities associated with
fluorinated surfactants, as well as their interference with

19

F nuclear magnetic resonance

(NMR) peaks resulting in 19F MRI artifacts, made the use of this method less practical. In
contrast to F68-stabilized emulsions, phospholipid-based surfactants render good stability
to PFC emulsions. The adsorbed phospholipid layer does not allow many non-electrolyte
molecules to diffuse,190 which could be the reason for high stability of PFC formulations
prepared with this system. Nevertheless, phospholipid-based surfactants are limited, in
addition to the cost, by chemical degradation (lipid oxidation) observed under storage.191
PFC nanoemulsions were generally formed with either lipid-based surfactants such as
phosphatidyl choline or block copolymer-based surfactants such as poloxamers.
3.1.4 Rationale
The motivation for developing new PFC conjugates is the problems associated
with the current formulations in terms of stability as well as imaging efficiency.
Lipophilic PFCs can overcome these problems by enhancing interactions with
hydrocarbon surfactants and thus leading to stable formulations. PFCs displaying
lipophilic character such as PFOB (Figure 2.3) are highly investigated because it has a
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low half-life (12 days) in the body and well-characterized elimination pathways, making
it more favorable candidate for clinical applications. Similarly, lipophilic-fluorophilic
constructs could also present with higher elimination. For 19F MRI applications, however,
PFOB may not be best due to multiple peaks that could likely produce 19F MRI artifacts.
Optimal PFC nanoemulsions for 19F MRI should mainly satisfy several design criteria152:
1) stability and long shelf life; 2) a simple 19F NMR spectrum, ideally showing a single,
narrow resonance in order to maximize sensitivity and prevent chemical shift imaging
artifacts; 3) resistance to sedimentation (due to large density difference between PFC and
aqueous phase) during storage; and 4) small molecular weight and lipophilic PFCs for
faster excretion.
Herein, we report chemical modifications with formulation strategies of
structurally simple, small molecular weight (<500 g/mole) perfluorocarbon-hydrocarbon
(PFC-HC) conjugates to obtain stable and biocompatible nanoemulsion for 19F MRI. We
attempted two distinct approaches to overcome OR while optimal 19F MRI reagent design
criteria (1-4) remain satisfied. In the first approach, the effect of hydrocarbon chain
length variation on the stability of PFC-HC nanoemulsion is investigated. The second
strategy evaluated the effect of adding a hydrocarbon on the inhibition of OR.

3.2 Materials and methods
3.2.1 Materials
All reagents and solvents used in synthetic experiments were purchased from
Sigma-Aldrich, Acros, TCI or Spectrum Chemicals (unless stated) and used without
further purification. Pluronic® P105 was obtained from BASF Corporation. Pluronic®
P123 and Cremophor-EL® (BASF) were obtained from Sigma Aldrich. Pluronic® F127
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was purchased from Spectrum Chemicals. Pluronic® L121 is a gift from Dr. Eric T.
Ahrens of Carnegie Mellon University. Olive oil used in nanoemulsion formulation was a
generous gift from Croda International Plc. Acetone and chloroform were obtained from
Fisher Scientific and Spectrum respectively. Trypan blue solution (0.4%) was obtained
from Sigma-Aldrich. CellTiter-Glo® Luminescent Cell Viability Assay was purchased
from Promega Corporation (WI, USA). Mouse macrophage cell line (RAW 264.7) was
purchased from American Type Culture Collection (ATCC) (Rockville, MD, USA) and
cultured according to the instructions. Dulbecco’s phosphate buffered saline (DPBS) was
purchased from Mediatech, Inc. (VA, USA). Dulbecco's modified eagle medium
(DMEM; GIBCO-BRL, Rockville, MD, USA) for cell culture experiments was
supplemented

with

10%

fetal

bovine

serum

(FBS)

or

fetal

clone

III,

Penicillin/Streptomycin (1%), L-Glutamine (1%), sodium pyruvate (1%), HEPES (2.5%),
and 45% D(+) glucose (1%). Trypsin EDTA, 1X was obtained from Mediatech, Inc. (VA,
USA). All cells were maintained in 37 °C incubator with 5% carbon dioxide (CO2).
3.2.2 Synthesis of C8/C12/C14 PFTEs
Triphenylphosphine (Ph3P, 11.11 g, 42.37 mmol) was added to a solution of 1octanol (C8, 5.25 g, 40.35 mmol) in anhydrous ether, and the mixture stirred at room
temperature (RT) for 15 minutes until the powder completely dissolved. The reaction
mixture was then placed on an ice bath and diisopropylazodicarboxylate (DIAD)
(8.71 mL, 44.38 mmol) was added dropwise. The addition was performed under argon
atmosphere. During the addition, the solution changed color to pale yellow and a yellow
precipitate was formed. After the addition was complete, the reaction mixture was stirred
for an additional 30 minutes on the ice bath and then perfluoro-tert-butanol (1, 10.00 g,
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42.37 mmol) was added in one portion, and the resulting mixture was stirred for 1.5 h at
room temperature (RT). The crude reaction mixture was filtered over a short SiO2 column
to remove the triphenylphosphine oxide precipitate. The filtrate was concentrated, redissolved in a small amount of ether and loaded on a SiO2 column. The product was
eluted with a perfluorohexanes/ether (1:1 v/v) mixture and concentrated in vacuo.
Removal of the unreacted perfluoro-tert-butanol under vacuum yielded C8 analog of
perfluoro-tert-butyl ether (PFTE) as a clear colorless oil (8.36 g, 59.5%). C12, C14 and
C18 analogs were synthesized following the same procedure using dodecanol,
tetradecanol, and octadecanol as the starting materials respectively.
3.2.3

Nanoemulsion preparation using probe sonication and microfluidization

3.2.3.1 Nanoemulsions with Cremophor® EL and Pluronic® P105

Cremophor® EL/P105 surfactant mixture
A solution containing mixed surfactants was prepared as follows. 4 g of
Pluronic® P105 (P105) was dissolved in 100 mL water by stirring slowly at RT for the
final concentration of 4% w/v (weight/volume). 6 g of Cremophor® EL (CrEL) was
dissolved in 100 mL water by stirring at RT for the final concentration of 6% w/v. The
two solutions were mixed at RT in 3:2 v/v (volume/volume) ratio in a round bottom flask,
placed in a water bath preheated to 45 °C, and heated while slowly rotating for 20
minutes on a rotary evaporator. The solution was then chilled on ice for 15 minutes, and
stored in the refrigerator until use. The final concentration of this mixed micelle solution
was 5% w/v, where 2% w/v was P105 and 3% w/v was CrEL.
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Nanoemulsion preparation
Nanoemulsions were prepared using sonication at 0.5 mL scale. PFTE
nanoemulsion contained 10% w/v PFTE (C8/C12/C14) and 0.5% w/v of CrEL and P105
in 3:2 ratios. Briefly, 50 mg of C8/C12/C14-PFTE and 50 μL of mixed micelle solution
were vortexed and later hydrated by appropriate amount of water. A white dispersion was
formed which was transferred to a 1.5 mL eppendorf tube for sonication. Probe
sonication using Sonic Dismembrator (Fisher scientific, model 100) was used to prepare
nanoemulsions. 1.5 mL eppendorf tube containing the sample was chilled on ice for 15
min before sonication. The dial reading was set at 3 which produce an output power of
~15 W during sonication. The sonication probe was inserted half-way inside the
eppendorf tube to avoid any air entrapment. Pulses (5 sec) were manually applied with 5
sec interval between each pulse for 2 min. Tubes were placed on ice during sonication to
avoid increase in temperature.
3.2.3.2 Nanoemulsions with single and mixed Pluronic® surfactants

Probe sonication
Nanoemulsions were prepared at 1 mL scale with Sonic Dismembrator (Fisher
scientific, model 100). Stock solutions of surfactants either in de-ionized water
(Pluronic® F127 and P105) or chloroform (Pluronic® P123 (P123) and L121) were
prepared. Olive oil stock solution was prepared in acetone. Stock solutions of
hydrophobic phases were mixed in a test tube to obtain the required final concentration of
each ingredient. In C8-PFTE containing nanoemulsions, C8-PFTE was added directly to
the mixture. The mixture was vortexed and blowing the air formed thin film. The samples
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were stored in a desiccator under vacuum for 1.5 h to ensure complete removal of organic
solvents. To the thin film, surfactant in water (where applicable) was added and vortexed
vigorously. To this mixture, de-ionized water was added and vortexed for 1 min before
transferring to a 1.5 mL eppendorf tube. Sonication was performed as described above.

Microfluidization
Stock solutions of P105 (5% w/v) in de-ionized water and P123 (10% w/v) in
chloroform were prepared. Nanoemulsions were prepared at a 25 mL scale. Olive oil
(1.25 g) and 4.5 mL of P123 (0.45 g) solution was transferred to a 250 mL round bottom
flask. This mixture was subjected to solvent removal under reduced pressure (474 bar) at
38 °C and 100 rpm for 2 h to form a thin film and later placed in a desiccator for 2-3 h
under vacuum. C8-PFTE (1.25 g) was added to this mixture under stirring, followed by 6
mL (0.3 g of P105) of aqueous P105 solution. The mixture was stirred for 15 min and deionized water was added in appropriate amount. The mixture was transferred to a precooled microfluidizer (M110S, Microfluidics) and processed under recirculation for 30
pulses at an operating pressure of 6 bar (~18-20000 psi pressure in the interaction
chamber). The nanoemulsion was sterilized using sterile 0.22 μm cellulose filter
(Millex®-GS, 33 mm). Samples (1.5 mL) of the nanoemulsion were taken and stored at
4, 25 and 37 °C to assess their stability. The bulk of the nanoemulsion was stored at 4 °C
and droplet size was monitored at different time points for all the samples. This
nanoemulsion was designated as M2. For control nanoemulsion (M1) without C8-PFTE,
2.5 g of olive oil was used and the same procedure as above was followed.

58

3.2.4 Characterization for colloidal attributes, and cytotoxicity and uptake in
RAW 264.7 cells

Droplet size and zeta potential measurements of nanoemulsions
The size distribution of the nanoemulsion droplets in aqueous medium was
determined by dynamic light scattering (DLS) using Zetasizer Nano (Malvern
Instruments, UK). DLS obtains hydrodynamic diameter (Dh) from the diffusion
coefficient of the particles under Brownian motion using Stokes-Einstein equation.192
Dh =

kT
3πηD

Equation 3.4

where, k is Boltzmann’s constant, T is absolute temperature, η is viscosity of the
dispersion medium, and D is diffusion coefficient of the particle.
Diffusion coefficient is obtained by fitting the time autocorrelation data of the
scattered light intensity with algorithms such as cumulants analysis. The two parameters
obtained from the cumulants analysis and Equation 3.4 are mean diameter and an
estimate of the width of the size distribution called polydispersity index (PDI).192,193 PDI
is a dimensionless number whose values range from 0 to 1. PDI is equal to the square of
the ratio of standard deviation (width of size distribution) to mean diameter.194
Measurements were taken after diluting the nanoemulsion in water and
equilibrating at RT for at least 20 minutes prior to each measurement. For nanoemulsions
prepared with olive oil alone, 1:200 v/v dilution ratio was used and C8-PFTE containing
nanoemulsions were diluted at 1:40 v/v ratio. Measurements were performed at 20 ºC and
an angle of 173º (to incident light) to avoid multiple scattering. The stability of the
nanoemulsions was assessed by measuring hydrodynamic diameter (Z average) and PDI
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at different time points (days). Zeta potential was measured using specialized zeta cells
(Malvern) with electrodes at same dilution used for size measurement. Following the
same procedure, droplet size measurements were also carried out for M2 nanoemulsion
dispersed (1:40 v/v) in di-water, serum-free cell culture medium (DMEM), and 10% v/v
FBS-containing medium. These samples were incubated at 5% CO2 and 37 °C and
monitored for 3 days.

In vitro cytotoxicity
In vitro cytotoxicity and labeling was performed in mouse macrophages (RAW
264.7, ATCC). For cytotoxicity, cells were plated at 10,000 per well in 96 well plate.
After overnight incubation at 37 °C and 5% CO2, cells were exposed to nanoemulsion
(M1 or M2) dispersed in culture medium. A wide range of concentrations
(0.375-12 mg/mL C8-PFTE or olive oil) was used. For M1 nanoemulsion, theoretical
olive oil concentration was used. Following 24 h of exposure, 50 μL of CellTiter-Glo®
analyte was added to each well and shaken for 20 min at RT. 100 μL of the cell lysate
was transferred to a white opaque plate and luminescence recorded on Perkin Elmer
Victor 2 Microplate Reader.

Cell uptake with nanoemulsion M2
For cell labeling, cells were plated at 0.8 million per well in 6 well plates and left
undisturbed overnight. After 24 h, cells were exposed to different doses of C8-PFTE in
nanoemulsion M2 (8, 4, 2, 1, 0.5 and 0 mg/mL). Each well contained 2 mL of medium
with or without nanoemulsion M2 and labeling was performed in duplicates. The
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attached cells were washed with DPBS (2x) and medium (1x). To collect the labeled
cells, 0.5 mL of TrypleE was added to each well, incubated for 2 min and cells collected
after repeated washing with medium. Collected cells were centrifuged at 1100 rpm for
5 min (Centrifuge 5804R, VWR) and the supernatant was aspirated. The obtained cell
pellet was re-dispersed in 3 mL medium. Only unexposed cells were counted. Briefly, an
equal volume of cell suspension and 0.4% Trypan blue solution was mixed and cells
counted using neubauer hemocytometer. To quantify the number of cells in nanoemulsion
M2 exposed cells, CellTiter-Glo® cell viability assay was used. Based on the cell counts,
a standard curve was constructed using serial dilutions of unexposed cells and recorded
luminescence from the CellTiter-Glo® assay. Briefly, 100 μL of cell suspension and
50 μL of the analyte were added to an opaque 96 well plate and shaken at RT for 20 min.
By using the obtained regression equation, cell numbers were predicted for
nanoemulsion-exposed samples. The cell suspensions were centrifuged at 2000 rpm for
10 min and supernatant aspirated. To the obtained cell pellet, 180 μL of de-ionized water
and 200 μL of 0.02% v/v aqueous trifluoroacetic acid (TFA) solution was added and
transferred to 5 mm NMR tube for 19F NMR analysis.

19

F NMR of nanoemulsion M2 and labeled cells
19

F NMR of the nanoemulsion and above prepared cell suspension was recorded

on Bruker Instruments (Bruker Instruments, 300 MHz). 200 μL of nanoemulsion was
diluted with 200 μL of 0.2% v/v aqueous TFA. Amount of C8-PFTE in the emulsion and
19

F per cell was quantified based on the following equations using TFA as the reference

(peak at -76.0 ppm).170
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Amount of PFTE per mL =

5(

Fne
)Nr
Fr

NA ∗

Equation 3.5

F

19

molecule

Fne
( Fr )
19F per cell =
Cell number
∗ Nr

Equation 3.6

Fne is the integrated PFC peak value around -71.5 ppm; Fr is the integrated reference
peak value under -76 ppm; Nr is the number of fluorine atoms in TFA used for analysis;
NA is Avogadro number (6.023 x 1023); Mwt is the molecular weight of PFC.
19

F/molecule are the number of fluorine atoms (nine) in PFTE structure. The

multiplication factor used is five (200 μL of nanoemulsion was used in NMR tube) to
obtain the amount per mL nanoemulsion. The equations are adapted from earlier

19

F

19

F

content calculations reported in the literature.164,170

3.3 Results and discussion
Currently used PFCs either possess high body residence time or multi-peak
NMR spectrum leading to imaging artifacts and a reduction in the

19

F MRI sensitivity.

PFOB has low body residence time and the newer imaging methods addressed the
problems associated with imaging artifacts to some extent.150 However, it has been shown
that PFOB only shows 37% of PFCE intensity in inflammation models.150 This reduced
sensitivity, in turn, requires high dose administration of PFOB, thus increasing body
burden. The number of 19F nuclei used for imaging is significantly lower (three 19F atoms
per molecule) compared to the total number of fluorines (17

19

F atoms) in PFOB.

Therefore, we set out to synthesize lipophilic analogs of a previously reported PFC
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conjugate and address formulation challenges pertaining to OR-dependent instability and
evaluation of methods to reduce the same.
Analogs of PFTE were synthesized in one step using an earlier reported
Mitsunobu protocol195 with some modifications (Figure 3.1A). The addition of aliphatic
hydrocarbon tails increased lipophilicity of the constructs, which facilitated PFC
interaction with hydrocarbon surfactants. Further, the overall density of the PFC
construct is substantially lower (1.18 g/mL). The construct shows only one peak at -71.4
ppm from the perfluoro-tert-butyl group, equivalent to nine

19

F atoms (Figure 3.1B). In

preliminary studies by Janjic et al.196, C8-PFTE emulsified with non-ionic surfactants in
water efficiently labeled mouse DCs and the cells injected into mouse leg were imaged
by 19F MRI. However, this nanoemulsion was not stable upon prolonged storage and its
preparation was not scalable.
Our C8-PFTE nanoemulsion formed with CrEL and P105 also showed an
increase in droplet diameter with time (Figure 3.2A). A plot of droplet volume (r3) vs.
time revealed a linear increase in size with time (Figure 3.2B) indicating an OR-like
phenomenon. Several reports have shown that OR rates decrease with increase in carbon
number in both hydrogenated and fluorinated alkanes.185,190 Therefore, PFTE with
increased chain length (C12 and C14) were synthesized and formulated employing the
same surfactant system. Increased chain length showed some stabilization in the droplet
size, but size fluctuations were observed during DLS analysis (Figure 3.2C). Chain length
was further increased to C18, which produced a waxy solid, not amenable for
incorporation in the nanoemulsion. The synthetic yields also reduced with increasing
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chain length. Therefore, alternate strategies were employed to reduce OR in the
nanoemulsion.

Figure 3.1. Synthesis and representative 19F NMR of PFTE analogs.
A. Synthetic scheme of PFTE formation. B.
single peak.178
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19

F NMR of C8 analog of PFTE showing

Figure 3.2. Instability of CrEL/P105/PFTE nanoemulsions based on droplet size
changes with time.
A. Increase of droplet diameter with days for C8-PFTE nanoemulsion (n=2). B. Data
from panel A plotted as cube of radius (r3) vs. days showing a linear increase in volume
with time. C. Cube of radius (r3) vs. days plot of C12- and C14-PFTE nanoemulsions
(n=2) showing fluctuation in size at the initial time points.

3.3.1 Formulation development of C8-PFTE
To stabilize the nanoemulsion prepared with C8-PFTE against OR, a large
molecular weight hydrophobic molecule (ripening inhibitor) miscible with the dispersed
phase, but practically insoluble in the continuous phase was utilized. It is well established
that nanoemulsions can be stabilized against OR using a low diffusive hydrophobic
component in the dispersed phase.197 Lipophilic C8-PFTE is readily miscible with olive
oil, thus avoiding the use of large molecular weight PFCs, which might produce
65

interfering signals for

19

F MRI. Here, the hydrocarbon oil and C8-PFTE are mixed in a

1:1 ratio forming a mixed internal phase, which is stabilized by surfactants in water. With
higher hydrocarbon oil content, there is an opportunity to incorporate additional imaging
agents (e.g. fluorescent dyes) or lipophilic drugs in the formulation.

Selection and optimization of surfactants
To obtain a stable nanoemulsion, systematic selection of surfactants and
optimization of their concentration was followed. Biocompatible phospholipids are
widely employed to provide stable nanoemulsions. However, phospholipids are
expensive and can undergo oxidation/peroxidation reactions upon prolonged storage.191
Alternatively, non-ionic block copolymers of PEO and PPO (Poloxamers/Pluronics®)
can be used for PFC nanoemulsion stabilization.152,170,196 Non-ionic block copolymers are
inexpensive, biocompatible and generally regarded as safe.198
The first phase of formulation development included selection of surfactants and
their amount(s) that form nanoemulsions of desired characteristics. Olive oil alone was
used as the dispersed phase because it is inexpensive compared to C8-PFTE. Also, olive
oil is part of the proposed final formulation, where it was intended to act as an OR
inhibitor. Olive oil is widely used in topical, oral and injectable pharmaceutical
formulations.199 Nanoemulsions were prepared at small scale (1 mL) using probe
sonication. Surfactants were screened either alone or in combination with another
surfactant. Optimized formulations were selected based on droplet diameter (< 200 nm),
PDI (< 0.2) and visual observation for formulation homogeneity. Table 3.1 summarizes
characterization of test formulations (S1-S6) prepared with olive oil. The dispersed phase
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concentration was maintained at 10% w/v while surfactants were screened at 1, 3 and 5%
w/v (Table 3.1). A 1:1 w/w ratio between surfactants was used for the dual surfactant
systems. Figure 3.3 shows nanoemulsion size dependence on surfactant concentration.
Droplet size and PDI were dependent on surfactant concentration, but not on the type or
combination of surfactants. Both 3 and 5% w/v showed droplet diameter and PDI less
than 200 nm and 0.2 respectively for formulations S1, S2, S5 and S6, whereas 1% w/v
produced nanoemulsions with size and PDI larger than 200 nm and 0.2 respectively. The
observed increase in size at low surfactant amount can be attributed to the relatively low
amount of surfactant available to stabilize the increased interfacial area during droplet
formation. Based on this result, it can be concluded that 3% w/v is the lowest surfactant
concentration meeting desired criteria. Formulation S3 containing L121 and P105
showed phase separation, while formulation S4 formed a gel during thin film leading to
further processing problems. Table 3.1 shows droplet size (diameter), half width of
polydispersity index (PDIw/2) and PDI of all formulations prepared at 3% w/v surfactant
concentration. Though P105 showed optimum stability, P123/P105 (S6) was selected due
to its low hydrophilic-lipophilic balance (HLB) value of 12.25. Average HLB values of
P123 and P105 were taken as 9.5 and 15 respectively.200

Optimization of relative amount of Pluronic® P123 and P105
Having selected P123/P105 surfactant combination, the relative ratio of P123 and
P105 was optimized based on droplet size (< 200 nm), PDI (< 0.2), and size changes with
time. For this set of experiments, a 1:1 combination of olive oil and C8-PFTE was
employed as the dispersed phase. C8-PFTE was introduced into the nanoemulsion by
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equal weight replacement of olive oil. The total dispersed phase concentration was
maintained at 10% w/v. The concentration of surfactant system was held constant at 3%
w/v. The relative ratios of P123 and P105 were changed as shown in Table 3.2.

Table 3.1. Summary of formulations prepared with 10% w/v olive oil and 3% w/v
surfactant system. Where two surfactants are used, they were at 1:1 w/w ratio.
Surfactant 1 Surfactant 2 Droplet size ±
PDI
Pluronic®
Pluronic®
PDIw/2 (nm)
F127
P123
180.0±29.5
0.11
S1
F127
P105
173.0±25.4
0.08
S2
L121
P105
S3
P123
S4
P105
173.4±33.7
0.15
S5
P105
P123
172.0±35.9
0.17
S6
a
Gel formation during thin film leading to surfactant loss during transfer
b
Thick texture based on visual observation
c
Phase separation
Formulation

Visual
Observation
a, b
b
c
a
Homogenous
Homogenous

Figure 3.3. Droplet diameter changes with surfactant amount for olive oil
nanoemulsions.
Nanoemulsions were prepared with probe sonication. Data for nanoemulsions S1, S2, S5
is an average of duplicate experiments. Data from S6 represents one experiment. Error
bars represent PDIw/2.178
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Table 3.2. Summary of nanoemulsions prepared with C8-PFTE/olive oil (1:1) and
Pluronic® P123 and P105 as surfactants (3% w/v).

Formulation P123:P105 HLB
S7
S8
S9

1:1
3:2
2:3

12.25
11.70
12.80

Droplet
diameter
±PDIw/2
(nm)
148.8 ± 27.3
152.0 ± 26.8
159.0 ± 33.7

PDI

Zeta Potential
±SD (mV)

Stability

0.13
0.12
0.19

-8.8 ± 1.9
-9.0 ± 2.0
-11.0 ± 3.4

Stable
Stable
Stable

Nanoemulsions (S7-S9) formulated using probe sonication showed droplet size
and PDI less than 200 nm and 0.2 respectively. All the formulations showed stability for
at least 12 days as assessed by DLS (Figure 3.4A). PDIw/2 was used as standard
deviation in order to follow the changes in size distribution with time. Zeta potential
values were in the range of -8 to -11 mV (Table 3.2). Formulation S8 was selected
because the surfactant ratio corresponds to a HLB value of 11.7, which is lowest among
the tested combinations. Due to the presence of hydrophobic dispersed phase, a lower
HLB value was preferred. Replacement of a portion of olive oil with C8-PFTE has not
affected the stability of the nanoemulsion. Also, by comparing formulations S6 (Table
3.1) and S7 (Table 3.2), the average droplet diameter was reduced by 20 nm after
replacing olive oil with C8-PFTE. This reduction in size can be attributed to the low
molecular weight and high density of C8-PFTE compared to olive oil. To validate the use
of olive oil as ripening inhibitor using this surfactant system, C8-PFTE alone
nanoemulsion with P123/P105 at the above selected ratio and amount was prepared. A
time-dependent increase in droplet diameter was seen (Figure 3.4B) further validating the
use of olive oil to stabilize the nanoemulsion.
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Preparation and characterization of microfluidized nanoemulsions
In the screening phase, all nanoemulsions were prepared using probe sonication.
To prepare S8 nanoemulsion on a scale necessary for further cell studies, processing was
changed from sonication to microfluidization. It was observed that microfluidization
formed nanoemulsions with smaller size and PDI compared to sonication. The thin film
formation step was modified for microfluidized C8-PFTE nanoemulsion compared to
sonicated samples (S7-S9). During thin film formation on rotary evaporator, we observed
that C8-PFTE evaporates at temperature (38 °C) and pressure (474 bar) utilized for
removal of chloroform. Therefore, C8-PFTE was added after thin film formation of olive
oil and Pluronic® P123. This new formulation is designated as M2. Control
nanoemulsion with olive oil alone was also prepared using microfluidization and
designated as M1. Nanoemulsions M1 and M2 were characterized for droplet size, PDI
and zeta potential using DLS.

Figure 3.4. Effect of olive oil on C8-PFTE nanoemulsion stability.
A. Nanoemulsion diameter changes with time for combined C8-PFTE and olive oil
containing nanoemulsions (n=2) and B. Nanoemulsion containing C8-PFTE, but not
olive oil (n=1).178
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Droplet size distribution showed a single peak (Figure 3.5A) indicating the
absence of significant portion of large and small droplets. The average droplet size and
PDI were around 180 and 0.2 for nanoemulsion M1 while nanoemulsion M2 showed a
reduced droplet size and PDI around 130 nm and 0.15 respectively (Figure 3.5A-C). This
reduced droplet size of nanoemulsion M2 is consistent with the sonicated nanoemulsions.
Zeta potential values for nanoemulsions M1 and M2 were negative, -5 to -7 mV. For
stable colloidal preparations, large zeta potential values (> ±30 mV) are preferred to
ensure repulsion between the droplets.201 However, Pluronics can provide stabilization
via steric hindrance rather than charge repulsion. Storage stability was evaluated at 4, 25
and 37 °C by analyzing nanoemulsion samples at regular time intervals using DLS. Both
formulations were shown to be stable for 160 days at all temperatures tested (Figure
3.5B-C).
Physical stability of nanoemulsions in cell culture relevant conditions was also
evaluated. Droplet size and PDI were characterized for nanoemulsion M2 dispersed in
water, serum-free medium, and 10% v/v fetal bovine serum (FBS)-containing medium. In
all the media tested, nanoemulsion M2 showed high physical stability for at least 72 h
stored at 37 °C and 5% CO2 (Figure 3.5D). A small increase in size (~10 nm) was noted
for serum-free and serum-containing medium. Quantification by

19

F NMR of

nanoemulsion M2 showed a high C8-PFTE loading (48.4±0.92 mg/mL) in the
nanoemulsion, which is 96% compared to theoretical concentration (50.4 mg/mL).
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Figure 3.5. Physical characterization of microfluidized olive oil (M1) and C8PFTE/olive oil (M2) nanoemulsions using DLS.
A. Representative size distribution of M1 (black) and M2 (red) nanoemulsions. B. Long
term storage stability of M2 and C. M1 nanoemulsions at 4, 25 and 37 °C assessed by
droplet size measurements. D. M2 nanoemulsion diameter changes in different media
(n=3). The error bars in panels B and C represent PDIw/2.178

In vitro stability results demonstrate that lipophilic PFC can interact effectively
with excipients and form stable formulations. Because the obtained droplet size is larger
than 100 nm with low PDI and a slight negative charge, these nanoemulsions meet the
design criteria discussed in section 1.4 and could be internalized by macrophages.
3.3.2 In vitro cell culture studies
To demonstrate the biocompatibility and potential biomedical use of C8-PFTE
nanoemulsions, in vitro cell culture studies were performed in a model phagocytic cell
line, mouse macrophages (RAW 264.7). These cells are commonly utilized for in vitro
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toxicity and uptake studies due to their phagocytic properties. Similar to primary
monocytes and macrophages, these cells can be activated in vitro to pro- and antiinflammatory states using LPS and interleukin-4 and 13 (IL-4 and 13) respectively.202,203
Nanoemulsion M2 was exposed to macrophages for 24 h at different doses of C8-PFTE
(0.375-12 mg/mL). A dose-dependent reduction in cell viability was observed (Figure
3.6A). Cell viability showed a plateau from 3-12 mg/mL concentration with 80% viable
cells. Bonetto et al.204 observed a similar level of cell viability for a PFC nanoemulsion
and the authors stated that this is acceptable toxicity for ex vivo cell labeling used in cell
tracking studies. Cell viability of nanoemulsion M1 (control) was assessed at the same
total oil concentration as that of nanoemulsion M2. It showed about 20% increase in cell
viability (Figure 3.6B).
Macrophages were labeled with nanoemulsion M2 at different concentrations of
C8-PFTE for 24 h. Unexposed macrophages were counted and serial dilutions were
prepared. Obtained luminescence values (CellTiter-Glo®) for serial dilutions were used
to get a regression equation (R2 = 0.998). Using this equation, cell numbers were
predicted for cells exposed to nanoemulsion M2. Labeled macrophages were subjected to
19

F NMR analysis to quantify the loading efficiency. As shown in Figure 3.6C, peak

shape was unaltered in cells showing that C8-PFTE is metabolically stable. A dosedependent uptake of nanoemulsion M2 in macrophages was observed (Figure 3.6D). At
the highest C8-PFTE concentration tested (8 mg/mL), cell loading was around 7 x 10 11
19

F per cell, which is comparable to cell loading reported earlier (1012 19F/cell).151,170 It

should be noted that the current nanoemulsion had only 5% w/v PFC compared to other
reports,

which

utilized

a

higher

PFC
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content

(~10-40

%

w/v)

in

the

nanoemulsion.169,170,196 Nanoemulsion with increased amount of C8-PFTE could further
increase 19F per cell.

Figure 3.6. In vitro characterization of olive oil (M1) and C8-PFTE/olive oil (M2)
nanoemulsions in mouse macrophages.
A. Macrophage viability (n=4) post 24 h exposure to dilutions of M2 and B. M1
nanoemulsions. Data is represented as percent of control (0 mg/mL C8-PFTE or olive
oil). C. 19F NMR of nanoemulsion M2-labeled macrophages; the resonance peak at -76.0
ppm is TFA reference. D. Dose-dependent uptake of nanoemulsion M2 in macrophages
(n=2). In panels A and D, data is represented as mean ± SD.178
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3.4 Conclusions, limitations and alternatives
In conclusion, the work presented in this chapter identifies a new class of PFCHC conjugates for biomedical applications. Lipophilicity, a large number of magnetically
equivalent 19F nuclei for imaging and low density are the hallmarks of this class of PFCs.
Addition of less soluble olive oil to C8-PFTE produced nanoemulsions resistant to OR
compared to nanoemulsion prepared with C8-PFTE. A combination of lipophilicity and
low density imparted high stability to the PFTE nanoemulsions under storage and
incubation with cell culture media. Dose-dependent uptake in macrophages showing

19

F

MR signature supports the nanoemulsion suitability for imaging.
Although, a stable formulation of C8-PFTE nanoemulsion was developed, a few
limitations were encountered during the course of formulation characterization to use this
emulsion as a theranostic system. At high doses, C8-PFTE showed up to 20% reduction
in cell viability, which necessitates further investigation for future in vivo applications
involving direct injection and in situ labeling of macrophages. We also noted that
celecoxib precipitated under storage in the nanoemulsions leading to its instability. This
result is expected as celecoxib shows very low solubility in olive oil. Hence, an
alternative or additional hydrocarbon solubilizer needs to be incorporated in the
formulation. Because large-scale synthesis of C8-PFTE that is required for further
optimization and drug incorporation studies is an expensive endeavor, our focus shifted
to commercially available PFCs (chapters 4, 5 and 6). Nevertheless, the reported
nanoemulsion can find applications in multi-spectral

19

F MRI due to its single

19

F

resonance peak, which is easily distinguishable from the widely used PFCs such as PFPE
and PFCE. C8-PFTE can be utilized in combination with these PFC nanoemulsions to
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detect two cell populations and their interactions in vivo, which could be applied in cell
therapy and understanding cell-cell interactions in a pathophysiological setting. This way
complicated MRI pulse sequences to separate
are not required. It can also be utilized as a

19

F signal from each of these compounds

19

F MRI tracer to monitor cell infiltration

changes in response to drug delivery by a distinct PFC nanoemulsion incorporating drug.
In this case, the availability of distinct peaks can be utilized separately to assess
therapeutic effect and visualize theranostic accumulation.
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4

Development of fluorescent celecoxib-loaded PFPE nanoemulsions
for drug delivery and imaging in macrophages

4.1 Introduction
Due to the limitations associated with C8-PFTE formulation, we investigated
linear perfluoropolyether, PFPE (Figure 2.3). PFPE is represented by the formula
CF3O(CF2CF2O)nCF3, where n = 4-16, with the average molecular weight of 1380 g/mol.
PFPE shows a single main peak around -91.5 ppm205 in the

19

F NMR spectrum

corresponding to the monomer repeats CF2CF2O. The total number of magnetically
equivalent fluorines around -91.5 ppm is 40. A small peak around -59 ppm from CF3 end
groups in the PFPE spectrum is spectrally separated and hence its presence does not
affect the image analysis.163 PFPE was previously used for in vivo 19F MRI tracking of ex
vivo labeled immune cells (T cells and DCs),163,170,204 in vivo cytometry,162 and it is also
evaluated in cancer patients to track injected immunotherapeutic DCs.156
PFPE is an ideal PFC to be applied for in vivo

19

F MRI studies due to its non-

toxic nature as well as the presence of large number of

19

F to increase imaging

sensitivity.156 Due to high biological inertness, PFPE elimination is slow and relies on the
RES followed by expiration through lungs.152 This is the general clearance profile for
most PFCs used in biomedical applications.151,152,190 Of note, in vivo assessment in our
studies (chapter 7) are conducted only up to 3 days and hence our study end points are
not affected by PFPE retention at the inflamed site. For studies involving chronic
inflammation models and utilizing multi-dose administration of PFPE nanoemulsions,
further characterization in vivo is necessary.
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Our goal was to prepare a theranostic system with acceptable storage stability and
following capabilities: 1) incorporates a selective COX-2 inhibitor; 2) can be imaged by
two complementary molecular imaging techniques - NIRF and 19F MR; 3) Non-toxic; 4)
can be internalized by macrophages in culture; and 5) produce therapeutic effect.
Since pure PFCs are lipophobic, they cannot incorporate lipophilic drugs.143
Previous reports showed the incorporation of therapeutic moieties in the surfactant layer
surrounding PFC core of a nanoemulsion droplet.172,173 Premature leaking or burst release
of the drug in vivo or during storage is a potential problem with this approach because the
surfactant layer resides at the oil/water interface. Since the surfactant amount used in
kinetically stabilized nanoemulsions is minimal (<5% w/w), amount of drug that can be
incorporated will be very low. An alternate approach is to use solubilizers in the
formulation. For example, coconut oil was used to solubilize lipophilic drug,
camptothecin, in a PFC emulsion.177
Celecoxib solubility in several natural and synthetic oils has been reported in the
literature.44 Oils such as safflower, olive and corn were reported to have less than 5
mg/mL solubility. Caprylic/capric triglycerides such as Capmul and Miglyol 810/812 N
showed up to 10 mg/mL solubility. Our target concentration of celecoxib in the oil phase
is 5 mg/mL, which corresponds to a theoretical concentration of 524 μM (0.2 mg/mL) in
the nanoemulsion. This concentration was selected based on the literature reported i.v.
dose for anticancer studies of celecoxib NPs. Venkatesan et al.46 showed anticancer effect
in a mouse xenograft model after administering 100 μg/kg dose of celecoxib-chitosan
NPs for three times making the cumulative dose 300 μg/kg Majority of the studies
utilized multiple doses of celecoxib formulations. We intended to use a single i.v.
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administration in the dose range of 100-200 μL of nanoemulsion per mouse, which
corresponds to 800-1600 μg/kg of celecoxib. Although our selected dose is higher than
the mentioned cancer study, the cumulative exposure to celecoxib compared to multiple
oral doses of celecoxib is significantly less with our formulation. It should be noted that
in one of the inflammatory models, rat neuropathic pain, significantly lower dose of
celecoxib (~180 μg/kg) in a PFC nanoemulsion showed pharmacological effects (chapter
7). In our preliminary attempts, nanoemulsions prepared with Capmul® showed toxicity
in mouse macrophages. Hence, we used Miglyol 810N (or 812N), as a solubilizer for
celecoxib. Miglyol 810 N, a medium-chain triglyceride of GRAS (generally regarded as
safe) category, is widely used in parenteral nutrition emulsions.206
An additional imaging modality was made possible by incorporating lipophilic
NIR dye for NIRF imaging. NIRF imaging can be fast, economical and quantitative for
preclinical studies. Combination of PFCs with optical imaging provides exceptional
advantage over using MRI alone as discussed before. NIRF overcomes potential issues in
biodistribution studies that use 19F detection alone in vivo, such as lack of access to a high
field magnet, sensitivity and cost. The work presented in this chapter was originally
published elsewhere.128

4.2 Materials and methods
4.2.1 Materials
Celecoxib was purchased from LC Laboratories® (Woburn, MA, USA). Miglyol
810N was generously donated by Sasol (NJ, USA). PFPE (produced by Exfluor Research
Corp., Roundrock, TX, USA) was generously provided by Celsense Inc. (Pittsburgh, PA,
USA) and used without further purification. CellVue® NIR815 (786 nm/814 nm) and
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CellVue® Burgundy (683 nm/707 nm) Fluorescent Cell Linker Kit was purchased from
Molecular Targeting Technologies, Inc. (MTTI) (West Chester, PA, USA). Purified
mouse anti-mouse CD45.1 monoclonal antibody conjugated to FITC (fluorescein
isothiocyanate) used for cell labeling was obtained from BD PharmingenTM. Antifade
ProLong® Gold (Invitrogen) was used as the mounting medium. Lysotracker® Green
DND-26 and Hoechst 33342 were obtained from Invitrogen. Bacterial lipopolysaccharide
(LPS) was obtained from Sigma Aldrich. PGE2 enzyme-linked immunosorbent assay
(ELISA) kit was obtained from Cayman Chemical Company (Ann Arbor, MI, USA). For
all other reagents and cell culture conditions, see section 3.2.1.
4.2.2 Preparation and characterization of PFPE nanoemulsions

Preparation
PFPE nanoemulsions were prepared using a mixture of nonionic surfactants, P105
and CrEL. A premade aqueous solution of mixed surfactants was used (section 3.2.3.1).
PFPE formulations were prepared to a final volume of 25 mL and the amount of
ingredients is shown in Table 4.1. Celecoxib (5 mg) was first dissolved in 0.95 g of
Miglyol 810N by overnight stirring while 6 μL of NIRF dye stock solution (1 mM in
ethanol) was added before blending with PFPE. PFPE oil (1.81 g) was transferred to a
500 mL round bottomed flask containing celecoxib, NIRF dye and Miglyol 810N and
stirred at 1200 rpm, RT for 15 min. To this 11.5 mL (0.575 g of mixed surfactant) of
mixed surfactant solution was added and stirred at 1200 rpm for additional 15 min. To
this mixture, 11.5 mL of deionized water was added and stirred under ice-cold conditions
for 5 min at 1200 rpm. The coarse emulsion was processed (Microfluidics M110S) for 30
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pulses under recirculation mode (inlet air pressure ~6 bar) and temperature was noted.
Sterile-filtered nanoemulsion samples (1.5 mL) were stored at 4 °C, 25 and 37 °C to
assess the stability. The bulk of the nanoemulsion was stored at 4 °C until use.
Nanoemulsion without celecoxib and NIRF dye was prepared in the same way to serve as
the control. Table 4.1 shows components of all the nanoemulsions (A, B and C)
formulated. Nanoemulsions were characterized by DLS measurements,

19

F NMR and

NIRF imaging.

Table 4.1. Table showing components of PFPE nanoemulsions A, B, and C.
Nanoemulsion
Component
Celecoxib
PFPE
Miglyol 810N
Cremophor® EL
Pluronic® P105

A
mg/mL
0
72
38
13.8
9.2

B
mg/mL
0.2
72
38
13.8
9.2

Ca
mg/mL
0.2
72
38
13.8
9.2

NIRF Dye
μM
μM
μM
Cellvue® NIR815
0
0.24
0
Cellvue® Burgundy 0
0
0.24
a
Nanoemulsion C is used for confocal microscopy of
labeled macrophages

Droplet size and zeta potential measurements by DLS
The size and zeta potential distribution of the nanoemulsion droplets in aqueous
medium was determined by DLS at 1:40 v/v as mentioned in section 3.2.4. The stability
of nanoemulsions incubated (37 ºC, 5% CO2) in cell culture medium (DMEM with 10%
FBS) for 24 h was tested under same conditions.
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19

F NMR measurements of nanoemulsions
19

F NMR was recorded (Bruker, 470 MHz) on nanoemulsions (and dilutions in

water) with 0.02% v/v TFA in water solution mixed in 1:1 v/v ratio (200 μL each).

19

F

NMR peak around -91.5 ppm corresponding to 40 fluorine nuclei was integrated with
TFA (set at -76.0 ppm) as reference. Amount of PFPE per mL nanoemulsion was
quantified based on the number of

19

F under PFPE peak at -91.5 ppm as shown in

Equation 3.5.

NIRF imaging of nanoemulsions
NIRF images of the above prepared NMR samples were recorded on an flat bed
imaging system (Odyssey® Infrared Imaging System, LI-COR Biosciences, NE, USA).
Nanoemulsion B loaded with celecoxib and NIRF dye was imaged. The NMR tubes with
nanoemulsions were aligned and carefully taped to a paper, placed in the sample
compartment and imaged. Images at 785 nm excitation wavelength and emission above
810 nm were collected. Imaging parameters include an intensity setting of 2 and 2.5 mm
focus offset. NIRF signal was quantified from the obtained images using the instrument
software (Odyssey® Imager v.3). Nanoemulsion A was used to correct for the
fluorescence background. Images were quantified by drawing region of interest (ROI)
around the total area corresponding to the nanoemulsion (with aqueous TFA) in the NMR
tube was carefully selected for quantification after setting the nanoemulsion A
fluorescence as background in the instrument software. Fluorescence is obtained as
relative fluorescence units (RFU).
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HPLC Method and Validation
A previously reported high performance liquid chromatography (HPLC) method
was adapted43 and required validation parameters such as linearity, accuracy, inter-day
precision, limit of detection (LOD) and limit of quantitation (LOQ) were evaluated for
celecoxib (Table 4.2) according to ICH Q2 (R1) guidelines.207 The HPLC method
consisted of a Waters Alliance (Waters Corporation, Milford, MA, USA) equipped with a
Waters 2690 separation module and Waters 996 Photodiode Array detector. Data was
acquired and analyzed by the Empower™ 2 Pro software. Analysis was performed using
C18 column (Hypersil Gold C18 150mm X 4.6mm, 5μm pore size) and 75:25
methanol:water as mobile phase with the flow rate of 1 mL/min at ambient temperature.
The detection wavelength was 252 nm.
Linearity and Range: The calibration curves were constructed with 6 concentrations
ranging from 5 to 0.15 μg/ml. The linearity was evaluated by linear regression analysis
using peak areas of celecoxib solutions.
Accuracy and Precision: Accuracy and precision of the assay method was evaluated for
both

intra-day

and

inter-day

variations

at

three

different

concentrations

(3.75, 1 and 0.31 μg/mL), different from calibration curve for three days. Accuracy and
precision were expressed in terms of percent mean recovery and percent relative standard
deviation (% RSD) respectively. Intermediate precision, which refers to inter-assay
variations was measured across three days.
Limit of Detection and Quantitation: LOD and LOQ were determined based on the
standard deviation (SD) of the response (σ) and slope (S) of the calibration curve
obtained from multiple calibration curves. LOD is calculated by 3.3σ/S and LOQ by
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10σ/S, where σ is the SD of the intercept of the calibration curves and S is the mean of
slope of the calibration curves.

Drug content in nanoemulsion
The above-mentioned method was used to assess celecoxib content in
nanoemulsions. Celecoxib was extracted from nanoemulsion using methanol. This
method was slightly modified from the previously published method, which utilized
methanol/water (75/25) for celecoxib extraction.43 Nanoemulsion B (250 μL) was
dispersed in 10 mL methanol and vigorously vortexed. The mixture was centrifuged at
4000 rpm (Centrifuge 5804 R, 15 amp version) for 10 min. PFPE was separated as a clear
oil at the bottom of the tube. Supernatant was collected and analyzed for celecoxib.
Analysis was carried out in triplicates. All the formulation ingredients were analyzed
separately for possible interference using same chromatographic conditions. The obtained
data is reported as percent drug loaded in the nanoemulsion compared to the theoretical
concentration.

Cell viability
Cell viability was assessed as outlined in section 3.2.4 with modifications using
CellTiter-Glo® luminescence assay. Briefly, mouse macrophages (RAW 264.7) were
plated in 96 well plate at 10,000 cells/well. After overnight incubation at 37 °C and 5%
CO2, culture medium was removed and adhered cells were exposed to nanoemulsions A
and B (prediluted in complete medium) at different PFPE concentrations and incubated
overnight. 50 μL of the medium was carefully removed and 25 μL of CellTiter-Glo®
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analyte was added to each well. The plate was shaken for 20 min at RT to induce cell
lysis. 60 μL of the cell lysate was transferred to a white opaque 96 well plate and
luminescence was recorded.

Cell uptake
To assess the in vitro behavior of the nanoemulsions, cell labeling studies were
conducted on mouse macrophages. Cells were cultured in 6 well plates at 0.3 million per
well for 48 h. After aspirating the medium, cultured cells were washed with medium and
DPBS. Cells were exposed to nanoemulsion B (prediluted in medium) with concentration
of PFPE ranging from 0.09 to 1.4 mg/mL. 2 mL of nanoemulsion B containing medium
was added to each well. Cells were incubated for 24 h at 37 °C and 5% CO2. Cells from
all samples were counted using neubauer hemocytometer. 19F NMR sample was prepared
as outlined in section 3.2.4.

19

F NMR measurements of labeled cells
NMR tubes with the labeled cell lysate (~400 μL) prepared as described above

were subjected to 19F NMR analysis to quantify the total fluorine content in the cells. The
number of 19F per cell was calculated using Equation 3.6 (section 3.2.4).

NIRF measurements of labeled cells
NMR tubes containing labeled cells, TFA and water were directly imaged on the
flat bed imaging system. Briefly, the NMR tubes were aligned and carefully taped to a
paper, placed in the sample compartment and imaged. Images at 785 nm excitation
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wavelength and emission above 810 nm were collected. Imaging parameters include an
intensity setting of 8 and 2.5 mm focus offset. Images were quantified by drawing ROI
around the sample to obtain integrated fluorescence intensity. Cells that are not exposed
to the nanoemulsion were used for background correction.

Fluorescence microscopy
Images of nanoemulsion labeled mouse macrophages were captured using
confocal microscopy (Leica TCS SP2 spectral confocal microscope, Leica Microsystems)
to assess the intracellular distribution of the nanoemulsion. Macrophages were cultured
for 24 h on glass cover slips (Fisherfinest, 22x22-1) placed in a 6-well plate at a
concentration of 105 cells per well. Cultured macrophages were exposed to nanoemulsion
C (21 μL nanoemulsion/mL medium; 2 mL total) for 24 h. After removing 1 mL
medium, cells were fixed in 1 mL of 4% paraformaldehyde for 30 min. The medium in
the cultured confocal plates (with glass cover slips) was carefully removed and washed
with DPBS / 1% FBS. A stock solution of FITC dye conjugated mouse antimouse
CD45.1 antibody (CD45-FITC) in DPBS / 1% FBS was prepared at 1 μg/mL
concentration. Cells in each well were exposed to 1 mL of the stock solution and left
undisturbed at RT. After 15 min, dye solution was removed and washed with DPBS / 1%
FBS twice. Each cover slip was transferred to a microscopy slide with antifade mounting
medium (ProLong® Gold, Invitrogen). Images were captured on a spectral analyzer
confocal microscope by Dr. John A. Pollock. For visualizing FITC, excitation was
achieved with the blue Ar laser 488 nm and emission window of 500 nm to 590 nm.
Visualizing the Cellvue® Burgundy dye was achieved with the red HeNe 633 nm laser
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excitation and emission window of 640 nm to 850 nm. Emission windows were selected
in order to avoid spectral overlap between FITC and Cellvue® Burgundy detection. A
transmission DIC image was acquired simultaneous to each confocal scan.
To further investigate the presence of droplets in the specific intracellular
compartments, lysosomal labeling was performed. Macrophages were seeded on glass
bottom confocal plates (P35G-1.0-14-C, MatTek Corporation) for 24 h at a concentration
of 0.25 x 106 cells per well. Cultured macrophages were exposed to nanoemulsion C for
24 h. After aspirating the medium and repeated washings with DPBS, cells were exposed
to Lysotracker® Green DND-26 (150 nM). After 1 h incubation, cells were washed and
fixed in 4% paraformaldehyde for 30 min. Fixed cells were washed with DPBS / 1% FBS
and exposed to Hoechst dye (1 μg/mL) dissolved in DPBS / 1% FBS for 5 min. Cells
were washed and stored in DPBS at 4 ºC until imaged. Imaging was performed on
Spinning Disk Confocal microscope (Andor Revolution XD) with 60x oil immersion
objective (NA 1.49). The emission filters were 447/60 nm band pass filter in the 405
channel (Hoescht 33342), 794/160 nm band pass filter in the 640 channel (Cellvue®
Burgundy), and 525-50/600-45/690 nm triple band pass filter in the 488 channel
(Lysotracker® Green DND-26).

PGE2 assay
To investigate the in vitro therapeutic efficacy of the drug carrier, effect of
nanoemulsions on PGE2 production by macrophages was assessed. Cells were plated in 6
well plates at 0.3 million cells/well and incubated overnight. Cells were exposed to
nanoemulsion B at 1.4 mg/mL PFPE concentration (9.28 μM celecoxib), dimethyl

87

sulfoxide (DMSO), and free drug dissolved in DMSO (9.28 μM). Fresh medium was
added to unexposed cells. After overnight incubation, all wells were washed (2x) with
medium and DPBS. Bacterial toxin, LPS, at 1 μg/mL diluted in medium (2 mL total)
was added to each well with cells (exposed and unexposed) and incubated. Unexposed
cells treated with LPS were designated as control and unexposed cells without LPS
activation were designated as untreated. After 4 h incubation, supernatant was collected
and analyzed using commercially available PGE2 ELISA kit. Samples were analyzed at
two different dilutions (1:5 and 1:10) and two replicates of each dilution were used.
Assessment of PGE2 production in the supernatant and data analysis was performed
according to the manufacturer instructions. In a separate experiment, macrophages were
exposed to either of the nanoemulsions A and B at 1.4 mg/mL PFPE concentration. LPS
treatment was performed post cell labeling with nanoemulsions A or B for 3 h. Fresh
medium was added to unexposed cells (untreated). PGE2 production was quantified in the
supernatant using PGE2 ELISA kit. Mean and standard error of mean (SEM) were
obtained for each treatment.

Statistical analysis
One-way analysis of variance (ANOVA) with Tukey's multiple comparison test
was conducted to evaluate statistical significance between treatments for PGE2 assay
using GraphPad Prism version 4. Statistical significance was defined at p < 0.05.

4.3 Results and Discussion
A novel COX-2 inhibiting PFC theranostic nanoemulsion with dual imaging
capabilities (NIRF and

19

F MR) was prepared to label macrophages upon exposure and
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inhibit their COX-2 activity. Each component in this design has a unique role in
achieving theranostic potential of the final nanoemulsion. The PFPE nanoemulsion
contains three key components: (a) the anti-inflammatory drug celecoxib (b) an NIRF dye
for fluorescence imaging and (c) PFPE to quantitatively image deep tissues using

19

F

MRI. The design included a combination of two imaging agents for future utilization of a
wide array of techniques such as fluorescence microscopy and imaging, flow cytometry,
19

F NMR and MRI to characterize the formulation and achieve complementary

information about in vitro and in vivo performance. Commercially available lipophilic
dyes fluorescing in the NIR region, CellVue® NIR815 (excitation maximum (Ex) =786
nm, emission max (Em) = 814 nm) or Burgundy (Ex = 683 nm, Em = 707 nm), were
selected.
A proposed nanoemulsion droplet structure schematic is shown in Figure 4.1. The
schematic shows PFPE core of the droplet surrounded by HC oil corona and stabilized by
surfactants (outermost layer) in the aqueous medium. It is known that PFCs show greater
hydrophobicity than lipophobicity, which suggests they would have lower affinity for
mixing with water than oils.142,143 Furthermore, in fluorous phase chemistry literature, it
was demonstrated that fluorocarbons can form a distinct liquid phase when mixed with
water and organic solvents.208 Based on these chemical properties of PFCs, PFPE was
hypothesized to be in the core of the droplet (Figure 4.1). Recent study by Zarzar et al.209
showed that emulsions containing mixtures of pure PFC (perfluorohexane) and a nonfluorinated HC (hexane) in aqueous medium displayed droplet structure dependent on the
type of surfactant utilized. Similar to our proposed droplet structure (Figure 4.1), this
study demonstrated that perfluorohexane forms core of the emulsion droplet, while
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hexane forms the corona, when hydrocarbon surfactant, sodium dodecyl sulfate, was
used. As a result of the preferentially reduced interfacial tension between hydrocarbon
and aqueous surfactant solution, the authors conclude that perfluorohexane resides in the
core of the droplet.209 Furthermore, the reported interfacial tensions of fully fluorinated
PFCs with aqueous surfactant solutions are higher (~17-20 mN/m)190 compared to
interfacial tension between PFC and HC oil (7 mN/m).210 Based on the
superhydrophobicity of PFCs and low interfacial tensions with HC oil, fully fluorinated
PFPE is expected to preferentially segregate in the core of the droplet to avoid less
favorable interaction with aqueous environment.

Figure 4.1. Proposed schematic of PFPE nanoemulsion droplet structure.128

The challenging task of stabilizing immiscible hydrocarbon oil (Miglyol 810N)
and PFPE was achieved by using a combination of CrEL and P105 under high shear.
CrEL is a polyethoxylated lipid produced by reacting castor oil and ethylene oxide in
1:35 molar.211 It is used in pharmaceutical preparations as solubilizer for hydrophobic
drugs and emulsifying agent.211 It is important to rationalize the use of CrEL in this
formulation, because of the studies showing associated toxicity. CrEL is associated with
hypersensitivity reactions, hyperlipidemia, abnormal lipoprotein patterns, aggregation of
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erythrocytes and peripheral neuropathy, which were observed with paclitaxel
formulation, Taxol.211 The amount of CrEL in Taxol is as high as 26 mL per
administration, with each mL of formulation containing 527 mg of CrEL.211,212 Paclitaxel
formulations with reduced amount of CrEL showed significantly decreased allergic
reactions suggesting that CrEL related toxicity is dose dependent.213,214 The formulation
reported in this work used only 13.8 mg of CrEL per mL emulsion, which is significantly
lower (~ 38 fold less compared to Taxol). Based on these calculations and prior
reports,213,214 we expect that allergic reactions are unlikely with the PFPE formulations
reported here.

Nanoemulsion preparation and characterization
Nanoemulsions with and without drug/dye (B, C and A respectively) are shown in
Table 4.1. Nanoemulsion A acts as a drug and dye free control for nanoemulsion B;
nanoemulsion C (containing Cellvue® Burgundy) was formulated to obtain confocal
images of labeled cells due to the unavailability of confocal excitation laser for Cellvue®
NIR815. During processing, use of organic solvents and thin film emulsification method
was avoided as residual solvents in the final formulation could lead to cell toxicity in test
cultures. DLS measurements showed an average initial droplet size and PDI less than 150
nm and < 0.15 respectively for nanoemulsions A, B and C, similar to C8-PFTE
formulation reported in chapter 3. A representative size distribution graph in Figure 4.2A
shows monomodal size distribution. Small droplet size helps end-process sterilization by
filtration214, which is needed for future in vivo experiments. Shelf life was determined by
following the droplet size and PDI upon storage at 4, 25 and 37 °C (Figure 4.2B). The
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inclusion of drug and dye in the nanoemulsion had no appreciable effect on droplet size
changes over time upon storage at 4 °C (Figure 4.2). Nanoemulsions A and B displayed
good stability at 4 °C, with mean droplet size and PDI below 160 nm and 0.15
respectively. However, samples stored at 25 and 37 °C showed temperature-dependent
increase in size (Figure 4.2C-D). Increase in storage temperature increases the rate of oil
diffusion from the droplets and rate of droplet collisions, which increases the droplet size.
Therefore, the nanoemulsions are recommended to be stored at 4 °C. Nanoemulsions A
and B, sterically stabilized by nonionic surfactants, showed a moderate zeta potential
value around -17±6 mV.

Figure 4.2. Characterization of nanoemulsions A and B using DLS.
A. Representative size and B. zeta potential distribution of nanoemulsions A (black) and
B (red). C. Droplet size changes with days for nanoemulsion A and D. Nanoemulsion B.
Error bars represent PDIw/2.128
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Reverse phase HPLC was utilized to evaluate drug loading in nanoemulsion B.
All the formulation ingredients were individually run for any possible interference with
the celecoxib peak. Excipients did not show UV absorbance around 252 nm. A
representative chromatogram of the nanoemulsion sample is shown in Figure 4.3.
Predicted celecoxib concentration based on calibration model was found to be
139.3±8.7 μg/mL nanoemulsion. The validation data is shown in Table 4.2.

Figure 4.3. Representative chromatogram of celecoxib from extracted nanoemulsion
sample.

Table 4.2. Compilation of assessed HPLC method parameters.

Linearity (0.15-5
μg/mL)
LOD
LOQ
Accuracy at 3
levels (n=3/level)
Intermediate
precision (interday)

Parameters
R2 of regression
analysis (peak area
vs. concentration)
Calibration curves
Calibration curves

Result

Criteria

> 0.999

> 0.99

Recovery

100.2-101.1%

95-105%

Overall %RSD

3.8%

<5%

45.7 ng/mL
138.5 ng/mL
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Nanoemulsions were further characterized by
representative

19

19

F NMR and NIRF imaging. A

F NMR peak and NIRF image of nanoemulsion B is shown in Figure

4.4A. A linear relationship was obtained for fluorine nuclei and NIRF signal for the
dilution series (Figure 4.4B). Based on this result, we believe that the NIRF imaging can
be used to assess the concentration-uptake relationship in cells without the need for
NMR. For absolute quantification,

19

19

F

F NMR is preferred due to the absence of

background. In summary, DLS results confirm the formation of nanoemulsion with stable
droplet size. 19F NMR and NIRF imaging clearly showed the incorporation of PFPE and
NIRF dye in the nanoemulsion. HPLC analysis quantified the drug content in
nanoemulsion B.

Figure 4.4. Characterization of nanoemulsion B for imaging functionalities.
A. Representative 19F NMR spectrum and NIRF image of diluted nanoemulsion. B.
Linear relationship between 19F atoms and RFU quantified in serial dilutions of
nanoemulsion in TFA containing media.128
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In vitro toxicity and uptake studies in macrophages
Before performing in vitro biological tests, colloidal stability of nanoemulsions in
cell culture medium was evaluated by monitoring changes in droplet size. No
considerable change in droplet size and PDI was noted under cell culture relevant
conditions (Table 4.3). This is crucial as any structural changes in the nanodroplets
during incubation with cells could give misleading results on the nanodroplet cellular
uptake and toxicity profile, which would further render the nanoemulsions unsuitable for
in vivo testing. As shown in Figure 4.5, no considerable effect on cell viability was
detected after 24 h exposure to nanoemulsions. Cell viability was between 92-104% of
the control group (untreated cells).

Table 4.3. Average droplet diameter and PDI of nanoemulsions A and B before and
after incubation in media.
Media incubation Nanoemulsion A
Average diameter
(nm)
Before
144.6
After
140.6

Utilizing

19

PDI
0.11
0.13

Nanoemulsion B
Average diameter
(nm)
123.8
128.7

PDI
0.15
0.14

F NMR and NIRF imaging, cellular uptake of nanoemulsion B was

characterized. Representative

19

F NMR and NIRF image of labeled cells is shown in

Figure 4.6A. PFPE line shape and peak position at -91.5 ppm was unchanged upon
uptake in cells when compared with PFPE in nanoemulsion B (Figure 4.4A). This result
suggests the chemical stability of PFPE in cells, which is crucial for their use as an
imaging tracer. Both

19

F NMR and NIRF measurements of labeled cells showed a

concentration-dependent increase in uptake of the nanoemulsion (Figure 4.6B).215 Since
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macrophages

can

internalize

colloidal

formulations

through

receptor-mediated

endocytosis, concentration-dependent saturation of uptake is expected. To facilitate
comparison between 19F NMR and NIRF, uptake vs. concentration data was fitted with a
one-site binding saturation model. This model is appropriate for NP uptake occurring
through receptors as the receptors get saturated at high concentration of nanoemulsion,
thus leading to saturation of uptake. The amount of nanoemulsion internalized is
proportional to the amount bound to the receptor. It should be noted that NP uptake is
triggered due to the binding of several receptors leading to receptor clustering and
endocytosis. To apply a one-site binding model, a set of receptors bound by NP can be
assumed as a single receptor. According to the one-site binding saturation model, the
amount of internalized nanoemulsion (Y) is given by:
Y=

Ymax ∗ X
Km + X

Equation 4.1

where, Y is uptake (19F or RFU normalized to cell number), Ymax is the maximum uptake,
X is the concentration of PFPE, Km is the concentration of PFPE required to obtain halfmaximum uptake (Ymax/2).
The uptake-concentration relationship obtained with 19F NMR and NIRF methods
showed good fitting to this model (R2 > 0.98) as shown in Figure 4.6C-D. The x-axis of
these graphs is shown as amount of PFPE, which is proportional to the amount of
emulsion. Km obtained from this model was very similar for 19F NMR and NIRF data (2.6
vs. 2.7 mg/mL PFPE) as shown in Figure 4.6C-D. This result indicates that NIRF and 19F
NMR can be used interchangeably to assess uptake, thus supporting the use of
complementary imaging methods for data validation. Interestingly, good correlation was
obtained without chemically conjugating PFPE and fluorescent dye as reported earlier.170
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Based on these results, it can be postulated that the nanoemulsion was not destabilized
before entering the cell in the labeling medium. Any instability of nanoemulsion would
lead to poor or no correlation between 19F NMR and NIRF signals due to the differences
in uptake of imaging agents. A strong correlation between the two imaging agents is a
requisite to utilize the nanoemulsion for in vitro and in vivo dual mode imaging studies.

Figure 4.5. Macrophage cell viability post 24-hour exposure to nanoemulsions A and
B.
Each data point represent mean of at least three replicates and the error bars are SD of the
mean. Values are reported as percent control (0 mg/mL PFPE).128
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Figure 4.6. Characterization of cellular uptake of nanoemulsion B.
A. Representative 19F NMR of cells labeled with nanoemulsion B. TFA reference peak is
set at −76.0 ppm. NIRF image of cells labeled with nanoemulsion B in NMR tube. B.
Dose-dependent increase in cell uptake demonstrated by 19F NMR and NIRF (n=2). C
and D. Cellular uptake from panel B fitted to a one-site binding saturation model.128

Presented nanoemulsions have lower amount (7.2% w/v) of PFPE than earlier
reported cell tracking formulations.169 However, we found that at a very low PFPE
concentration of only 1.4 mg/mL, significant cell uptake (1.0 x 1011 fluorine atoms per
cell) is achieved. With this labeling efficiency, approximately 7.5 x 105 cells per voxel
are required to obtain in vivo 19F MR images at 11.7 T.151,163 These findings suggest that
this formulation platform could be utilized for cell tracking of ex vivo labeled cells. The
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utility of this nanoemulsion to detect in situ labeled macrophages would require further
investigation because the detection sensitivity also depends on the severity of
inflammation, extent of macrophage infiltration and injection volume (discussed in
chapter 5).
Although 19F NMR and NIRF imaging of the nanoemulsion labeled cells showed
dose-dependent cell labeling, conclusions about membrane-adsorbed versus internalized
nanodroplets cannot be made from this data alone. Therefore, fluorescence confocal
microscopy was performed on macrophages exposed to nanoemulsion. To more closely
match the excitation and emission capabilities of the confocal microscope system, an
alternate drug loaded nanoemulsion (nanoemulsion C, Table 4.1) was prepared with
Cellvue® Burgundy dye (683 nm / 707 nm). Cells exposed to nanoemulsion C were
stained with anti-CD45.1 antibody conjugated with FITC dye (CD45-FITC) to visualize
cell membrane. CD45 is a protein tyrosine phosphatase, receptor type C cell membrane
associated protein. The nanoemulsion uptake was visualized by Cellvue® Burgundy dye.
Figure 4.7 clearly shows the presence of the CD45 protein (green) and the
Cellvue® Burgundy labeled nanodroplets (red) in the cytoplasm. As a control, cells not
exposed to nanoemulsion were labeled with CD45-FITC. No evidence of NIRF signal
was observed in the control group. The presence of nanoemulsion as distinct entities,
which is also evident in the transmitted DIC view of the cells (Figure 4.8A), indicates
their presence in endosome-like compartments. Simultaneous presence of CD45 protein
and nanoemulsion droplets (green and red fluorescent signals) further supports the
speculation that nanodroplets are present in the endocytic compartments. CD45
internalization has been previously reported.216 Three-dimensional view of the cell
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revealed that the nanodroplets are within the cytoplasm, specifically in the maximum
projection cross-sectional view of the cell (Figure 4.8B). In a separate experiment,
presence of nanoemulsion droplets in the intracellular compartments was assessed by
labeling acidic endosomal/lysosomal compartments with Lysotracker® Green. It appears
that nanoemulsion droplets are distributed in the entire volume of the cytoplasm and no
preferential accumulation in the lysosomes was observed after 24 h (Figure 4.8C).

Figure 4.7. Confocal microscopy of macrophages exposed to nanoemulsion C.
A. Cells labeled with anti-CD45 (FITC) green and incorporated nanoemulsion C
containing celecoxib and Cellvue® Burgundy dye represented as red. Cells not exposed
to the nanoemulsion C exhibit CD45 labeling with FITC (green) but no red signal.
Transmitted light DIC image acquired simultaneously shows field of view (Bar = 30 μm).
Image by Dr. John A. Pollock, 2013.128
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Figure 4.8. Confocal microscopy to assess intracellular localization of nanoemulsion
C.
A. Cells labeled with CD45-FITC (green) and incorporated nanoemulsion C containing
Cellvue® Burgundy dye exhibit broad expression of CD45 as well as concentrated
fluorescent signal coincident with Cellvue® Burgundy, indicating internalization of
CD45 protein and nanoemulsion C. The transmitted light DIC view of the cell reveals the
black refractive droplets, coincident with the red and green fluorescent signals (Bar =
5 μm). B. A single cell imaged in serial section and rendered by maximum-projection to
represent all of the Cellvue® Burgundy labeled droplets viewed from above and 90°
cross-section, to reveal that the droplets are distributed throughout the cell cytoplasm. C.
Cells showing concentrated red fluorescence from nanoemulsion C, not clearly localized
with acidic compartment label, Lysotracker® Green DND-26. Nucleus labeled with
Hoechst dye is shown in blue (Bar = 5 μm). Panels A and B images by Dr. John A.
Pollock, 2013.128
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COX-2 inhibition in macrophages
The potential anti-inflammatory effect of celecoxib-loaded nanoemulsion B on
the production of PGE2 by LPS activated macrophages was studied (Figure 4.9A). LPS
activated cells showed significant increase (p < 0.001) in PGE2 as compared to untreated.
A statistically significant difference (p < 0.001) between nanoemulsion B and LPS
treated control was observed. Cells labeled with nanoemulsion B produced, on average,
50.6±8.2 pg of PGE2 per mL as compared to 504.5±41.2 pg/mL by LPS activated control.
Exposing LPS activated macrophages to DMSO (vehicle for free drug) has not shown
any effect on PGE2 production compared to control. Although, PGE2 reduction by
nanoemulsion B is not statistically different from free drug, nanoemulsion mediated
celecoxib delivery may be advantageous in reducing systemic exposure to the drug and
related side effects. Additionally, dual mode imaging capabilities allow for non-invasive
imaging of nanoemulsion biodistribution. In a separate experiment, effect of
nanoemulsions A and B on PGE2 production was studied (Figure 4.9B). Nanoemulsion B
showed significant reduction in PGE2 production compared to nanoemulsion A and
control (Figure 4.9B). Nanoemulsion A has not shown any significant contribution to
changes in PGE2 levels proving that the drug free vehicle is inert towards PGE2
production. These results clearly demonstrate that the presented theranostic PFPE
nanoemulsion is internalized by macrophages and act to inhibit COX-2 through celecoxib
delivery.
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Figure 4.9. Effect of nanoemulsion-mediated celecoxib delivery on PGE2 production
by LPS activated macrophages.
A. PGE2 produced by LPS-activated macrophages exposed to nanoemulsion B, free drug
dissolved in DMSO and DMSO. Cells not exposed to LPS were designated as untreated.
* # $ represent statistical significance comparisons (p < 0.001) between treatments. B.
Separate experiment comparing nanoemulsion A and B. Each data point represents the
mean ± SEM of at least four independent measurements.128

4.4 Conclusion
In this chapter, a novel celecoxib carrying nanoemulsion formulation equipped
with dual mode imaging capabilities is prepared and characterized. The prepared
nanoemulsions showed good stability for 70 days. Correlation of dose-dependent cellular
uptake between NIRF and

19

F NMR signals showed the complementary nature of dual

mode imaging functionality.

19

F NMR, NIRF imaging and confocal fluorescence

microscopy evidently demonstrated the uptake of nanoemulsion droplets by
macrophages. Nanoemulsion delivery of celecoxib is established in macrophages by their
inhibitory effect on PGE2 production. Before in vivo studies ensued, a modified
nanoemulsion incorporating additional fluorescent dye was prepared, which is described
in chapter 5.
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5

Dual fluorescent PFPE nanoemulsions for improved optical imaging
capabilities

5.1 Introduction
In this chapter, we addressed a common problem associated with standard
epifluorescent microscopy methods for cell and tissue imaging, which use excitation
lasers and filters that do not alternately support NIRF dye detection. In chapter 4, we
found that in a cellular imaging experiment, full excitation of the NIRF dye by a standard
633 nm laser is difficult to achieve, which led to low fluorescent signal from labeled cells
and possibly in future histology samples. Commonly used epifluorescent microscopes
lack the optics required for NIRF imaging. To overcome the problem, a lower
wavelength dye (e.g. Cellvue® Burgundy) was introduced to the system in order to
match the optical properties of available fluorescence instruments. Although lower
wavelength dyes are advantageous for experiments involving tissues and cells, NIRF
dyes are required for in vivo imaging to obtain images with reduced background
fluorescence. Therefore, in some reports, two dyes are introduced in the formulation to
facilitate in vivo imaging as well as ex vivo histology and flow cytometry.171 However,
the presence of two dyes in the same environment has higher chance for chemical and
optical interaction. To avoid these issues, the PFPE nanoemulsion (chapter 4) was
modified with distinct fluorescent reporters with non-overlapping fluorescence spectra,
introduced into distinct oil phases of the PFC nanoemulsion. Having each oil phase
separately labeled by a fluorescent dye allows for improved correlation between in vivo
imaging and histological data. Dual fluorescent labeling can improve intracellular
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tracking of the nanodroplets and it can be used to assess nanoemulsion integrity in cells
and tissues. Furthermore, long-term stability of NIRF dye in biological samples can be
deduced by comparing the stability with lower wavelength dye. The in vivo imaging
potential of the nanoemulsion is discussed at the end of the chapter. Development and in
vitro characterization shown in this chapter was originally published elsewhere.217

5.2 Materials and methods
5.2.1 Materials
Cy3-PFPE conjugate was synthesized by Michael J. Patrick at Carnegie Mellon
University per Patrick, and Janjic et al.218 and Janjic et al.170 synthetic methods, and used
without

further

purification.

DiR

(1,1'-Dioctadecyl-3,3,3',3'-

Tetramethylindotricarbocyanine Iodide) lipophilic tracer was purchased from Invitrogen
and used without further purification. RAW 264.7 cells were cultured similar to section
3.2.1. Fluorescence measurements were performed on Tecan Safire2 fluorescence plate
reader at Carnegie Mellon University.
5.2.2 Preparation and characterization of dual fluorescent nanoemulsions

Nanoemulsion preparation
Nanoemulsions were prepared at 25 mL scale following the method described in
section 4.2.2. with some modifications. PFPE oxide (0.98 mL) and Cy3-PFPE (0.02 mL)
were blended by vortex mixing in a 50 mL eppendorf tube. A mixture of 1 mL Miglyol
810N and 100 μL of 5 mM DiR dye in absolute ethanol (20 μM) was added to the Cy3PFPE/PFPE mixture and vortex mixed. The remaining procedure is same as described in
section 4.2.2. For stability studies, samples were stored at 4 °C. To prepare drug-
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containing nanoemulsion, 5 mg celecoxib was dissolved in 1 mL of Miglyol 810N by
overnight stirring and the nanoemulsion prepared following above procedure.

Nanoemulsion characterization
Nanoemulsions were characterized for droplet size, PDI, zeta potential, NIR
imaging on a LiCOR Odyssey® imager at an 800 nm emission wavelength, 19F NMR and
19

F content determination as noted in sections 3.2.1 and 4.2.2. Fluorescence

measurements (by Michael Patrick) were performed on Tecan plate reader using a 10 nm
bandwidth. Nanoemulsions were diluted 20 μL into 480 μL (4% v/v) of de-ionized
water, and 150 μL of diluted sample was measured. Excitation spectra were obtained
with an emission wavelength of 590 nm for Cy3 and 790 nm for DiR. The excitation
wavelengths were scanned with a 2 nm step from 400 nm to 570 nm for Cy3 and 400 nm
to 770 nm for DiR. Emission spectra were obtained with an excitation wavelength of 530
nm for Cy3 and 730nm for DiR, and emission wavelengths were scanned with a 2 nm
step from 550 nm to 850 nm for Cy3 and 750 nm to 780 nm for DiR. Fluorescence signal
stability measurements were determined by fluorescence synchronous scan (excitation
500 to 830 nm, with emission at a 20 nm offset and 4 nm step) using samples prepared as
above in duplicate. Detector gain setting was automatically calculated by the instrument
for the first time point and the same value kept for follow-up measurements. Correlation
of fluorescence signals with nanoemulsion concentration was determined by preparing
serial dilutions of nanoemulsion in deionized water and using 100 μL of sample in
triplicate for fixed Ex/Em wavelength measurements at 544/564 nm (Cy3) and
748/768 nm (DiR).
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Confocal microscopy
To visualize the cellular uptake of nanoemulsion, confocal microscopy was
recorded for nanoemulsion-labeled macrophages (RAW 264.7). Briefly, 0.1 million
macrophages were seeded in 6-well plate on a coverslip and incubated at 5% CO2 and
37 °C. After 48 h, medium was aspirated, and cells washed with DPBS. Macrophages
were exposed to nanoemulsion containing medium at 1.4 mg/mL concentration of PFPE.
Dye-free nanoemulsion was used as a control, and macrophages that were not exposed to
nanoemulsions were treated as negative control. Cover slips were transferred to glass
slides and mounted with Prolong Gold. Dr. John A. Pollock performed confocal imaging.
Imaging was achieved with 543 nm excitation and emission detection from 550-625 nm
on a Leica SP2 spectral confocal for the detection of the Cy3 dye. DiR was detected with
633 nm excitation and emission detection from 650-850 nm, with simultaneous
acquisition of transmitted DIC images of the cells. Multicolor merge was achieved with
Leica image software version 2.3 and the image contrast/brightness was adjusted in
Adobe® Photoshop CS6.

5.3 Results and discussion
PFC nanoemulsions have been labeled by fluorescent dyes before, either by
introducing the fluorescent dye into the surfactant layer160 or the fluorocarbon core of the
PFC nanodroplet.170 In the present PFC nanoemulsion, two fluorescent dyes are
introduced, a cyanine dye (Cy3)219 and a NIRF carbocyanine dye (DiR) into two distinct
oil phases of the nanoemulsion. Cy3 is conjugated directly to PFPE and DiR was added
to the Miglyol oil. Fluorescent dye conjugated to the PFPE chain is expected to remain
entrapped in the PFPE core of the nanoemulsion droplet, following typical fluorous phase
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colloidal behavior.152,170 The Miglyol oil phase carries the NIRF tracer (DiR) and
celecoxib, while the PFPE phase carries the Cy3-PFPE.
5.3.1 Colloidal and imaging characterization of dual fluorescent nanoemulsions
The present nanoemulsion is designed to serve two roles: the carrier of COX-2
inhibitors to macrophages, and a triple-imaging agent for fluorescent in vitro imaging of
labeled cells and tissues, in vivo NIRF and

19

F MR imaging. Figure 5.1 shows the

colloidal stability of the dual fluorescent nanoemulsion. The presence of celecoxib did
not significantly affect the droplet size, PDI, and zeta potential of the nanoemulsion.
Average droplet size was around 175 nm and PDI was 0.2. The zeta potential was
negative (-43 ± 7.4 mV). Compared to the nanoemulsion reported in chapter 4, a larger
zeta potential value was observed, possibly due to the presence of multiple fluorescent
dyes in this complex system. Nanoemulsions stored at 4 °C and followed for at least 45
days showed no significant change in droplet size or PDI during that period (Figure 5.1).

Figure 5.1. Droplet size changes with days of dual fluorescent nanoemulsions stored
at 4 ° C. Originally published elsewhere. 217
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Fluorescence measurements were conducted to evaluate the stability of the two
fluorescent dyes present in the nanoemulsion. Our goal was to assure that the entire
formulation remains stable over time, including all three imaging modalities, to assure
reproducibility of in vivo studies. Nanoemulsions with and without the drug were stored
at three different temperatures, 4 °C, RT and 37 °C. Storage at higher temperatures (RT
and 37 °C) led to loss of DiR fluorescence, Figure 5.2A (top). Figure 5.2A (bottom)
shows visual color differences in representative nanoemulsion samples stored at the three
different temperatures, indicating changes in the incorporated dyes. Synchronous
excitation and emission scan measurements confirmed the presence of Cy3-PFPE,
revealed some DiR conversion into a lower wavelength emitting product, DiI-(5) (peak
around 650 nm). However, Figure 5.2C-D shows retention of normal spectral behavior of
both dyes when incorporated into the nanoemulsion. Ex and Em of the dyes in the
nanoemulsion are 552 nm and 564 nm for Cy3, and 750 nm and 768 nm for DiR.
Fluorescence measurements show that nanoemulsions stored at 4 °C retained
fluorescence signals for both Cy3 and DiR dyes. Fluorescent signals of Cy3-PFPE barely
decreased (4%) upon storage for 49 days at 4 °C. Whereas, DiR showed a reduced
fluorescence of 23% compared to day 0. Most NIRF dyes have stability issues.220 For
example, indocyanine green and cyanine 5 dyes have shown to undergo photobleaching
and degradation mechanisms leading to reduced fluorescence intensity.221,222 Therefore,
presence of highly stable Cy3 can be advantageous for histological assessments, where a
tissue undergoes several processing steps, which might degrade the labile NIRF dyes. It
should be noted that NIRF dye is indispensible in the formulation in order to reduce
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interference from autofluorescence in in vivo imaging. This combination is therefore an
improvement to our nanoemulsion reported in chapter 4.

Figure 5.2. Optical assessment of dual fluorescent PFPE nanoemulsions.
A. NIR fluorescence image of nanoemulsions stored at different temperatures taken at
800 nm emission using Li-COR Odyssey® NIR imager (top). Representative photo of the
nanoemulsion samples stored at 4 °C, RT and 37 °C (left to right) showing changes in
color resulting from DiR changes. B. Synchronous excitation / emission scan of Cy3 and
DiR in nanoemulsions with and without the drug. C. Excitation and D. Emission spectra
showing both dyes in the nanoemulsion (fluorescence measurements by Michael J.
Patrick, CMU, 2013).217

In this study, optical and

19

F MR properties of dual fluorescent theranostic

nanoemulsions were evaluated in vitro. In order to use fluorescence and
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F MRI as

complementary imaging techniques, a linear correlation between imaging signals and
nanoemulsion concentration is expected. As shown in Figure 5.3, we observed a linear
relationship between nanoemulsion concentration and

19

F atoms, DiR, and Cy3

fluorescence signal intensities. Lack of this relationship would potentially render the
theranostics inflexible, in utilizing the imaging techniques interchangeably.
Similar to the results from chapter 4, confocal microscopy showed the presence of
nanoemulsion droplets in the cytoplasm of macrophages (Figure 5.4) as distinct entities.
In the transmitted light (DIC) image (Figure 5.4A bottom row), macrophages labeled
with emulsions showed granularity in the cytoplasm, compared to untreated macrophages
(no emulsion), confirming the uptake of nanoemulsion droplets. Macrophages with dyefree nanoemulsion did not show fluorescence, although granularity was observed in the
DIC image (Figure 5.4A middle). Macrophages labeled with the dual fluorescent
nanoemulsion showed fluorescence corresponding to DiR and Cy3 dyes (Figure 5.4A
right column). Interestingly, a merged image showed that Cy3 and DiR signals are mostly
co-incident indicating their co-presence (Figure 5.4B) in the endocytic compartments and
probably in the nanoemulsion droplets. This image cannot conclusively prove that Cy3PFPE and DiR are present in the nanodroplet together due to the resolution and
instrument sensitivity issues to detect < 200 nm droplets. However, a qualitative
assessment regarding the co-presence of both dyes from PFPE and HC phases in the
nanoemulsion droplets indicate the integrity of nanoemulsion droplets during cell
labeling.
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Figure 5.3. Linear correlation of imaging signals with nanoemulsion concentration.
Linear correlation is observed for A. 19F atoms (n=2). B. Cy3 (n=3). C. DiR (n=3). Errors
bars are standard deviation from mean.217
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Figure 5.4. Confocal images of macrophages exposed to dual fluorescent
nanoemulsion.
A. Confocal fluorescence images of RAW 264.7 macrophages exposed to culture
medium (left column), nanoemulsion with no dyes (middle), and dual fluorescent
celecoxib nanoemulsion (right). The scale bar = 11.37 μm. B. Merged image showing
coincident DiR and Cy3 signals (scale bar = 5.43 μm). Image by Dr. John A. Pollock,
2013.217
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5.3.2 Evaluation in a neuropathic pain rat model
For experimental details and results, see chapter 7. The goal of this study was to
evaluate if nanoemulsion can be detected at the inflamed site using the two imaging
functionalities. A neuropathic pain model was utilized, where ligation of sciatic nerve
causes local inflammation and neuropathic pain. Of note, we evaluated a fluorescent
PFCE nanoemulsion in this model for simultaneous imaging and therapy (reduced
inflammation and pain), which is partly described in chapter 7. Doctoral thesis by Kiran
Vasudeva contains the full details of the study. In the current study, fluorescence was
observed at the inflammatory site confirming the delivery of nanoemulsion. Live animal
fluorescence imaging and ex vivo tissue imaging (Figure 7.10) separately confirmed the
presence of nanoemulsion at the injured sciatic nerve, but not in the contralateral nerve
and the sciatic region of healthy animal. However,

19

F NMR assessed after tissue

collection showed undetectable 19F signal in the injured nerve. These results necessitated
further studies to be conducted to increase the 19F MRI sensitivity, which is described in
chapters 6 and 7.

5.4 Conclusions
The study clearly shows that the nanoemulsion platform developed in chapter 4 is
amenable to modifications to obtain a dual fluorescent theranostic system. The reported
theranostic nanoemulsion was designed to offer flexibility for in vitro and in vivo
inflammation imaging, and histological analysis using three distinct imaging
functionalities (visible and NIRF, and

19

F MR). Despite the multifunctional nature, the

nanoemulsion displayed moderate storage stability based on size analysis for at least
45 days. Both dyes were detected in the nanoemulsion and in cells. The spectral
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characteristics of the two dyes in the nanoemulsion were retained following processing
and storage at low temperature. Due to the degradation of DiR dye to a lower wavelength
product, careful consideration has to be given for possible spectral interference during
imaging. The pilot in vivo experiment showed encouraging results for the utility of this
nanoemulsion to detect inflammation using NIRF imaging. However, the complementary
imaging method (19F MR) requires further investigation to increase imaging sensitivity
(described in chapters 6 and 7).
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6

Development and in vitro characterization of PFPE nanoemulsion
for increased MR sensitivity

6.1 Rationale
Our goal was to design, develop and evaluate fluorescent PFC theranostic
nanoemulsions for macrophage imaging and monitoring of therapeutic efficacy. In
chapters 3, 4, and 5, our efforts to develop stable non-toxic nanoemulsions were
encountered with problems pertaining to toxicity, cost, drug solubility and imaging
functionality. The results from these studies provided valuable information to be
considered for successful theranostic design. For example, the choice of the components
needs careful investigation in order to attain drug solubility, while realizing formation of
a stable and non-toxic nanoemulsion. Due to the instability of NIRF (DiR) dye, a balance
has to be maintained to achieve optimum stability and in vivo imaging. In this chapter,
the formulation from chapter 4 is further modified with increased amount of PFPE and a
lower wavelength carbocyanine dye (DiD) to resolve 19F MR sensitivity problem as well
as instability of NIRF dye. In vivo evaluation of the developed theranostic is presented in
chapter 7.
As mentioned before, formulations utilized for in situ macrophage labeling
contain high amount of PFCs, 10-40% v/v (18-72% w/w). The high concentration of
PFCs is required due to the inherent insensitivity of NMR principles. The amount of 19F
at the inflamed site depends on the extent of macrophage infiltration. If passive
accumulation through damaged vasculature is involved in the accumulation, then the
extent of EPR in the inflammation model also dictates the nanoemulsion accumulation,
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thus affecting the sensitivity. The concentration of PFPE reported in chapters 4 and 5 is
4% v/v, which is significantly lower than the formulations reported in the literature.
Additionally, the low EPR effect and macrophage infiltration in the localized nerve
inflammation would have led to low accumulation of nanoemulsion, thus affecting the
MR sensitivity. Previously, a fluorescent nanoemulsion containing high PFC content
(20 % v/v) detected neuronal injury by
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F MRI and fluorescence.223 Therefore, we

proposed to prepare nanoemulsions with increased amount of PFPE.

Nanoemulsion design
The droplet size and stability of the nanoemulsion could be affected by the
amount of surfactant (seen in chapter 3) and processing conditions. An increase in
surfactant amount could be required in order to stabilize the increased interfacial area due
to proposed use of high PFPE content. The effect of surfactant amount and processing
conditions on the PFPE nanoemulsion size and stability is not investigated in the previous
chapters. We initially proposed to evaluate the effect of these factors on droplet size, PDI
and stability by employing statistical design of experiments. Specifically, we proposed to
use Box-Behnken design with three factors (surfactant, pulses, PFPE) and three levels as
shown in Table 6.1. The levels for PFPE are selected between 8-12.5% v/v
(15-22.5% w/v), which is still lower than literature reported concentrations for PFCE223
because PFPE has two-fold greater 19F atoms compared to PFCE. The amount of Miglyol
was not changed. Surfactant levels were proposed based on oil-to-surfactant ratio (O/S)
and the total amount utilized in the nanoemulsion. Due to the presence of CrEL,
concentration more than 5-6% w/v were not preferred. The range of O/S (3.4 to 13.1)
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obtained includes the O/S (3.4) for formulations reported in chapters 4 and 5. Based on
this design, three nanoemulsions were experimented and one of them met the desired
criteria. Therefore, the design was not completed. This nanoemulsion was further
modified with fluorescent dye for dual mode imaging and evaluated for colloidal
stability, toxicity, effect on phenotype, and uptake kinetics in RAW 264.7 cells.

Table 6.1. Proposed factors and levels for nanoemulsion optimization
Factors/levels

Old formulation

Low

Medium

High

PFPE (w/v)

7.2

15

18.75

22.5

Surfactant (w/v)

2.3

2

3.75

5.5

Pulses

30

30

38

46

6.2 Materials and methods
6.2.1 Materials
All chemicals and cell culture reagents were obtained from commercial sources
and

used

without

purification.

DiD

(1,1'-Dioctadecyl-3,3,3',3'-

tetramethylindodicarbocyanine perchlorate) dye was purchased from Life Technologies.
Cytochalasin B was obtained from Sigma Aldrich. Griess Reagent System for nitrite
measurements was purchased from Promega (Madison, WI, USA). Phycoerythrin
conjugated Rat anti-mouse CD86 (CD86-PE) antibody and Rat IgG2a,k conjugated to PE
(isotype control) were obtained from BD Biosciences (San Jose, CA, USA). RAW 264.7
cells were cultured as previously reported in chapters 3, 4, and 5. The sources of all other
reagents are same as mentioned in chapters 3, 4, and 5.
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6.2.2 Preparation and characterization of fluorescent PFPE nanoemulsions

Preparation of nanoemulsions
Nanoemulsion formulation components and their amounts are shown in Table 6.2.
Nanoemulsions were prepared as discussed in chapter 4 with some modifications.
Celecoxib (5 mg) was solubilized in neat hydrocarbon oil, Miglyol 810N (0.95 g), by
overnight stirring. For drug-free nanoemulsions, neat Miglyol 810N with or without the
DiD dye was used. For dye-loaded nanoemulsions, DiD dye (100 μL of 2.5 mM ethanol
stock) was added to Miglyol 810N with or without the solubilized drug and vortexed in
the dark. PFPE, in required amounts (Table 6.2), was added and vortexed followed by the
addition of surfactant mixture in 2 mL portions. The surfactant mixture contained 3% w/v
CrEL and 2% w/v Pluronic® P105 dissolved in de-ionized water. After the addition of
deionized water, the mixture was vortexed and processed on a microfluidizer
(Microfluidics, M110S) for 30, 38 or 46 pulses at 6 bar inlet pressure. The total volume
of the prepared nanoemulsions was 25 mL. The obtained nanoemulsions were sterile
filtered (0.22 μm, Millipore) after equilibration for one day at 4 °C. pH of the drug-free
nanoemulsion (DFNE) and celecoxib-loaded nanoemulsion (CXBNE) were recorded
after filtration.

Colloidal characterization
Size and zeta potential analyzed similar to chapter 4. To assess serum stability,
nanoemulsions were dispersed in complete cell culture media at 1:40 dilution, stored at
37 °C, and the sizes were recorded without further dilution. Similarly, nanoemulsions
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were dispersed in buffered solutions at pH 5.0 and 7.4 at 1:40 dilution, incubated at 37 °C
and sizes recorded at predetermined intervals. Samples for follow-up stability analysis
were stored at 4, 25 and 37 °C. For formulation optimization studies, samples were also
stored at 60 °C and analyzed for droplet size and PDI.

Drug loading
Briefly, 50 μL of nanoemulsion was dispersed in methanol in a glass centrifuge
tube and vortexed for 1 min. This dispersion was subjected to centrifugation at 2000 rpm
for 5 min at 4 °C to separate PFPE oxide. The supernatant was assayed without further
dilution in triplicate using HPLC method reported in section 4.2.2.

Nanoemulsion characterization for fluorescent properties
To assess fluorescent properties, nanoemulsions were diluted with de-ionized
water (8% v/v) and 150 μL of this dispersion was measured for fluorescence excitation
and emission on Tecan Safire2 plate reader using a 10 nm bandwidth. Emission spectrum
was obtained by measuring fluorescence intensity from 630-798 nm with 4 nm step size
using excitation wavelength of 610 nm. The excitation spectrum was obtained by
measuring fluorescence intensity for wavelengths 400-668 nm with 4 nm step size using
emission wavelength of 690 nm. To assess fluorescence of dye in solution, the stock
solution of DiD dye (2.5 mM in ethanol) was dispersed 40 μL in 460 μL of ethanol. This
solution was further diluted 40 μL with 460 μL of di-water. 150 μL of this dispersion was
assessed for fluorescence emission. To obtain nanoemulsion spectra, 40 μL of
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nanoemulsion (10 μM DiD dye) was diluted with 460 μL of di-water and 150 μL of this
dispersion was assessed for fluorescence.

In vitro cytotoxicity
The effect of nanoemulsions on the viability of RAW 264.7 macrophages was
evaluated after a 24 h incubation at 37 °C with different concentrations of nanoemulsion
dispersed in whole media. Control cells were not exposed to any treatments. Cells were
plated at 10,000/well in 96 well plates and incubated overnight for adhesion, followed by
24 h incubation with treatments. After incubation, cells were washed twice with DPBS
(1x). CellTiter-Glo® analyte was added (40 μL/well) to induce cell lysis by shaking in
the dark for 20 min at RT. The obtained cell lysates (80 μL) were transferred to a white
opaque plate and luminescence recorded. To assess the effect of nanoemulsion on cell
number, a microscopy cell counting experiment was conducted after labeling the cells
with Hoechst dye, which stains the nucleus. In this experiment, cells exposed to
nanoemulsion as mentioned above in 96 well plates were fixed in 150 μL of 4% PFA and
50 μL cell culture media. Plates were incubated at RT for 20 min, washed twice with
DPBS and exposed to Hoechst nuclear staining dye (5 μg/mL in DPBS) for 20 min at RT
in dark. Cells were washed twice with DPBS and stored in 100 μL of DPBS at 4 °C until
imaging on EVOS fluorescence microscope.

CD86 expression and nitric oxide release
In order to evaluate if nanoemulsion delivery affects any inflammatory mediators,
nitric oxide (NO) release and CD86 cell surface markers were assessed in macrophages.
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Cells plated in 6-well plates were incubated with DFNE or CXBNE (9.3 μM celecoxib)
overnight. Cells exposed to LPS (200 ng/mL) were used as positive control, while the
negative control cells were left untreated. Supernatants were analyzed for NO
concentration using commercially available Griess reagent according to manufacturer
instructions. Cells were collected by trypsinization and labeled with PE-conjugated antiCD86 antibody or isotype control. After repeated washings with centrifugation (300g, 5
min) in DPBS / 2% FBS, cells were fixed with 2% paraformaldehyde, washed and resuspended in DPBS. Samples were analyzed using flow cytometry (BD™Accuri) and
50,000 events were recorded. Nanoemulsion was detected in FL4, while CD86
fluorescence was recorded in FL2 channel. Gating was applied based on forward scatter
(FSC) and side scatter (SSC) as shown in Figure 6.1. The mean fluorescence of gated
cells was utilized for analysis. A moderate 20% reduction in viability was observed with
LPS at 200 ng/mL.

Figure 6.1. Gating strategy employed in flow cytometry based on FSC and SSC of
cells.
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Cellular uptake
Time- and concentration-dependent uptake kinetics of nanoemulsions was
determined in macrophages. RAW 264.7 cells were grown in 6-well plates (0.3 x
106/well), incubated overnight for attachment, and followed by exposure to different
doses of nanoemulsion (0, 2, 4, 6, 8 mg/mL PFPE) for 24 h in triplicates. Cells were
trypsinized and washed by centrifugation. Cells were lysed using lysing buffer containing
Triton-X100 (1%) (Sigma-Aldrich). A portion of the lysate was used for measuring
protein content using Bradford protein assay (Bio-Rad, Hercules, CA). Cell lysates
(150 μL) were transferred to a clear bottom 96-well plate and fluorescence intensity was
recorded on a plate reader (Tecan Safire 2) at excitation wavelength of 610 nm and
emission wavelength of 670 nm. The obtained fluorescence intensity was normalized to
protein content (RFU/μg) and plotted against nanoemulsion concentration. For timedependent uptake, cells were grown in 12-well plates (0.25 x 106/well). After overnight
incubation, cells were exposed to nanoemulsion at single dose (4.2 mg/mL PFPE) for
different time points (5, 15, 30, 60, 120, 240, 360 and 420 min) in triplicates. Cells were
collected by trypsinization, re-suspended in DPBS / 2% FBS, and washed twice by
centrifugation (300g, 5 min). Cells were fixed with 2% PFA and analyzed by flow
cytometry (BD Accuri™). 20,000 events were recorded in the gated region (Figure 6.1)
and the nanoemulsion was detected in FL4. Data were plotted as mean fluorescence at
each time point for triplicate samples.
To assess the effect of phagocytosis inhibition on uptake, cells were plated in 12
well plates (0.2 x 106 cells) and left for attachment overnight. After aspiration of media
and washing with DPBS, cells were exposed to different doses of nanoemulsion with or
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without cytochalasin B (5 μg/mL) for 2.5 h in triplicates. Cells were collected by
trypsinization, washed twice by centrifugation (300g, 5 min, 4 °C) in DPBS / 2% FBS,
and fixed with 2% PFA. Cells re-suspended in DPBS were analyzed by flow cytometry
(BD Accuri™). Nanoemulsion was detected in FL4 and 30,000 events per sample were
collected in the gated region (Figure 6.1). The concentration of cytochalasin B was
chosen based on a dose-dependent toxicity assessment performed in these cells for 2.5 h.
Effect on cell viability was assessed by luminescent assay as described in chapter 3.

Confocal microscopy
RAW 264.7 macrophages (0.2 x 106 cells) were seeded on glass coverslips in a 24
well plate and left for adhesion overnight. Cells were then incubated with nanoemulsion
(30 μL) in culture media (1 mL) for two hours at 37 °C. Cell were then washed with
DPBS and fixed with 4% paraformaldehyde (PFA) for 20 min at RT and stained with
Hoechst for nuclei visualization. For kinetic studies, cells were incubated with
nanoemulsion (30 μL in 1 mL medium) for 5, 15, 30 and 60 min at 4 and 37 °C, fixed
with 4% PFA, and stained with DAPI. After washing with DPBS, coverslips were
mounted using Diamond anti-fading medium (Invitrogen, Grand Island, NY).
Fluorescence was monitored using a Zeiss Apotome system equipped with a Zeiss HPO
PL APO 63x oil immersion lens (numerical aperture 1.4-0.6). For co-localization with
acidic compartments, cells were seeded on a glass bottom dishes and left for adhesion.
Cells were then incubated with nanoemulsion (30 μL in 1 mL medium) for 45 min at
37 °C, and Lysotracker Green DND-26 (1 μM) (Invitrogen, Grand Island, NY) was added
for 15 min at 37 °C. Cells were washed with DPBS and immediately imaged using a
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Zeiss Apotome system equipped with a Zeiss HPO PL APO 63x oil immersion lens
(numerical aperture 1.4-0.6). Kinetics study and co-localization study was performed by
Dr. Wissam Beaino at University of Pittsburgh.

PGE2 assessment
To assess the effect of CXBNE delivery on COX-2 inhibition, PGE2 was
quantified in activated macrophages (RAW 264.7). Cells were plated at 0.3 million/well
in 6 well plates and left to adhere overnight. Cells were exposed to DFNE, CXBNE,
DMSO, and free celecoxib in DMSO or media. Celecoxib was used at 10 μM in
nanoemulsion and free drug treatment groups. After 24 h exposure, cells were washed 2x
with DPBS and exposed to LPS containing media (0.5 μg/mL) or media alone. LPS was
used at 0.5 μg/mL. After 3.5 h, supernatant was collected and analyzed according to
manufacturer instructions (PGE2 ELISA kit) for PGE2 assessment.

6.3 Results and discussion
6.3.1 Preparation and characterization of nanoemulsions
The PFPE nanoemulsions reported in chapters 4 and 5 required further
optimization to increase detection sensitivity using in vivo
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F MRI. In an attempt to

achieve this, three design points were experimented from Table 6.1. However, the full
design was not completed as one of the three tested nanoemulsions met the desired
criteria. Our criteria was size < 150 nm, PDI < 0.2 and stability at 60 °C for at least one
month. All nanoemulsions were devoid of multiple size populations showing monomodal
distribution and displayed PDI less than 0.15 (Table 6.2). Nanoemulsions prepared with
2% w/v surfactant (NE2 and NE3) showed smaller droplet size compared to 3.75% w/v
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(NE1) (Table 6.2). We observed an increase in average size of approximately 20 nm in
nanoemulsion with increased surfactant amount (NE1), while NE2 and NE3 showed
comparable average droplet size (Table 6.2, Figure 6.2A). At elevated temperature
(60 °C), size was monitored for at least 2 months in order to select the nanoemulsion with
superior stability. NE1 did not show significant increase in size for up to 2 months
compared to NE2 and NE3, which increased size within two weeks of high temperature
exposure (Figure 6.2B), demonstrating high colloidal stability of NE1. To compare
storage stability of the nanoemulsions, droplet size was monitored for samples stored at
4, 25, and 37 °C (Figure 6.2C-E). The droplet size for all nanoemulsions tested showed
no significant changes at 4 and 25 °C. However, samples stored at 37 °C showed an
increase in size for NE2 and NE3, while NE1 remained stable throughout the test period
of one month (Figure 6.2C-E). All the nanoemulsions showed a negative zeta potential
(Table 6.2). Based on the results from these three formulations, it appears that high
surfactant amount (low O/S) is required for high colloidal stability under storage and at
elevated temperature. However, in comparison to PFPE formulations in chapters 4 and 5,
the optimized nanoemulsion has higher O/S (5.96 vs. 4.78) i.e. lower amount of
surfactant to total oil content.

Table 6.2. DLS characterization of nanoemulsions NE1, NE2 and NE3.
PFPE
Surfactant Pulses O/Sa
Size
PDI
Zeta potential
(%w/v) (%w/v)
(nm)
(mV)
18.75
3.75
38
5.96
156
0.12
-14.0
NE1
18.75
2
30
11.17
136
0.10
-12.1
NE2
18.75
2
46
11.17
133
0.10
-12.8
NE3
a
O/S = Oil to surfactant ratio. Oil phase includes Miglyol 810N and PFPE oxide
Code
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The effect on cell viability was comparable for nanoemulsions with low and high
surfactant amounts (Figure 6.3). We observed an increase in cell metabolic activity with
these nanoemulsions. In order to assess if this increase in metabolic activity is due to
increased cell number, a separate experiment was conducted. Cell number was obtained
for each treatment in triplicates by counting the nuclei of fluorescently stained cells. An
increase in cell number at some concentrations of nanoemulsion was observed
(Figure 6.3B) for NE1. A plausible explanation for this cellular behavior is the gasdissolving capability of PFCs. During processing and storage, nanoemulsions could
dissolve oxygen. An increased cell metabolic activity and number could be the result of
the oxygen supplied to cells in culture. Of note, this increase in cell metabolic activity
and numbers is not a toxic event and hence further studies to explore the associated
mechanisms were not attempted. Based on these results, the composition and processing
conditions of NE1 were selected as optimized to prepare fluorescent nanoemulsions for
in vitro and in vivo studies.
The optimized nanoemulsion was modified for fluorescence imaging using a
lipophilic fluorescent dye, DiD. The addition of the dye reduced the droplet size by 20-25
nm, probably due to its adsorption in the surfactant layer. A small reduction in zeta
potential was also observed compared to dye-free nanoemulsions (-6 mV vs. -14 mV).
There was no influence of drug incorporation on average droplet size and zeta potential
(Figure 6.4A). The stability of the nanoemulsions was investigated by monitoring
average size changes with time at 4 °C storage, serum exposure, and variation in
dispersant pH. Both DFNE and CXBNE displayed high stability under storage at 4 °C
(Figure 6.4B). Even after 100 days, the size distribution by intensity showed a single
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peak (Figure 6.4C). A small increase in size of less than 15 nm was noted after 100 days
and PDI remained below 0.15. Incubation of nanoemulsions with serum-containing
media showed a small reduction in size (Figure 6.4D). However, the serum did not affect
the size distribution (Figure 6.4E). Average droplet size and size distribution of
nanoemulsions remained unaltered after incubation at pH 5.0 and 7.4 for 5 days (Figure
6.4F). The pH of the undiluted nanoemulsions was between 6.75 and 7.1, which is close
to physiological pH of 7.4. These results clearly indicate that the nanoemulsion is stable
under different stress conditions and was acceptable for in vitro and in vivo biomedical
applications.
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Figure 6.2. Size and stability of dye-free PFPE nanoemulsions.
A. Size distribution of nanoemulsions NE1 (red), NE2 (blue), and NE3 (green). B.
Nanoemulsion droplet diameter changes with time stored at 60 °C. Storage stability of
nanoemulsions C. NE1, D. NE2, and E. NE3 stored at 4, 25 and 37 °C. Error bars
represent PDIw/2.
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Figure 6.3. Effect of dye-free PFPE nanoemulsions on macrophage viability.
A. Cell viability assessed for NE1 and NE2 by quantitation of ATP. B. Effect of cell
growth based on nuclei counts of NE1 exposed cells. C. Representative microscopy
image of nuclei for nanoemulsion-exposed and untreated cells showing visible difference
in cell number. Data is obtained from at least triplicate measurements.
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Figure 6.4. Characterization of the optimized fluorescent dye-loaded nanoemulsions,
DFNE and CXBNE, using DLS.
A. Zeta potential distribution of DFNE (red) and CXBNE (green). B. Graph showing
droplet diameter changes with time (days) for nanoemulsions stored at 4 °C. C.
Comparison of size distribution for CXBNE at day 0 vs. day 112, showing single peak.
D. Droplet diameter changes in serum containing cell culture media at 37 °C. E. Overlay
of size distribution for media exposed CXBNE showing monomodal distribution. F.
Droplet diameter changes of CXBNE incubated in pH 5.0 and 7.4 buffer at 37 °C.
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Nanoemulsions were characterized by
19

19

F NMR spectroscopy and fluorescence.

F NMR of the nanoemulsions (not included) showed characteristic peaks similar to the

spectrum of pure PFPE oxide.205 In order to determine the appropriate fluorescence
conditions for in vitro and in vivo studies, emission and excitation spectra for DFNE and
CXBNE were determined. Ex/Em of 648 / 668 nm were observed for both nanoemulsions
(Figure 6.5A-B). The presence of drug did not show any shift in the emission and
excitation spectra. A slight blue shift was observed compared to the free dye (Figure
6.5C) dissolved in ethanol/water mixture (654 / 678 nm), possibly due to the presence of
surfactants in the nanoemulsion. However, the fluorescence properties remained in the
NIR region, which is ideal for in vivo imaging due to the reduced autofluorescence.

Figure 6.5. Fluorescence characterization of DiD dye in nanoemulsions and solution.
A. Excitation and B. Emission spectra. C. Comparison of emission spectra for DiD dye in
ethanol/water mixture and nanoemulsion.
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6.3.2 In vitro evaluation in RAW 264.7 macrophages
The optimized nanoemulsion, with and without celecoxib, was tested at different
doses in macrophages and did not affect their viability after 24 h exposure (Figure 6.6A).
In order to ascertain that these nanoemulsions did not produce any pro-inflammatory
effects, NO release and CD86 expression changes were monitored after 24 h of exposure.
A non-toxic concentration of LPS was used and cells were activated for 18 h. NO and
CD86 were chosen as the markers for macrophage activation. LPS was used as a positive
control to induce the pro-inflammatory phenotype in macrophages, which leads to
increased CD86 expression and NO release. CD86 expression and NO release were not
altered by nanoemulsions (Figure 6.6B-C). CD86 and NO levels were comparable to
untreated cells, and significantly lower than LPS-activated cells, which clearly indicate
that nanoemulsions do not stimulate pro-inflammatory phenotype in macrophages.

Figure 6.6. Effect of DFNE and CXBNE on macrophage viability and activation.
A. Viability of RAW 264.7 macrophages exposed to DFNE and CXBNE for 24 h (n = 4).
B. Nitric oxide release from macrophages exposed to nanoemulsions for 24 h (n = 3).
Data in panels A and B is shown as mean ± SD C. CD86 expression in macrophages
exposed to nanoemulsions for 24 h. Cells not exposed to any treatment are designated as
NT (no treatment).
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To understand the uptake and intracellular fate of nanoemulsions, cellular uptake
studies were conducted in RAW 264.7 macrophages. Fluorescence analysis of cells
exposed to nanoemulsion showed an identical emission profile (Figure 6.7A) to that of
dye in solution and nanoemulsion (Figure 6.5). Whereas, untreated cells did not display
fluorescence. This result confirms that the fluorescent properties of the theranostics are
not altered and can be detected in cells using fluorescence microscopy. Confocal
microscopy showed that the nanoemulsions were readily internalized by macrophages
(Figure 6.7B) and localized to acidic endosomal/lysosomal compartments (Figure 6.7BC). This experiment was conducted 45 minutes after labeling the cells with the
nanoemulsion. Typically, NPs sort through the endosomal-lysosomal compartments,
unless a lysosomal escape mechanism is made part of the system. Based on the
pharmacological effect we observed in the cells (demonstrated in the next section), it is
likely that the nanoemulsion could physically dissociate and release the drug to act on the
COX-2 enzyme. In order to probe the exact mechanism, a time-dependent co-localization
study with endosomal and lysosomal-specific antibodies has to be conducted.
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Figure 6.7. Characterization of nanoemulsion uptake in macrophages using
fluorescence methods.
A. Comparison of fluorescence emission of cells treated with or without CXBNE
showing Em at 670 nm. B. Confocal microscopy of cells incubated with nanoemulsion
(30 μL/mL) for 2 h at 37 °C. C. Confocal images showing co-localization of
nanoemulsion (red) with acidic compartments (green) labeled with Lysotracker GreenDND. Merged image show the co-localized pixels (yellow). Nuclei are stained with
DAPI (blue). Images are recorded by Dr. Wissam Beaino, University of Pittsburgh, 2014.
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F NMR of cells exposed to nanoemulsion also confirmed the uptake based on

characteristic peaks of PFPE (not included). Two possible mechanisms of nanoemulsion
internalization exist in macrophages. Nanoemulsions can enter cells either passively
through membrane penetration or actively via phagocytosis, endocytosis and
pinocytosis.224 In order to identify the mechanism of internalization, RAW 264.7
macrophages were incubated with the nanoemulsion for 5, 15, 30, and 60 min. At 37 °C,

135

nanoemulsion was easily detected at the cell membrane as early as 5 min, and the
internalization increased overtime with a punctuated fluorescent staining pattern
indicative of localization in discrete vesicular compartments, suggestive of an endocytic
pathway of internalization. At 4 °C, barely detectable levels of nanoemulsion was
observed after 5 min, and minimal internalization was noted after 60 min (Figure 6.8A).
These results demonstrate predominantly energy-dependent active mechanisms of
nanoemulsion internalization in macrophages. In addition, dose- and time-dependent
uptake of nanoemulsion was observed in macrophages (Figure 6.8B-C). The cellassociated fluorescence reached saturation at higher nanoemulsion concentrations, which
is typical for an endocytic pathway of uptake.225 A similar uptake profile was observed
with the PFPE nanoemulsion reported in chapter 4, Figure 4.6, suggesting a related
mechanism of uptake of these nanoemulsions. A linear increase in uptake with time was
observed at a single concentration of nanoemulsion; within 2 h of exposure, more than
90% of cells were shown to be positive for nanoemulsion. The uptake is expected to
saturate with increased incubation time and higher concentration. The highest incubation
time used was below 12 h in order to avoid variation in cell number across time points
due to the excepted cell division at longer time points.
One of the key mechanisms of NP uptake in macrophages is phagocytosis. To
assess if phagocytosis is involved in the internalization of nanoemulsions, cellular uptake
was compared in the presence and absence of the phagocytosis inhibitor cytochalasin B.
Cellular uptake was significantly lower with cytochalasin B (Figure 6.8D). In the
presence of cytochalasin B, nanoemulsion uptake was reduced at least by 70%, and this
result was observed at all tested nanoemulsion concentrations, confirming that the uptake
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is predominantly mediated through phagocytosis. Based on the presented results, it can be
proposed that nanoemulsion enters the cells via an endocytic mechanism and moves
intracellularly via the endosome-lysosome pathway.
The pharmacological effect of celecoxib delivery was evaluated by quantitation of
PGE2 in activated macrophages. Similar to our previously reported results in chapter 4,
CXBNE produced significant reduction in PGE2 produced by LPS-activated
macrophages compared to DFNE (Figure 6.9). This reduction was comparable to free
drug delivered in DMSO. Together, these data strongly suggest that the nanoemulsion,
efficiently internalized by macrophages in a dose- and time-dependent manner and
inhibiting COX-2 enzyme activity can produce anti-inflammatory effects in vivo. To test
the in vivo efficacy of these nanoemulsions as imaging and therapeutic agents, a paw
inflammation mouse model was used, which is described in chapter 7.
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Figure 6.8. Cellular uptake kinetics of nanoemulsions.
A. Confocal images of cells exposed to nanoemulsion for 5, 15, 30, and 60 min incubated
at 4 and 37 °C (Microscopy by Dr. Wissam Beaino, University of Pittsburgh, 2014). B.
Dose dependent uptake of nanoemulsion in macrophages. Dose is represented on x-axis
as PFPE (mg/mL). C. Time-dependent uptake of nanoemulsion (4 mg/ml PFPE) in
macrophages. D. Comparison of uptake between cells exposed to different doses of
nanoemulsion with or without phagocytosis inhibitor cytochalasin B (5 μg/mL). Uptake
was performed for 2.5 h. Data in panels B, C, and D is from triplicates expressed as
mean ± SD.
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Figure 6.9. Comparison of PGE2 in supernatants of LPS activated macrophages
pretreated with celecoxib in solution and nanoemulsion.
Cells that are not exposed to LPS are designated as no-treatment (NT). All the groups
were compared with one-way ANOVA and Tukey’s post-hoc multiple comparison test
with statistical significance set at p < 0.05. Data is represented as mean ± SEM (n = 3).

6.4 Conclusions
The optimized nanoemulsions with increased PFPE content showed comparable
droplet size and PDI to nanoemulsions reported in chapter 4. These nanoemulsions were
shown to be stable under storage, serum exposure and varying pH. The individual
imaging signatures namely
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F MR and fluorescence excitation/emission were well

conserved in the nanoemulsion and cells. Most importantly, nanoemulsions did not
induce toxicity and inflammatory markers. The cellular uptake was shown to be doseand time-dependent occurring predominantly through phagocytosis. In addition to
internalization by macrophages, the multimodal theranostic was able to achieve
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pharmacological activity in macrophages. With these encouraging results, the theranostic
nanoemulsion was tested in a mouse inflammation model as described in chapter 7.
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7

In vivo evaluation of PFC nanoemulsions in inflammatory models

7.1 Introduction
In this chapter, in vivo application of the theranostic nanoemulsions developed in
chapters 5 and 6 is described. Specifically, PFPE nanoemulsion developed in chapter 6
was assessed for its capability to detect macrophages in inflammation and monitor
changes in macrophage infiltration using optical in vivo imaging. This study was
conducted in collaboration with Dr. Carolyn Anderson and Dr. Wissam Beaino at the
University of Pittsburgh. The imaging potential of dual fluorescent PFPE nanoemulsion
developed in chapter 5 is also demonstrated in a neuropathic pain rat model. Furthermore,
the utility of a previously reported fluorescent PFCE theranostic nanoemulsion to detect
neuronal injury and assessment of pain behavior in response to celecoxib delivered to
macrophages will be discussed. The studies in neuropathic pain rat model were
conducted in collaboration with Dr. John A. Pollock, Kiran Vasudeva and Muzamil
Saleem at Duquesne University.

7.2 Materials and methods
7.2.1 Inflammation models
A mouse paw inflammation model was generated by subcutaneous (s.c.) injection
of complete Freund’s adjuvant (CFA) or carrageenan (CG) in the right hind paw. In these
studies six to eight week old female ICR animals and SKH1 hairless (immunecompetent) were purchased from Charles River Laboratories (Horsham, Pennsylvania).
All animal studies were performed under the Guide for the Care and Use of Laboratory
Animals under the auspices of Division of Laboratory Animal Resources (DLAR) of the
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University of Pittsburgh. Mouse imaging was performed on IVIS® Lumina XR (Perkin
Elmer, Waltham, MA, USA) at University of Pittsburgh Cancer Institute.
A neuropathic pain rat model included neuronal injury by sciatic nerve ligation.
The studies with this model were performed by Kiran Vasudeva as previously
described.223 Rats were imaged on LiCOR Pearl® Impulse imaging station (LI-COR
Biosciences, Lincoln, NE, USA) at Duquesne University.
7.2.2 In vivo studies in a mouse paw inflammation model
7.2.2.1 Pilot study to assess the imaging potential of nanoemulsion
In the pilot study, ICR animals were divided into two groups receiving either CFA
or CG. Animals were injected with DFNE (150 μL) via tail vein under anesthesia. After
12 h, each group (n=3/group) received CFA (50 μL) or CG (40 μL) via s.c. injection in
the right hind paw, while the left hind paw received normal saline. Animals were imaged
at 2, 6, 9, 12, 24, 27, 30, and 48 h post-inflammation using the same imaging parameters.
Paw thickness was measured before the injection of adjuvants and at all imaging time
points. Lateral, translateral and ankle thickness was noted using Vernier calipers. Imaging
was performed on IVIS® Lumina XR (Perkin Elmer, Waltham, MA). For each mouse,
X-ray, white light and fluorescence images were co-registered. Imaging parameters
included F/stop 2, medium binning, 3 sec exposure, high lamp level, and excitation and
emission of 640 and 700 nm respectively. Settings were optimized to obtain an image
that did not lead to detector saturation. To avoid saturation from the bladder and the
abdominal region, a black cloth was used to cover these areas during imaging (Figure
7.1). At the end of the study, representative paws were collected for ex vivo
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F NMR

analysis. After 24 h, one animal from each group was sacrificed for cell collection and
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development of flow cytometry method to detect nanoemulsion labeled macrophages. In
vivo images were quantified by drawing a region of interest (ROI) around the inflamed
leg and the contralateral control leg (Figure 7.1). Total fluorescence radiant efficiency
was calculated after background subtraction. Data are presented as the fluorescence ratio
of inflamed to control leg.

Figure 7.1. Representative fluorescence/white light image showing in vivo imaging
method and ROIs used for quantification.

7.2.2.2 In vivo study to evaluate theranostic potential of nanoemulsions
SKH1 hairless mice were injected via tail vein with CXBNE (150 μL, 437.6 μM)
(n = 5) or DFNE (150 μL) and free celecoxib dissolved in a surfactant mixture containing
CrEL and P105 (115 μL) (n= 5) 12 h prior to paw inflammation induction by CFA. Live
animals under anesthesia were imaged using in vivo fluorescence imaging using an
IVIS® Lumina XR (Perkin Elmer; Waltham, MA) imaging station with 640 nm and
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700 nm filters for excitation and emission, respectively. Images were acquired at 2, 6, 10,
24, 34, 48 and 72 h post CFA injection. Imaging parameters (exposure 1 sec, binning
medium, lamp high, F/stop 2) were maintained for all time points. Images were
quantified as described above. Mice were sacrificed (n = 3) after 72 h imaging time point,
and organs were collected and imaged using the IVIS® Lumina XR imaging station, and
then weighed. ROIs were drawn around each organ, and total radiant efficiency was
calculated and normalized to the organ weight. The total dose was calculated by
quantifying the fluorescence of a standard nanoemulsion dilution imaged with the same
imaging parameters.

Ex vivo histological analysis
Following the in vivo studies at 72 h post-inflammation, mice injected with either
CXBNE or DFNE and free celecoxib dissolved in the surfactant mixture were sacrificed
and the inflamed paw was collected and snap frozen. In a separate experiment, SKH1
hairless mice were injected with DFNE (150 μL), and paw inflammation was induced by
injection of CFA (50 μL) s.c. in the right hind paw. After 24 h, mice were sacrificed;
spleens and paws were collected and snap frozen.
Dr. Wissam Beaino at University of Pittsburgh performed histology. Briefly,
tissues were embedded in optimal cutting temperature (OCT) medium. 10 µm sections
were obtained using a cryotome. Sections were fixed and stained for macrophages and
neutrophils using CD68 and Gr1 antibodies, followed by secondary fluorescent
antibodies for microscopy using a Zeiss Apotome system equipped with a Zeiss HPO PL
APO 40x or 63x oil immersion lens (numerical aperture 1.4-0.6).
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Statistical Analysis
A Two-way repeated-measures ANOVA with Bonferroni post-hoc test was
utilized to compare mean fluorescence intensity of groups treated with DFNE or CXBNE
at each imaging time point. Imaging time point and treatment were chosen as factors for
this analysis. A student’s t-test was used to compare mean fluorescence intensity of
organs between groups treated with DFNE or CXBNE. Statistical significance level was
set at p < 0.05 and data was analyzed using GraphPad Prism 6.
7.2.3 In vivo imaging in a neuropathic pain rat model
In vivo neuropathic pain model was utilized as a proof of principle study to assess
whether the dual fluorescent nanoemulsion (prepared in chapter 5) can be detected in vivo
at the inflammation site. Additionally, a previously published DiR-labeled PFCE
nanoemulsion215 from our lab was also utilized in this model to assess the effect of
celecoxib delivery on pain behavior changes.
The following procedure was performed by Kiran Vasudeva in Dr. John Pollock’s
laboratory. Briefly, on 8th day post-sciatic nerve ligation, 0.3 mL of the nanoemulsion
(chapter 5) was injected via tail vein. A healthy rat was used as the control. After 72 h,
anesthetized animals were imaged on LiCOR Pearl® small animal imaging station. Due
to the limited field of view, only a portion of the rat could be imaged. Rats were laid on
the side and images were collected ensuring sciatic nerve regions are captured within the
obtained image. Fluorescence (800 nm) and white light images were co-registered at
focus offset -1. After live animal imaging, tissues, namely left and right sciatic nerves,
lungs, kidneys, heart, liver and spleen, from both animals were collected and stored in 2%
PFA in DPBS fixing solution at 4 °C.
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The same procedure was utilized to evaluate the DiR-labeled PFCE
nanoemulsion. Kiran Vasudeva, in her dissertation thesis, described experimental details
and full results of the study. Figure 7.11 shows the author credits for this work. Briefly,
animals receiving sham surgery and sciatic nerve ligation were used. Sham rats were used
as control for pain behavior. Pain behavior was tested according to the protocol published
in Vasudeva et al.223, before the surgery and different days (up to 12 days) after the
surgery. Sham rats did not receive any treatment. On day 8, rats with induced neuropathic
pain were injected via tail vein, either drug-free or drug-loaded PFCE nanoemulsion or
free drug dissolved in the surfactant mixture. Pain behavior was assessed on day 9, 10,
11, and 12. At the end of the study, sciatic nerves were collected from drug-free and
drug-loaded nanoemulsions and assessed for
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F content and NIRF imaging. Sciatic

nerves were fixed, weighed and transferred to NMR tubes with fixing solution.

Ex vivo tissue 19F NMR and NIRF imaging
The collected organs were cut into thin slices to fit into 5 mm NMR tubes.
Inflamed sciatic nerves were cut, while the control and non-inflamed ones are placed
intact in the NMR tubes. All the tissues were weighed on a digital balance, followed by
the addition of fixing solution. These NMR tubes were imaged on LiCOR Odyssey® in
800 nm channel. ROIs were drawn using instrument software and the integrated
fluorescence was obtained. Same tubes with tissues were assessed for
19

19

F content using

F NMR. For reference, a sealed capillary containing 0.02% v/v aq. TFA was placed

inside the NMR tube. The height of the tube was adjusted such that the tissue sample is
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with in the active region of NMR machine. NMR was performed on Bruker 500 MHz
with delay time of 10 sec and 128 scans.

7.3 Results and discussion
7.3.1 In vivo studies in a mouse paw inflammation model
To test the in vivo diagnostic and therapeutic potential of the theranostic
nanoemulsion, a murine inflammation model was utilized. The goal of these studies was:
1) to test the efficiency of nanoemulsions to detect the inflammation loci and 2) to image
the response to celecoxib delivery i.e. changes in macrophage infiltration. Our working
hypothesis is summarized in Figure 7.2.

Figure 7.2. Schematic showing the proposed theranostic potential of PFPE
nanoemulsion.

In the pilot study, CFA and CG were compared to assess the severity of
inflammation based on the nanoemulsion fluorescence from the inflamed paw. CFA is an
emulsion containing inactivated mycobacterium tuberculosis and it has been shown to
induce local inflammation leading to increased leukocyte recruitment.226,227 CG is a sugar
and widely employed to induce local inflammation in rodents and arthritis in rats.228

147

Drug-free fluorescent PFC nanoemulsion, DFNE, was injected (tail vein) 12 h prior to
inducing paw inflammation in order to label the monocytes/macrophages with
nanoemulsion and subsequently monitor their infiltration to the inflamed site.
Fluorescence imaging showed higher paw fluorescence from right paw injected with
adjuvant (CFA/CG) compared to left paw receiving normal saline (Figure 7.3A). As
shown in Figure 7.3B, paw thickness increased immediately after the adjuvant injection.
Inflammation was higher and persisted longer with CFA compared to CG (Figure 7.3C).
Ex vivo 19F NMR of a paw tissue section from CFA-injected animal showed peaks from
PFPE (Figure 7.3D), further confirming the presence of nanoemulsion at the inflamed
site. Due to the high fluorescence observed, CFA was utilized for further studies.
To test the theranostic potential of the nanoemulsion, hairless SKH1 mice were
used because our study showed background fluorescence due to shaving-induced skin
irritation in ICR mice complicating the fluorescence quantification from the paw region.
In these mice, first we evaluated the potential of the nanoemulsion to be delivered to
macrophages. Immunofluorescence staining of the inflamed paw and spleen from mice
injected with the nanoemulsion showed a strong and major co-localization of the
nanoemulsion with macrophages and undetectable co-localization with neutrophils
(Figure 7.4). These results show that the nanoemulsion is specifically internalized by
macrophages in vivo at the site of inflammation and in spleen and is suitable to image and
deliver therapeutics to macrophages. It should be noted that other antigen presenting or
phagocytic cells like DCs and B cells, which are not investigated in our study, could also
internalize the nanoemulsion.
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Figure 7.3. Pilot in vivo study showing characterization of CFA and CG mouse
models.
A. Representative X-ray/fluorescence composite images show high fluorescence signal
from CFA and CG injected paw compared to saline. B. Evolution of paw thickness for
CFA and CG injected animals. C. Paw fluorescence changes with time of individual
animals. D. Representative 19F NMR of paw section showing presence of specific PFPE
peaks. Data in panel B is represented as mean ± SD from three animals until 27 h and two
animals thereafter.

With these results, the theranostic potential of the nanoemulsion in vivo in an
inflammation setting was assessed by delivering celecoxib to macrophages and
monitoring the subsequent therapeutic response using longitudinal fluorescence imaging.
We evaluated this effect by comparing changes in fluorescence from inflamed paws
between free drug and drug encapsulated in the nanoemulsion. In order to visualize
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macrophage accumulation changes in the group receiving free drug, a drug-free
nanoemulsion, DFNE (vehicle), was also co-administered. Based on the live animal
imaging at different time points, a visible difference in fluorescence intensity was seen
between the groups with time (Figure 7.5A). For both groups, we did not observe a
statistically significant difference in the ratio of fluorescence intensity between inflamed
paw and control paw until 10 h (Figure 7.5B). At the 24 h, significant reduction in the
fluorescence ratio was observed for the group receiving CXBNE, which further reduced
at 34 h time point and persisted till 72 h (Figure 7.5B). In the animals receiving free drug,
paw fluorescence remained high at all the time points. The fluorescence intensity was
assessed for both the nanoemulsions in order to exclude the contribution of differential
nanoemulsion fluorescence to the observed fluorescence changes between the animal
groups. Fluorescence intensity was observed to be slightly higher in CXBNE, which
further supports the claim that CXBNE group showed reduced fluorescence with time
compared to DFNE.
A plausible rationalization for the differences observed between the two groups
could be attributed to the elimination of celecoxib from the body in the free drug group.
Because there was a 12 h lag time before inducing inflammation, systemic concentration
of celecoxib would have reduced (t1/2 = 11.2 h for celecoxib) compared to celecoxib
encapsulated in the nanoemulsion. Nanoemulsion-mediated celecoxib delivery is
advantageous because it may reduce the drug elimination and also increases target
accumulation, which leads to lower frequency of administration in future studies to
induce anti-inflammatory effects.
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Figure 7.4. Tissue analysis for nanoemulsion accumulation in macrophages and
neutrophils.
Representative immunofluorescence sections of inflamed paw and spleen from mouse
injected with nanoemulsion 24 h post-inflammation. Nanoemulsion was injected 12 h
pre-inflammation. Sections were stained with anti-CD68 for macrophages and anti-Gr-1
for neutrophils. Merge images shows co-localization (arrows) of the nanoemulsion (red)
with macrophages (green) in inflamed paw and spleen and no co-localization (arrow
head) of nanoemulsion (red) with neutrophils (green). Histology by Dr. Wissam Beaino,
University of Pittsburgh, 2014.
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Figure 7.5. In vivo NIRF imaging of DFNE and CXBNE in mouse paw inflammation
model.
A. Representative fluorescence/X-ray images showing the accumulation of nanoemulsion
in the site of inflammation (right paw) at different time points. B. Ratio of quantified
fluorescence of inflamed paw compared to non-inflamed paw. Data is shown as mean ±
SD (n = 5).

The biodistribution study revealed that the majority of the nanoemulsion is
accumulated in liver and spleen (Figure 7.6A). This result is expected because these
organs are sites at which macrophages accumulate to the greatest extent. Interestingly, the
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percent-injected dose accumulated in the spleen was higher for the group receiving
CXBNE compared to the free drug (Figure 7.6B). Recently, it has been reported that
monocytes/macrophages of spleen, in addition to blood monocytes, are recruited to the
injured site during inflammation.229 We speculate that the increased nanoemulsionassociated fluorescence in the spleen of these animals is due to the reduced recruitment of
nanoemulsion-internalized monocytes/macrophages to the inflamed paw, owing to the
reduced production of chemokines required for macrophage recruitment. This result also
coincides with the decrease in macrophage infiltration of the inflamed paw observed in
CXBNE group compared to the free drug group (Figure 7.5B).
Finally, a 19F MR image of the excised paw was registered in 8 min and 32 sec as
shown in Figure 7.7. A clear presence of PFPE can be seen throughout the excised paw,
indicating that

19

F MRI can detect the nanoemulsion with increased PFPE content.

Because the image was obtained in reasonable amount of time (clinically applicable time
scale), nanoemulsions could be utilized for longitudinal live animal imaging using

19

F

MRI for quantitative assessment of nanoemulsion at the inflamed site. Unlike NIRF, this
method is applicable to image and quantify surface and deep tissue inflammation.
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Figure 7.6. Biodistribution of DFNE and CXBNE.
A. Representative fluorescence images of different organs showing nanoemulsion
biodistribution at 72 h after inducing inflammation evaluated by fluorescence ex vivo
imaging. B. Biodistribution of nanoemulsion in different organs. Data is shown as mean
± SD (n = 3).

Figure 7.7. Representative 1H/19F MRI composite image of excised inflamed paw.
Images were obtained at 4 x 4 cm field of view in 8 min and 32 sec on Bruker Biospec
Avance III 7-T. PFPE is seen in the paw as red hot iron signal superimposed on the
anatomical 1H MRI shown in grey. Image by Dr. Kevin Hitchens, Pittsburgh NMR
Center for Biomedical Research, Carnegie Mellon University, 2014.
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Histological analysis of the inflamed paw revealed a high level of macrophage
infiltration (Figure 7.8). A majority of the nanoemulsion droplets are co-localized with
macrophages (CD68+) expressing the target enzyme, COX-2. Further, CXBNE and
DFNE showed accumulation specifically in macrophages compared to neutrophils
(Figure 7.9), similar to the histology data from 24 h after inflammation (Figure 7.4). The
combination of in vivo imaging and histological studies confirm that the nanoemulsion is
efficiently taken up by macrophages in the inflamed tissue. In vivo live animal data
indicate that by delivering celecoxib in a nanoemulsion, macrophage infiltration is
reduced over time. We showed that the theranostic system not only delivered celecoxib to
the target cells, but also facilitated the visualization of therapeutic response (reduced
macrophage infiltration). Most importantly, the combined therapy and response
monitoring was achieved after a single dose administration of the theranostic system. We
acknowledge that the approach presented in this study utilized theranostic injection prior
to inducing inflammation, which is contrary to the common mode of treatment, where
therapeutic intervention ensues after the disease state is established. Prior labeling of
blood monocytes was expected to facilitate visualization of these labeled monocytes
fluxing to the inflamed site and reduces interference due to accumulation of
nanoemulsion at the inflamed site through EPR. Yet, this approach has clinical
significance, for example, to monitor macrophages in post-surgery and transplantation
settings. In the next section, combined imaging and diagnostic features were
demonstrated in a neuropathic pain model, which is more representative of clinical
treatment setting for chronic pain.
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Figure 7.8. Histology of excised paw 72 h after CFA injection showing nanoemulsion
accumulation in COX-2 expressing macrophages.
Representative immunofluorescence sections of inflamed paw from mouse injected with
DFNE and CXBNE (purple) and stained for macrophages (Rat anti mouse-CD68, green)
and COX-2 (Goat anti mouse-COX-2, red). Merged panel shows the co-localization of
nanoemulsion fluorescence (DiD) with macrophages and COX-2 staining. Experiment by
Dr. Wissam Beaino, University of Pittsburgh, 2014.
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Figure 7.9. Histology of paw 72 h after inducing inflammation to assess
nanoemulsion accumulation in macrophages and neutrophils.
Representative immunofluorescence sections of inflamed paw stained for macrophages
(Rat anti mouse-CD68, green) or (Rat anti mouse-Gr-1-FITC, green) show nanoemulsion
co-localization with macrophages (arrows), but not neutrophils (arrow head) in the
merged panel.
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7.3.2 In vivo studies in a neuropathic pain rat model
A neuropathic pain model was utilized to test the imaging potential of dual
fluorescent PFPE nanoemulsion reported in chapter 5. As described in chapter 5, live
animal imaging showed fluorescence at the surgical site (right sciatic nerve), but not in
the contralateral side of the neuropathic pain animal (Figure 7.10). Both sciatic nerve
regions of control rats were also lacking fluorescence signal. This result confirms that the
nanoemulsion is specifically accumulated at the injured site. Ex vivo fluorescence (Figure
7.10) of the nerves also validate this result. Unfortunately, 19F NMR did not detect PFPE
at the inflamed site. Spleen and liver of both rats showed significant accumulation of
nanoemulsion by fluorescence and

19

F NMR. This led to the speculation that PFPE is

below the detection limits at the inflamed site in this animal model. Previously Dr. Janjic
and Dr. Pollock’s group223 has employed a nanoemulsion incorporating 20% v/v PFCE
for successful detection of nerve injury in this model. The results from this study were
crucial to design new nanoemulsions in chapter 6 to increase 19F MRI sensitivity.
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Figure 7.10. In vivo and ex vivo NIRF imaging of neuropathic pain rat model to
assess dual fluorescent PFPE nanoemulsion accumulation. Arrow points to the
surgical site showing fluorescence at the injured sciatic nerve in chronic constriction
injury (CCI) rat.

This model was also utilized to investigate the pain sensitivity changes in
response to COX-2 inhibition in macrophages using a celecoxib theranostic
nanoemulsion.215 This theranostic system is prepared with same ingredients as
nanoemulsions reported in chapter 4, 5, and 6, but PFCE was utilized instead of PFPE.
Animals with neuropathic pain were injected with free drug or drug-loaded or drug-free
fluorescent PFCE nanoemulsions. Animals injected with free-drug also received drugfree fluorescent PFCE nanoemulsion (vehicle) to facilitate imaging. Sham animals were
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used as controls for pain behavior testing. As shown in Figure 7.11, animals experienced
less pain with celecoxib-loaded nanoemulsion compared to free drug and drug-free
nanoemulsion starting on day 8 (2nd day after nanoemulsion injection). Representative
sciatic nerves (from one animal) from drug-loaded and free drug treated groups were
analyzed by ex vivo

19

F NMR,

19

F MRI and NIRF imaging. The results from three

methods show a reduction in imaging signal in the animals receiving celecoxib
nanoemulsion compared to free drug. There was also a significant difference in CD68
macrophages between these groups (Kiran Vasudeva, Dissertation 2015). These results
indicate that by inhibiting COX-2 in macrophages, macrophage infiltration as well as
pain sensitivity will be reduced, validating the theranostic potential of the nanoemulsion
in a different inflammation model.
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Figure 7.11. Imaging and pain behavior assessment of theranostic PFCE
nanoemulsion in a neuropathic pain rat model.
A. Pain sensitivity test performed in rats with sham surgery (grey) and sciatic nerve
ligation (red blue, light blue), chronic constriction injury (CCI). Mechanical
hypersensitivity is quantified based on paw withdrawal in response to filament poking.
Reduction in withdrawal threshold is read as increase in pain. Comparison between rats
(neuropathic pain) injected with and without celecoxib-loaded theranostic using B. Ex
vivo NIRF, C. 19F MRI, D. 19F NMR and E. CD68-macrophages. Author credits:
Behavior testing by Kiran Vasudeva and Muzamil Saleem, nanoemulsion designed by Dr.
Jelena M. Janjic and Sravan kumar Patel, in vivo NIRF imaging, ex vivo NIRF and 19F
NMR by Sravan Kumar Patel, in vivo NIRF imaging by Dr. John A. Pollock, 19F MRI by
Dr. Kevin Hitchens, CMU, and histology for CD68 detection by Kiran Vasudeva.

7.4 Conclusions
As hypothesized, theranostic nanoemulsions detected inflamed locus in preclinical
inflammatory models. 19F NMR, MRI, and fluorescence imaging methods unequivocally
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confirmed the nanoemulsion presence at the inflammation site. In the mouse paw
inflammation model, theranostic nanoemulsion was specifically localized to macrophages
compared to neutrophils. In both inflammation models, a temporal reduction in
fluorescence intensity at the inflammation site with celecoxib-nanoemulsion indicated a
reduced macrophage accumulation. Further, reduced mechanical hypersensitivity as a
measure of pain in response to macrophage-targeted drug delivery was observed. This
result was concomitant with reduced number of macrophages and imaging signal at the
injured sciatic nerve. Ultimately, the studies presented in this chapter showed that the
celecoxib-loaded theranostic nanoemulsion produces anti-inflammatory effects i.e.
reduced macrophage accumulation and the associated pain, while the effect can be
simultaneously visualized.
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Summary and future directions
The treatment of chronic inflammatory diseases needs a personalized approach to

increase therapeutic efficacy and reduce unwanted side effects. NP-based theranostics
can be effective towards driving disease management strategy to a personalized medicine
realm by reducing intra- and inter-patient variability. A common aspect among several
inflammatory diseases is the infiltration of macrophages that participate in disease
pathogenesis. Targeting these cells for combined therapeutic and diagnostic purposes is
an attractive approach applicable to multiple diseases. In this dissertation, the treatment
aspects of macrophages (i.e. diagnosis and therapy) were carefully exploited to
demonstrate the concept of simultaneous therapy and therapy response monitoring
through the use of theranostic nanoemulsions.
The work presented in this dissertation identified that the inhibition of COX-2 in
macrophages is an effective strategy for obtaining both therapeutic and diagnostic
information. Furthermore, the dissertation led to the development of PFC nanoemulsions
that can be utilized for therapeutic and diagnostic purposes, separately and together. A
rational methodology was followed from idea conception to theranostic platform design
and development, and ultimately, to in vivo application. In the first phase of research,
lipophilic PFC conjugates were synthesized to address specific challenges in the current
19

F magnetic materials pertaining to MR sensitivity, body residence time and formulation

challenges. After solving the instability problems, nanoemulsions with high droplet
stability and macrophage labeling potential were produced. This formulation was not
taken forward to in vivo studies due to the large time and cost investments that would be
required for large-scale synthesis and pre-formulation studies. Nevertheless, this work led
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to the development of a stable formulation of a new PFC conjugate. Due to its single 19F
resonance peak, which is easily distinguishable from the widely used PFCs, the reported
nanoemulsion can be used as an imaging tracer in multi-spectral

19

F MRI applications.

The developed platform serves as a starting point for future investigations involving drug
and dye incorporation for the development of a potential theranostic system.
In the second phase of the work presented in chapters 4, 5, and 6, PFPE
nanoemulsions were developed and sequentially optimized for increased MR imaging
efficiency. The developed platform was amenable to the incorporation of additional dye,
which can facilitate in vivo fluorescence and 19F MR imaging as well as ex vivo histology.
The formulation could not be detected in a neuropathic pain model using

19

F MR. Most

likely, this was due to the low amount of PFPE in the nanoemulsion, as well as the
presence of a localized low degree of inflammation. However, this formulation has the
potential to be used in models with significant inflammation such as cancer and graft
rejection. To address the MR sensitivity, nanoemulsions with increased PFPE content
were prepared. In this multimodal theranostic platform, therapeutic and imaging
functionalities were preserved in cells and tissues. In the mouse paw inflammation model,
these nanoemulsions showed specific localization in macrophages (CD68+) expressing
COX-2 compared to neutrophils. With a single dose administration of the celecoxibloaded theranostic, we observed a reduction in fluorescence in the inflamed paw with
time, indicating a reduction in macrophage infiltration. Essentially, infiltrating
macrophages that would, otherwise, produce pro-inflammatory effects by PGE2 release
and further recruitment of blood monocytes, were converted into immunotherapeutic
cells carrying theranostics. Evaluation in a neuropathic model validated our results that
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the inhibition of macrophage COX-2 leads to a reduction in neuropathic pain and
macrophage infiltration, which can be sensed by the theranostic nanoemulsion. Our data
strongly suggest that the delivery of select agents to infiltrating macrophages can
potentially lead to new inflammatory disease treatments in which macrophage behavioral
changes are monitored in vivo. For the first time, the work presented here showed both
simultaneous therapy and response monitoring after a single dose administration.
One can envision that additional inflammatory drugs could be delivered using the
above-presented theranostic nanoemulsions, and that select pathways inside these cells
could be inhibited or modulated for potentially therapeutic effects. Therefore, the work
presented here sets the stage for a new type of inflammation treatment, with macrophages
as the therapeutic and diagnostic targets. With PFCs showing ultrasound echogenic
properties and suitability of the developed theranostic system for photoacoustic imaging,
a suite of imaging methods could be used for noninvasive detection. The gas-dissolving
capacity of PFCs could be exploited to deliver oxygen to hypoxic tumor tissue, as well as
to increase sensitivity to radiation therapy. Given these functionalities, the PFC
theranostic platform has great potential to be applied in varied inflammatory models. A
potential future study could employ a graft rejection model to assess if pre-administration
of theranostic nanoemulsion is able to reduce macrophage burden and rejection at the
graft site. In addition to providing mechanistic information in preclinical pathological
settings, application of these theranostics in the clinic could assist physicians in risk
assessment, decision-making and strategizing treatment options leading to personalized
medicine.
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